



US009267136B2

(12) **United States Patent**  
**Collard et al.**

(10) **Patent No.:** **US 9,267,136 B2**  
(45) **Date of Patent:** **Feb. 23, 2016**

(54) **TREATMENT OF PANCREATIC DEVELOPMENTAL GENE RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO A PANCREATIC DEVELOPMENTAL GENE**

(71) Applicant: **CuRNA, Inc.**, Miami, FL (US)

(72) Inventors: **Joseph Collard**, Delray Beach, FL (US);  
**Olga Khorkova Sherman**, Tequesta, FL (US)

(73) Assignee: **CuRNA, Inc.**, Miami, FL (US)

(\*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **14/534,323**

(22) Filed: **Nov. 6, 2014**

(65) **Prior Publication Data**

US 2015/0057338 A1 Feb. 26, 2015

#### **Related U.S. Application Data**

(62) Division of application No. 13/520,496, filed as application No. PCT/US2011/020321 on Jan. 6, 2011, now Pat. No. 8,912,157.

(60) Provisional application No. 61/323,027, filed on Apr. 12, 2010, provisional application No. 61/297,847, filed on Jan. 25, 2010, provisional application No. 61/297,863, filed on Jan. 25, 2010, provisional application No. 61/294,129, filed on Jan. 12, 2010, provisional application No. 61/292,508, filed on Jan. 6, 2010.

(51) **Int. Cl.**  
**C07H 21/04** (2006.01)  
**C12N 15/113** (2010.01)  
**A61K 31/7088** (2006.01)  
**C12Q 1/68** (2006.01)

(52) **U.S. Cl.**  
CPC ..... **C12N 15/113** (2013.01); **A61K 31/7088** (2013.01); **C12Q 1/6813** (2013.01); **C12N 2310/11** (2013.01)

(58) **Field of Classification Search**  
None  
See application file for complete search history.

(56) **References Cited**

#### **U.S. PATENT DOCUMENTS**

|             |        |                  |
|-------------|--------|------------------|
| 4,683,195 A | 7/1987 | Mullis et al.    |
| 4,683,202 A | 7/1987 | Mullis           |
| 4,754,065 A | 6/1988 | Levenson et al.  |
| 4,800,159 A | 1/1989 | Mullis et al.    |
| 5,034,506 A | 7/1991 | Summerton et al. |
| 5,138,045 A | 8/1992 | Cook et al.      |
| 5,218,105 A | 6/1993 | Cook et al.      |
| 5,288,512 A | 2/1994 | Seiden           |
| 5,288,514 A | 2/1994 | Ellman           |
| 5,319,080 A | 6/1994 | Leumann          |
| 5,393,878 A | 2/1995 | Leumann          |

|              |         |                   |
|--------------|---------|-------------------|
| 5,432,272 A  | 7/1995  | Benner et al.     |
| 5,457,189 A  | 10/1995 | Crooke et al.     |
| 5,459,255 A  | 10/1995 | Cook et al.       |
| 5,474,796 A  | 12/1995 | Brennan           |
| 5,491,084 A  | 2/1996  | Chalfie et al.    |
| 5,506,337 A  | 4/1996  | Summerton et al.  |
| 5,519,134 A  | 5/1996  | Acevedo et al.    |
| 5,525,735 A  | 6/1996  | Gallop et al.     |
| 5,539,083 A  | 7/1996  | Cook et al.       |
| 5,549,974 A  | 8/1996  | Holmes            |
| 5,569,588 A  | 10/1996 | Ashby et al.      |
| 5,576,302 A  | 11/1996 | Cook et al.       |
| 5,593,853 A  | 1/1997  | Chen et al.       |
| 5,605,662 A  | 2/1997  | Heller et al.     |
| 5,661,134 A  | 8/1997  | Cook et al.       |
| 5,708,161 A  | 1/1998  | Reese             |
| 5,739,119 A  | 4/1998  | Galli et al.      |
| 5,739,311 A  | 4/1998  | Lackey et al.     |
| 5,756,710 A  | 5/1998  | Stein et al.      |
| 5,849,902 A  | 12/1998 | Arrow et al.      |
| 5,891,725 A  | 4/1999  | Soreq et al.      |
| 5,902,880 A  | 5/1999  | Thompson          |
| 5,908,779 A  | 6/1999  | Carmichael et al. |
| 5,965,721 A  | 10/1999 | Cook et al.       |
| 5,985,663 A  | 11/1999 | Bennett et al.    |
| 6,005,095 A  | 12/1999 | Capaccioli et al. |
| 6,013,639 A  | 1/2000  | Peyman et al.     |
| 6,013,786 A  | 1/2000  | Chen et al.       |
| 6,034,233 A  | 3/2000  | Ecker et al.      |
| 6,100,090 A  | 8/2000  | Monia et al.      |
| 6,140,492 A  | 10/2000 | Morelli et al.    |
| 6,147,200 A  | 11/2000 | Manoharan et al.  |
| 6,165,712 A  | 12/2000 | Foulkes et al.    |
| 6,165,990 A  | 12/2000 | Singh et al.      |
| 6,175,409 B1 | 1/2001  | Nielsen et al.    |
| 6,221,587 B1 | 4/2001  | Ecker et al.      |
| 6,239,265 B1 | 5/2001  | Cook              |
| 6,242,589 B1 | 6/2001  | Cook et al.       |
| 6,268,490 B1 | 7/2001  | Imanishi et al.   |
| 6,303,374 B1 | 10/2001 | Zhang et al.      |
| 6,307,040 B1 | 10/2001 | Cook et al.       |

(Continued)

#### **FOREIGN PATENT DOCUMENTS**

|    |           |        |
|----|-----------|--------|
| CA | 2686933   | 4/2008 |
| EP | 335451 A3 | 3/1988 |

(Continued)

#### **OTHER PUBLICATIONS**

Ausubel, Current Protocols in Molecular Biology vol. 1, 1994, 6.0.1—6.4.10.

(Continued)

Primary Examiner — Kimberly Chong

(74) Attorney, Agent, or Firm — CuRNA, Inc.; Monte R. Browder

(57) **ABSTRACT**

The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of a Pancreatic Developmental gene, in particular, by targeting natural antisense polynucleotides of a Pancreatic Developmental gene. The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of Pancreatic Developmental genes.

**34 Claims, 5 Drawing Sheets**

(56)

**References Cited****U.S. PATENT DOCUMENTS**

|           |    |         |                        |              |      |         |                          |
|-----------|----|---------|------------------------|--------------|------|---------|--------------------------|
| 6,316,198 | B1 | 11/2001 | Skouv et al.           | 7,572,582    | B2   | 8/2009  | Wengel et al.            |
| 6,335,434 | B1 | 1/2002  | Guzaev et al.          | 7,582,745    | B2   | 9/2009  | Sah et al.               |
| 6,376,541 | B1 | 4/2002  | Nixon et al.           | 7,585,893    | B2   | 9/2009  | Baguley et al.           |
| 6,403,566 | B1 | 6/2002  | Wang                   | 7,589,190    | B2   | 9/2009  | Westergaard et al.       |
| 6,444,464 | B1 | 9/2002  | Wyatt                  | 7,598,227    | B2   | 10/2009 | Crooke et al.            |
| 6,451,991 | B1 | 9/2002  | Martin et al.          | 7,605,251    | B2   | 10/2009 | Tan et al.               |
| 6,525,191 | B1 | 2/2003  | Ramasamy               | 7,622,453    | B2   | 11/2009 | Frieden et al.           |
| 6,528,262 | B1 | 3/2003  | Gilad et al.           | 7,662,948    | B2   | 2/2010  | Kurreck et al.           |
| 6,528,631 | B1 | 3/2003  | Cook et al.            | 7,666,854    | B2   | 2/2010  | Seth et al.              |
| 6,617,122 | B1 | 9/2003  | Hayden et al.          | 7,674,895    | B2   | 3/2010  | Reich et al.             |
| 6,617,442 | B1 | 9/2003  | Crooke et al.          | 7,687,617    | B2   | 3/2010  | Thruet et al.            |
| 6,630,315 | B1 | 10/2003 | Miwa et al.            | 7,691,995    | B2   | 4/2010  | Zamore et al.            |
| 6,639,059 | B1 | 10/2003 | Kochkine et al.        | 7,695,902    | B2   | 4/2010  | Crooke                   |
| 6,656,730 | B1 | 12/2003 | Manoharan              | 7,696,345    | B2   | 4/2010  | Allerson et al.          |
| 6,667,337 | B2 | 12/2003 | Wilson                 | 7,709,456    | B2   | 5/2010  | Corey et al.             |
| 6,670,461 | B1 | 12/2003 | Wengel et al.          | 7,709,630    | B2   | 5/2010  | Gaarde et al.            |
| 6,710,174 | B2 | 3/2004  | Bennett et al.         | 7,713,738    | B2   | 5/2010  | Hansen et al.            |
| 6,734,291 | B2 | 5/2004  | Kochkine et al.        | 7,718,629    | B2   | 5/2010  | Bamcrot et al.           |
| 6,762,169 | B1 | 7/2004  | Manoharan              | 7,723,508    | B2   | 5/2010  | Crooke et al.            |
| 6,794,499 | B2 | 9/2004  | Wengel et al.          | 7,732,422    | B2   | 6/2010  | Gleave et al.            |
| 6,833,361 | B2 | 12/2004 | Hong et al.            | 7,732,590    | B2   | 6/2010  | Bhanot et al.            |
| 6,861,514 | B2 | 3/2005  | Cook et al.            | 7,737,264    | B2   | 6/2010  | Thruet et al.            |
| 6,867,294 | B1 | 3/2005  | Sanghvi et al.         | 7,737,265    | B2   | 6/2010  | Akinc et al.             |
| 6,936,467 | B2 | 8/2005  | Kmiec et al.           | 7,741,305    | B2   | 6/2010  | Crooke et al.            |
| 6,936,593 | B1 | 8/2005  | Agrawal et al.         | 7,741,309    | B2   | 6/2010  | Hansen et al.            |
| 6,977,295 | B2 | 12/2005 | Belotserkovskii et al. | 7,741,457    | B2   | 6/2010  | Seth et al.              |
| 6,986,988 | B2 | 1/2006  | Gilad et al.           | 7,745,609    | B2   | 6/2010  | Bennett et al.           |
| 7,034,133 | B2 | 4/2006  | Wengel et al.          | 7,749,978    | B2   | 7/2010  | Sah et al.               |
| 7,034,145 | B2 | 4/2006  | Shen et al.            | 7,901,882    | B2 * | 3/2011  | Cao et al. .... 435/6.12 |
| 7,053,195 | B1 | 5/2006  | Goff                   | 2003/0139359 | A1   | 7/2003  | Dobie                    |
| 7,053,199 | B2 | 5/2006  | Imanishi et al.        | 2003/0186920 | A1   | 10/2003 | Sirois                   |
| 7,053,207 | B2 | 5/2006  | Wengel                 | 2003/0191075 | A1   | 10/2003 | Cook et al.              |
| 7,060,809 | B2 | 6/2006  | Wengel et al.          | 2003/0228618 | A1   | 12/2003 | Levanon et al.           |
| 7,084,125 | B2 | 8/2006  | Wengel                 | 2003/0233670 | A1   | 12/2003 | Edgerton et al.          |
| 7,087,589 | B2 | 8/2006  | Jacobson et al.        | 2004/0006031 | A1   | 1/2004  | Dean et al.              |
| 7,125,982 | B1 | 10/2006 | Frayne                 | 2004/0033480 | A1   | 2/2004  | Wong                     |
| 7,144,995 | B2 | 12/2006 | Wise et al.            | 2004/0101858 | A1   | 5/2004  | Ward et al.              |
| 7,144,999 | B2 | 12/2006 | Ward et al.            | 2004/0137423 | A1   | 7/2004  | Hayden et al.            |
| 7,148,204 | B2 | 12/2006 | Bennett et al.         | 2004/0138155 | A1   | 7/2004  | Baird et al.             |
| 7,153,954 | B2 | 12/2006 | Koch et al.            | 2004/0175803 | A1   | 9/2004  | Meritet et al.           |
| 7,169,916 | B2 | 1/2007  | Krotz et al.           | 2004/0180336 | A1   | 9/2004  | Gilad et al.             |
| 7,199,107 | B2 | 4/2007  | Dobie et al.           | 2004/0254137 | A1   | 12/2004 | Ackermann et al.         |
| 7,202,357 | B2 | 4/2007  | Crooke et al.          | 2005/0009771 | A1   | 1/2005  | Levanon et al.           |
| 7,217,572 | B2 | 5/2007  | Ward et al.            | 2005/0026160 | A1   | 2/2005  | Allerson et al.          |
| 7,220,549 | B2 | 5/2007  | Buzby                  | 2005/0113326 | A1   | 5/2005  | Siwkowski et al.         |
| 7,226,785 | B2 | 6/2007  | Kmiec et al.           | 2005/0143357 | A1   | 6/2005  | Pousette et al.          |
| 7,229,974 | B2 | 6/2007  | Peyman et al.          | 2005/0153286 | A1   | 7/2005  | Clements                 |
| 7,229,976 | B2 | 6/2007  | Dobie et al.           | 2005/0215504 | A1   | 9/2005  | Bennett et al.           |
| 7,235,534 | B2 | 6/2007  | Tanguay et al.         | 2005/0222029 | A1   | 10/2005 | Bartel et al.            |
| 7,235,653 | B2 | 6/2007  | Bennett et al.         | 2006/0009410 | A1   | 1/2006  | Crooke et al.            |
| 7,238,858 | B2 | 7/2007  | Marraccini et al.      | 2006/0142196 | A1   | 6/2006  | Klein et al.             |
| 7,276,599 | B2 | 10/2007 | Moore et al.           | 2006/0178333 | A1   | 8/2006  | Soreq et al.             |
| 7,285,288 | B1 | 10/2007 | Tormo et al.           | 2007/0082848 | A1   | 4/2007  | Alitalo et al.           |
| 7,297,786 | B2 | 11/2007 | McCray et al.          | 2007/0197459 | A1   | 8/2007  | Milner                   |
| 7,314,923 | B2 | 1/2008  | Kaneko et al.          | 2007/0213274 | A1   | 9/2007  | Salonen                  |
| 7,320,965 | B2 | 1/2008  | Sah et al.             | 2007/0213292 | A1   | 9/2007  | Stoffel et al.           |
| 7,321,828 | B2 | 1/2008  | Cowsert et al.         | 2007/0231816 | A1   | 10/2007 | Chaussabel et al.        |
| 7,335,764 | B2 | 2/2008  | Crooke et al.          | 2007/0248590 | A1   | 10/2007 | Milne et al.             |
| 7,335,765 | B2 | 2/2008  | Kaneko et al.          | 2008/0146788 | A1   | 6/2008  | Bhat et al.              |
| 7,339,051 | B2 | 3/2008  | Crooke et al.          | 2008/0221051 | A1   | 9/2008  | Becker et al.            |
| 7,371,833 | B1 | 5/2008  | Weiss                  | 2008/0293142 | A1   | 11/2008 | Liu et al.               |
| 7,399,845 | B2 | 7/2008  | Seth et al.            | 2009/0191263 | A1   | 7/2009  | Reich et al.             |
| 7,402,434 | B2 | 7/2008  | Newman et al.          | 2009/0192106 | A1   | 7/2009  | Dobie et al.             |
| 7,402,574 | B2 | 7/2008  | Iversen et al.         | 2009/0208479 | A1   | 8/2009  | Jaye et al.              |
| 7,420,050 | B2 | 9/2008  | Park et al.            | 2009/0258925 | A1   | 10/2009 | Wahlestedt               |
| 7,423,142 | B2 | 9/2008  | Vornlocher             | 2009/0318536 | A1   | 12/2009 | Freier et al.            |
| 7,425,545 | B2 | 9/2008  | Crooke et al.          | 2009/0326041 | A1   | 12/2009 | Bhanot et al.            |
| 7,427,675 | B2 | 9/2008  | Capaldi et al.         | 2010/0105760 | A1   | 4/2010  | Collard et al.           |
| 7,456,154 | B2 | 11/2008 | Soreq et al.           |              |      |         |                          |
| 7,462,642 | B2 | 12/2008 | Wang et al.            |              |      |         |                          |
| 7,468,431 | B2 | 12/2008 | Bhanot et al.          |              |      |         |                          |
| 7,510,830 | B2 | 3/2009  | Baguley et al.         |              |      |         |                          |
| 7,541,344 | B2 | 6/2009  | Bhat et al.            |              |      |         |                          |
| 7,547,684 | B2 | 6/2009  | Seth et al.            |              |      |         |                          |
| 7,569,575 | B2 | 8/2009  | Sorensen et al.        |              |      |         |                          |

**FOREIGN PATENT DOCUMENTS**

|    |             |    |         |
|----|-------------|----|---------|
| EP | 335451      | A2 | 10/1989 |
| WO | WO-84/03564 |    | 9/1984  |
| WO | WO-91/19735 |    | 12/1991 |
| WO | WO-92/00091 |    | 1/1992  |
| WO | WO-92/08796 |    | 5/1992  |
| WO | WO-93/20242 |    | 10/1993 |
| WO | WO-94/26887 | A1 | 11/1994 |
| WO | WO-94/28143 |    | 12/1994 |

(56)

## References Cited

## FOREIGN PATENT DOCUMENTS

|    |                |    |         |
|----|----------------|----|---------|
| WO | WO-95-15373    | A2 | 6/1995  |
| WO | WO-95/22618    |    | 8/1995  |
| WO | WO-95/25116    |    | 10/1995 |
| WO | WO-95/35505    |    | 12/1995 |
| WO | WO-96-27663    | A2 | 9/1996  |
| WO | WO-97-39120    | A1 | 10/1997 |
| WO | WO-99-14226    | A1 | 3/1999  |
| WO | WO-99-39352    | A1 | 8/1999  |
| WO | WO-00-57837    | A1 | 10/2000 |
| WO | WO-00-61770    | A2 | 10/2000 |
| WO | WO-01-00669    | A2 | 1/2001  |
| WO | WO-01-21631    | A2 | 3/2001  |
| WO | WO-01-25488    | A2 | 4/2001  |
| WO | WO-01-51630    | A1 | 7/2001  |
| WO | WO-02-062840   | A1 | 8/2002  |
| WO | WO-02-068688   | A1 | 9/2002  |
| WO | WO-2004-016255 | A1 | 2/2004  |
| WO | WO-2004-024079 | A2 | 3/2004  |
| WO | WO-2004-030750 | A1 | 4/2004  |
| WO | WO-2004-041838 | A1 | 5/2004  |
| WO | WO-2004-104161 | A2 | 12/2004 |
| WO | WO 2005-045034 | A2 | 5/2005  |
| WO | WO-2005-070136 | A2 | 8/2005  |
| WO | WO-2005-079862 | A1 | 9/2005  |
| WO | WO-2007-028065 | A2 | 3/2007  |
| WO | WO-2007-071182 | A1 | 6/2007  |
| WO | WO-2007-087113 | A1 | 8/2007  |
| WO | WO-2007-138023 | A1 | 12/2007 |
| WO | WO-2008-057556 | A2 | 5/2008  |
| WO | WO-2008-066672 | A2 | 6/2008  |
| WO | WO-2008-087561 | A2 | 7/2008  |
| WO | WO-2010-002984 | A1 | 1/2010  |
| WO | WO-2010-040571 | A2 | 4/2010  |
| WO | WO-2010-054364 | A1 | 5/2010  |
| WO | WO-2010-058227 | A2 | 5/2010  |

## OTHER PUBLICATIONS

- Barak, et al., "A  $\beta$ -Arrestin/Green Fluorescent Protein Biosensor for Detecting G Protein-Coupled Receptor Activation," *J. Biol. Chem.* 272:27497-27500 (1997).
- Barber, et al., "Delivery of membrane-impermeant fluorescent probes into living neural cell populations by lipotransfer," *Neuroscience Letters* 207:17-20 (1996).
- Baum, "Solid-phase synthesis of benzodiazepines," *C&EN News*, Jan. 18, p. 33-34 (1993).
- Bernstein, E., et al., "Role for a Bidentate Ribonuclease in the Initiation Step of RNA Interference," *Nature* 409:363-366 (2001).
- Boutlla, A., et al., "Short 5'-phosphorylated double-stranded RNAs induce RNA interference in *Drosophila*," *Curr. Biol.* 11:1776-1780 (2001).
- Boyd-Kimball et al., "Proteomic Identification of Proteins Specifically Oxidized by Intracerebral Injection of Amyloid  $\beta$ -Peptide (1-42) into Rat Brain: Implications for Alzheimer's Disease," *Neuroscience* 132, 313-324 (2005).
- Brazma & Vilo, "Gene expression data analysis," *FEBS Lett.*, 480:17-24 (2010).
- Bright, et al., "Chapter 6. Fluorescence Ratio Imaging Microscopy," *Methods in Cell Biology* vol. 30, Taylor and Wang (eds) p. 157-192 (1989).
- Bright, et al., "Delivery of Macromolecules Into Adherent Cells via Electroporation for Use in Fluorescence Spectroscopic Imaging and Metabolic Studies," *Cytometry* 24:226-233 (1996).
- Bright, et al., "Fluorescence Ratio Imaging microscopy: Temporal and Spatial Measurements of Cytoplasmic pH," *J. Cell Biology* 104:1019-1033 (1987).
- Campbell, et al., "Phosphonate Ester Synthesis Using a Modified Mitsunobu Condensation," *J. Org. Chem.* 59:658-660 (1994).
- Caplen, N. J. et al., "Specific inhibition of gene expression by small double-stranded RNAs in invertebrate and vertebrate systems," *PNAS Sci. USA* 98:9742-9747 (2001).
- Carninci, et al., "The transcriptional landscape of the mammalian genome," *Science* 309:1559-1563 (2005).
- Carulli, et al., "High Throughput Analysis of Differential Gene Expression," *J. Cell Biochem. Suppl.*, 3:286-296 (1998).
- Celis, et al., "Gene expression profiling: monitoring transcription and translation products using DNA microarrays and proteomics," *FEBS Lett.*, 480:2-16 (2000).
- Chabala, J.C., "Solid-phase combinatorial chemistry and novel tagging methods for identifying leads," *Curr Opin Biotechnol.* 6:632-639 (1995).
- Cech, J., "Ribozymes and Their Medical Implications," *American Med Assoc.* 260:3030-3035 (1988).
- Chen, et al., "Expression of ssDNA in Mammalian Cells," *BioTechniques* 34:167-171 (2003).
- Chen, et al., "Analogous Organic Synthesis of Small-Compound Libraries: Validation of Combinatorial Chemistry in Small-Molecule Synthesis," *J. Amer. Chem. Soc.* 116:2661-2662 (1994).
- Cheng, J. et al., "Transcriptional maps of 10 human chromosomes at 5-nucleotide resolution," *Science* 308:5725:1149-1154 (2005).
- Cho, et al., "An Unnatural Biopolymer," *Science* 261:1303-1305 (1993).
- Christensen N. K. et al., "A Novel Class of Oligonucleotide Analogues Containing 2'-O,3'-C-Linked [3.2.0]Bicycloarabinucleoside Monomers: Synthesis, Thermal Affinity Studies, and Molecular Modeling," *J. Am. Chem. Soc.*, 120:5458-5463 (1998).
- Cubitt, et al., "Understanding, improving and using green fluorescent proteins," *Trends in Biochemical Science* 20:448-455 (1995).
- Curiel, D. T. et al., "Adenovirus enhancement of transferrin-polylysine-mediated gene delivery," *PNAS* 88:8850-8854 (1991).
- Dai et al., "SIRT1 Interacts With p73 and Suppresses p73-Dependent Transcriptional Activity," *J Cell Physiol* 210(1):161-165 (2007).
- Davidson, et al., "A model system for in vivo gene transfer into the central nervous system using an adenoviral vector," *Nat. Genet* 3:219-223 (1993).
- Davis, et al., "Direct Gene Transfer into Skeletal Muscle In Vivo: Factors Affecting Efficiency of Transfer and Stability of Expression," *Hum Gene Ther* 4:151-159 (1993).
- De Mesmaeker, et al., "Antisense Oligonucleotides," *Acc. Chem. Res.* 28:366-374 (1995).
- Deng et al., "Small Interfering RNA Targeting the PINK1 Induces Apoptosis in Dopaminergic Cells SH-SY5Y," *Biochemical and Biophysical Research Communications*, vol. 337, No. 4, pp. 1133-1138 (2005).
- Dixon, et al., "Anthrax," *New England J. Med.* 341:815-826 (1999).
- Dolle, "Discovery of Enzyme inhibitors through combinatorial chemistry," *Mol Divers.* 2:223-236 (1997).
- Dykxhoorn, D. et al., "Determinants of Specific RNA Interference-Mediated Silencing of Human  $\beta$ -Globin Alleles Differing by a Single Nucleotide Polymorphism," *PNAS*, vol. 103, No. 15, pp. 5953-5958, (2006).
- Eguchi, et al., "Antisense RNA," *Annu. Rev. Biochem* 60:631-652 (1991).
- Eichler, et al., "Generation and utilization of synthetic combinatorial libraries," *Mol Med Today* 1:174-180 (1995).
- Eichler, et al., "Peptide Peptidomimetic and organic synthetic combinatorial libraries," *Med Res Rev* 15:481-496 (1995).
- Espeseth, et al., "A genome wide analysis of ubiquitin ligases in APP processing identifies a novel regulator of BACE1 mRNA levels," *Mol. Cell Neurosci.* 33: 227-235 (2006).
- Faghihi, M. & Wahlestedt, C., "RNA interference is not involved in natural antisense mediated regulation of gene expression in mammals," *Genome Biol* (2005).
- Fauchere, et al., "Peptide and nonpeptide lead discovery using robotically synthesized soluble libraries," *Can J. Physiol Pharmacol.* 75:683-689 (1997).
- Felgner and Holm, "Cationic Liposome-Mediated Transfection," *Bethesda Res. Lab Focus*, 11:2:21 (1989).
- Fields, et al., "How many genes in the human genome?" *Nature Genetics* 7:345-346 (1994).
- Freier & Altman, "The ups and downs of nucleic acid duplex stability: structure-stability studies on chemically-modified DNA:RNA duplexes," *Nucl. Acid Res.*, 25:22:4429-4443(1997).

(56)

## References Cited

## OTHER PUBLICATIONS

- Fuchs, et al., "Identification of Differentially Expressed Genes by Mutually Subtracted RNA Fingerprinting," *Anal. Biochem.*, 286:91-98 (2000).
- Gebeyehu, G., et al., "Novel biotinylated nucleotide-analogs for labeling and colorimetric detection of DNA," *Nucl. Acids Res.* 15:4513 (1987).
- Geller, A.I. et al., "An HSV-1 Vector Expressing Tyrosine Hydroxylase Causes Production and Release of L-DOPA from Cultured Rat Striatal Cells," *J. Neurochem* 64:487-496 (1995).
- Geller, A.I. et al., "Long-term increases in neurotransmitter release from neuronal cells expressing a constitutively active adenylate cyclase from a herpes simplex virus type 1 vector," *PNAS U.S.A.* :90:7603-7607 (1993).
- Geller, A.I., et al., "Infection of cultured central nervous system neurons with a defective herpes simplex virus 1 vector results in stable expression of *Escherichia coli*  $\beta$ -galactosidase," *PNAS USA* 87:1149-1153 (1990).
- GenBank Accession No. NM\_000559, Homo Sapiens Hemoglobin, Gamma A (HBG1), mRNA, (2008).
- Giuliano, et al., "FLuorescent Protein Biosensors: Measurement of Molecular Dynamics in Living Cells," *Ann. Rev. of Biophysics and Biomolecular Structure*, 24:405-434 (1995).
- Giuliano, et al., "Light-Optical-Based Reagents for the Measurement and Manipulation of Ions, Metabolites, and Macromolecules in Living Cells," *Methods in Neuroscience* 27:1-16 (1995).
- Giuliano, et al., "Determination of Intracellular pH of BALB/c-3T3 Cells Using the Fluorescence of Pyranine," *Anal. Biochem* 167:362-371 (1987).
- Going & Gusterson, "Molecular Pathology and Future Developments," *Eur. J. Cancer*, 35:1895-1904 (1999).
- Hagihara, et al., "Vinyllogous Polypeptides: An Alternate Peptide Backbone," *J. Amer. Chem. Soc.* 114:6568-6571 (1992).
- Haussecker, D., et al., "Dicer-Dependent Turnover of Intergenic from the Human  $\beta$ -Globin Gene Cluster," *Molecular and Cellular Biology*, vol. 25, No. 21, pp. 9724-9793, (2005).
- Heller, et al., "Discovery and Analysis of Inflammatory Disease-Related Genes Using cDNA Microarrays," *PNAS U.S.A.* 94:2150-2155 (1997).
- Herdewun P., "Heterocyclic Modifications of Oligonucleotides and Antisense Technology," *Antisense & Nucleic Acid Drug Dev.*, 10:297-310 (2000).
- Hirschmann, et al., *J. Amer. Chem. Soc.*, 114:9217-9218 (1992).
- Hobbs-DeWitt, et al., "Diversomers: An approach to nonpeptide, nonoligomeric chemical diversity," *Proc. Nat. Acad. Sci USA* 90:6909-6913 (1993).
- Houghton AN, Gold JS, Blachere NS, Immunity against cancer: lessons learned from melanoma., *Curr Opin Immunol* 13:134-140 (2001).
- International Human Genome Sequencing Consortium "Finishing the deuchromatic sequence of the human genome," *Nature* 431:7011:931-945 (2004).
- Janda, K.D. "Tagged versus untagged libraries: Methods for the generation and screening of combinatorial chemical libraries," *PNAS* 91:1079-10785 (1994).
- Janowski, et al., "Inhibiting gene expression at transcription start sites in chromosomal DNA with antigene RNAs," *Nature Chemical Biology*, 1(4):216-222 (2005).
- Jungblut, et al., "Proteomics in human disease: Cancer, heart and infectious diseases," *Electrophoresis* 20:2100-2110 (1999).
- Jurecic & Belmont, "Long-distance DD-PCR and cDNA microarrays," *Curr. Opin. Microbiol.*, 3:316-321 (2008).
- Kabanov, et al., "A new class of antivirals: antisense oligonucleotides combined with a hydrophobic substituent effectively inhibit influenza virus reproduction and synthesis of virus-specific proteins in MDCK cells," *FEBS Lett.* 259:327-330 (1990).
- Kaplit, M.G., et al., "Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain," *Nat. Genet.* 8:148-154 (1994).
- Kapranov, P. et al., "Examples of the complex architecture of the human transcriptome revealed by RACE and high-density tiling arrays," *Genome Res* 15:7:987-997 (2005).
- Katayama, S. et al., "Antisense Transcription in the Mammalian Transcriptome," *Science* 309:1564-1566 (2005).
- Kawahara & Nishikura, "Extensive adenosine-to-inosine editing detected in Alu repeats of antisense RNAs reveals scarcity of sense-antisense duplex formation," *FEBS Lett* 580:2301-2305 (2006).
- Kay, et al., "Identification or enzyme inhibitors from phage-displayed combinatorial peptide libraries," *Comb Chem High Throughput Screen* 4:535-543 (2001).
- Kenan, et al., "Exploring molecular diversity with combinatorial shape libraries," *Trends Biochem Sci* 19:57-64 (1994).
- Kornberg, A., *DNA Replication*, W.H. Freeman & Co., San Francisco, pp. 75-77, (1980).
- Larson, et al., "Rapid DNA Fingerprinting of Pathogens by Flow Cytometry," *Cytometry*, 2000, 41:203-208 (2000).
- Larsson, et al., "High-Throughput Protein Expression of cDNA Products as a Tool in Functional Genomics," *J. Biotechnology*, 80:143-157 (2000).
- Lebl, et al., "One-bead-one-structure combinatorial libraries," *Biopolymers* 37:177-198 (1995).
- LeGal Lasalle et al., "An Adenovirus Vector for Gene Transfer into Neurons and Glia in teh Brain," *Science* 259:988-990 (1993).
- Letsinger, et al., "Cholesteryl-conjugated oligonucleotides: Synthesis, Properties, and Activity as Inhibitors of Replication of Human Immunodeficiency Virus in Cell Culture," *PNAS* 86:6553-6556 (1989).
- Li et al., "Control of APP processing and A $\beta$  generation level by BACE1 enzymatic activity and transcription," *Faseb J* 20; 285-292 (2006).
- Li, et al., *J. Neurochem* 89 1308-1312 (2004).
- Liang, et al., "Parallel Synthesis and Screening of a Solid Phase Carbohydrate Library," *Science* 274:1520-1522 (1990).
- Luther, "Role of endogenous antisense RNA in cardiac gene regulation," *J. Mol. Med.* 83:26-32 (2005).
- Madden, et al., "Serial analysis of gene expression: from gene discovery to target identification," *Drug Discov. Today* 5:415-425 (2000).
- Makalowska I, Lin CF, Makalowski W., "Overlapping genes in vertebrate genomes," *Comput Biol. Chem* 29:1:1-12 (2005).
- Mannino and Gould-Fogerite, "Liposome Mediated Gene Transfer," *BioTechniques* 6:682-690 (1988).
- Manoharan et al., "Lipidic Nucleic Acids," *Tetrahedron Lett* 36 3651-3654 (1995).
- Manoharan, et al., "Chemical Modificatons to Improve Uptake and Bioavailability of Antisense Oligonucleotides," *Ann. N.Y. Acad. Scie* 660:306-309 (1992).
- Manoharan, et al., "Introduction of a Lipophilic Thioether in teh Minor Groove of Nucleic Acids for Antisense Applications," *Bioorg. Med. Chem. Let* 3:2765-2770 (1993).
- Manoharan, et al., "Cholic Acid-Oligonucleotide Conjugates for Antisense Applications," *Bioorg. Med. Chem. Let* 4:1053 (1994).
- Manoharan, et al., "Oligonucleotide Conjugates: Alteration of the Pharmacokinetic Properties of Antisense Agents," *Nucleosides & Nucleotides* 14:969-973 (1995).
- Manoharan, M., "2'-Carbohydrate modifications in antisense of oligonucleotide therapy: importance of conformation, configuration, and conjugation," *Biochemica et Biophysica Acta* 1489:117-139 (1999).
- Mattick, J. S. "RNA regulation: a new genetics?" *Nat. Rev. Genet* 5:4:316-323 (2004).
- Maurer, R.A., "Cationic Liposome-Mediated Transfection of Primary Cultures of Rat Pituitary Cells," *Bethesda Res. Lab. Focus* 11:2:25 (1989).
- McNeil in *Methods in Cell Biology* Vol 29, Taylor and Wang (eds.) p. 153-173 (1989).
- Morelli et al., "The antisense *bel-2-IgH* transcript is an optimal target for synthetic oligonucleotides," *PNAS USA* 94:8150-8155 (1997).
- Nielsen, et al., "Sequence-Selective Recognition of DNA by Strand Displacement with a Thymine-Substituted Polyamide," *Science* 254:1497-1500 (1991).

(56)

## References Cited

## OTHER PUBLICATIONS

- Oberhauser, et al., "Effective incorporation of 2'-O-methyl-oligoribonucleotides into liposomes and enhanced cell association through modification with thiocholesterol," *Nucl. Acids Res.* 20:333-538 (1992).
- Petit et al., "Wild-type Pink 1 Prevents Basal and Induced Neuronal Apoptosis, a Protective Effect Abrogated by Parkinson Disease-Related Mutations", *Journ. Biol. Chem.*, vol. 280, No. 40, pp. 34025-334032 (2005).
- Prasanth, et al., "Regulating Gene Expression through RNA Nuclear Retention," *Cell* 123, 249-263 (2005).
- Prashar & Weissman, "READS: A Method for Display of 3'-End Fragments of Restriction Enzyme-Digested cDNAs for Analysis of Differential Gene Expression," *Methods Enzymol.*, 303:238-272 (1999).
- Quantin, et al., "Adenovirus as an expression vector in muscle cells in vivo," *PNAS* 89:2581-2584 (1992).
- Rosenfeld, et al., "In Vivo Transfer of the Human Cystic Fibrosis Transmembrane Conductance Regulator Gene to the Airway Epithelium," *Cell*, 68:143-155 (1992).
- Rosok and Sioud, "Systematic identification of sense-antisense transcripts in mammalian cells," *Nature Biotech.* 22(1):104-108 (2004).
- Saison-Behmoaras, et al., "Short modified antisense oligonucleotides directed against Ha-ras point mutation induce selective cleavage of the mRNA and inhibit T24 cells proliferation," *EMBO J.* 10:1111-1118 (1991).
- Sanghvi, Y.S., in Crooke, S.T. And Lebleu, B., eds., *Antisense Research and Applications*, CRC Press, Boca Raton, 1993, p. 276-278.
- Scheele et al., "The Human PINK1 Locus is Regulated and Vivo by a Non-Coding Natural Antisense RNA During Modulation of Mitochondrial Function", *BMC Genomics*, vol. 8, No. 1 p. 74 (2007).
- Schena, et al., "Parallel human genome analysis: Microarray-based expression monitoring of 1000 genes," *PNAS* 93:10614-10619 (1996).
- Shea, et al., "Synthesis, hybridization properties and antiviral activity of lipid-oligodeoxynucleotide conjugates," *Nucl. Acids Res* 18:3777-3783 (1990).
- Shen, T., et al., "Modification of Globin Gene Expression by RNA Targeting Strategies," *Experimental Hematology*, vol. 35, No. 8, pp. 1209-1218 (2007).
- Shimomura, et al., "Semi-synthetic aequorin," *J. of Biochemistry (Tokyo)* 251:405-410 (1988).
- Singer, et al., "Targeting BACE1 with siRNAs ameliorates Alzheimer disease neuropathology in a transgenic model," *Nat Neurosci* 8:1343-1349 (2005).
- Southwick, et al., "Cyanine Dye Labeling Reagents-Carboxymethylindocyanine Succinimidyl Esters," *Cytometry* 11:418-430 (1990).
- Stratford-Perricadot, et al., "Widespread Long-term Gene Transfer to Mouse Skeletal Muscles and Heart," *J. Clin. Invest.*, 90:626-630 (1992).
- Sullenger, et al., "Overexpression of TAR sequences Renders Cells Resistant to Human Immunodeficiency Virus Replication," *Cell* 63:601-608 (1990).
- Sun, et al., "Downregulation of Sirt1 by antisense oligonucleotides induces apoptosis and enhances radiation sensitization in A549 lung cancer cells," *Lung Cancer* 58(1):21-29 (2007).
- Sutcliffe, et al., "TOGA: An automated parsing technology for analyzing expression of nearly all genes," *PNAS*, 97:1976-1981 (2000).
- Sutton, et al., "TIGR Assembler: A New Tool for Assembling Large Shotgun Sequencing Projects," *Genome Science & Tech.*, 1:9-19 (1995).
- Svinarchuk, et al., "Inhibition of HIV proliferation in MT-4 cells by antisense Oligonucleotide conjugated to lipophilic groups," *Biochimie* 75:49-54 (1993).
- Tamagno, et al., "The various aggregation states of  $\beta$ -amyloid 1-42 mediate different effects on oxidative stress, neurodegeneration, and BACE-1 expression," *Free Radic Biol Med* 41:202-212 (2006).
- Thakker, D.R., et al., "siRNA-mediated knockdown of the serotonin transporter in the adult mouse brain," *Mol Psychiatry* 10:782-789 (2005).
- Thakker, et al., "Neurochemical and behavioral consequences of widespread gene knockdown in the adult mouse brain by using nonviral RNA interference," *PNAS* 101:17270-17275 (2004).
- Thomas et al., "Intracellular pH Measurements in Ehrlich Ascites Tumor Cells Utilizing Spectroscopic Probes Generated in Situ," *Biochemistry* 18:2210-2218 (1979).
- Thompson, et al., "Synthesis and Applications of Small Molecule Libraries" *Chem Rev* 96:555-600 (1996).
- To, K.Y., "Identification of Differential Gene Expression by High Throughput Analysis," *Comb. Chem. High Throughput Screen* 3:235-241 (2000).
- Tong, et al., "Oxidative stress potentiates BACE1 gene expression," *Neural Transm* 112, 455-469 (2005).
- Toulme, J.J., "New candidates for true antisense," *Nature Biotechnology* 19:17-18 (2001).
- Tsien in *Methods in Cell Biology* vol. 30 Taylor and Wang (eds) p. 127-156 (1989).
- Uhlman, E., "Recent advances in the medical chemistry of antisense oligonucleotide," *Current Opinions in Drug Discovery & Development* 3:203-213 (2000).
- Van Den Eynde BJ, "T cell defined tumor antigens," *Curr Opin Immunol* 9:684-693 (1997).
- Van Der Bruggen, et al., "Tumor-specific shared antigenic peptides recognized by human T cells," *Immunol Rev* 188:51-64 (2002).
- Vanhee-Brossolet and Vaguero, "Do natural antisense transcripts make sense in eukaryotes?" *Gene* 211:1-9 (1998).
- Vaughn et al., "Human Antibodies with Sub-nanomolar Affinities Isolated from a Large Non-immunized Phage Display Library," *Nature Biotechnology*, 14:3:309-314 (1996).
- Velculescu, et al., "Serial Analysis of Gene Expression," *Science* 270:484-487 (1995).
- Wahlestedt, "Natural antisense and noncoding RNA transcripts as potential drug targets," *Drug Discovery Today* 11 (11/12):503-508 (2006).
- Wahlestedt, C., "Antisense oligonucleotide strategies in neuropharmacology," *Trends Pharmacol Sci* 15:2:42-46 (1994).
- Walsh, et al., "The role of cell-derived oligomers of A $\beta$  in Alzheimer's disease and avenues for therapeutic intervention," *Biochem Soc Trans* 33: 1087-1090 (2005).
- Wang, B.B, et al., "Identification of a nuclear-specific cyclophilin which interacts with the proteinase inhibitor eglin c," *Biochem J*, 314 (Pt 1) 313-319 (1996).
- Wiesenhof, et al., "Glial cell line-derived neurotrophic factor (GDNF) is a proliferation factor for rat C6 glioma cells: evidence from antisense experiments," *Antisense & Nucleic Acid Drug Development* 10(5):311-321 (2000).
- Xue, et al., "Hypoxia and reoxygenation increased BACE1 mRNA and protein levels in human neuroblastoma SH-SY5Y cells," *Neurosci Lett* 405,231-235 (2006).
- Yamada, et al., "Endothelial Nitric-Oxide Synthase Antisense (NOS3AS) Gene Encodes an Autophagy-Related Protein (APG9-like2) Highly Expressed in Trophoblast" (2005).
- Yang, et al., "Cellular and Humoral Immune Responses to Viral Antigens Create Barriers to Lung-Directed Gene Therapy with Recombinant Adenoviruses," *J. Virol* 69:2004-2015 (1995).
- Yoshiagi, et al., "Characterization of Natural Antisense Transcripts Expressed from Interleukin 1 $\beta$ -inducible Genes in Rat Hepatocytes," *HOAJ Biology*; 1-10 (2012).
- EP Application No. 06850393.7 Examination Report dated Oct. 18, 2011.
- International Search Report and Written Opinion for PCT Application No. PCT/US2010/033078 mailed Jun. 29, 2011.
- PCT/US2010/026119 Search Report and Written Opinion mailed Feb. 7, 2011.
- PCT/US2010/024079 Search Report and Written Opinion mailed Jan. 31, 2011.
- PCT/US2010/027394 Search Report and Written Opinion mailed Nov. 5, 2010.
- PCT/US96/10287 (WO97/000271) The Regents of the University of California Jan. 3, 1997.

\* cited by examiner

Figure 1




Figure 2




Figure 3






Figure 4





Figure 5



1

# **TREATMENT OF PANCREATIC DEVELOPMENTAL GENE RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO A PANCREATIC DEVELOPMENTAL GENE**

The present application claims the priority of U.S. provisional patent application 61/292,508 filed Jan. 6, 2010; U.S. provisional patent application No. 61/294,129 filed Jan. 12, 2010; U.S. provisional patent application No. 61/297,847 filed Jan. 25, 2010; U.S. provisional patent application No. 61/297,863 filed Jan. 25, 2010; U.S. provisional patent application No. 61/323,027 filed Apr. 12, 2010 and which are incorporated herein by reference in their entirety.

## **FIELD OF THE INVENTION**

Embodiments of the invention comprise oligonucleotides modulating expression and/or function of a Pancreatic Developmental gene and associated molecules.

## **BACKGROUND**

DNA-RNA and RNA-RNA hybridization are important to many aspects of nucleic acid function including DNA replication, transcription, and translation. Hybridization is also central to a variety of technologies that either detect a particular nucleic acid or alter its expression. Antisense nucleotides, for example, disrupt gene expression by hybridizing to target RNA, thereby interfering with RNA splicing, transcription, translation, and replication. Antisense DNA has the added feature that DNA-RNA hybrids serve as a substrate for digestion by ribonuclease H, an activity that is present in most cell types. Antisense molecules can be delivered into cells, as is the case for oligodeoxynucleotides (ODNs), or they can be expressed from endogenous genes as RNA molecules. The FDA recently approved an antisense drug, VITRAVENE™ (for treatment of cytomegalovirus retinitis), reflecting that antisense has therapeutic utility.

## **SUMMARY**

In one embodiment, the invention provides methods for inhibiting the action of a natural antisense transcript by using antisense oligonucleotide(s) targeted to any region of the natural antisense transcript resulting in up-regulation of the corresponding sense gene. It is also contemplated herein that inhibition of the natural antisense transcript can be achieved by siRNA, ribozymes and small molecules, which are considered to be within the scope of the present invention.

One embodiment provides a method of modulating function and/or expression of a Pancreatic Developmental gene polynucleotide in patient cells or tissues in vivo or in vitro comprising contacting said cells or tissues with an antisense oligonucleotide 5 to 30 nucleotides in length wherein said oligonucleotide has at least 50% sequence identity to a reverse complement of a polynucleotide comprising 5 to 30 consecutive nucleotides within nucleotides 1 to 1235 of SEQ ID NO: 6, 1 to 17,964 of SEQ ID NO: 7, 1 to 1 to 50,003 of SEQ ID NO: 8, 1 to 486 of SEQ ID NO: 9, 1 to 494 of SEQ ID NO: 10, 1 to 1992 of SEQ ID NO: 11, or 1 to 1767 of SEQ ID NO: 12 thereby modulating function and/or expression of the Pancreatic Developmental gene polynucleotide in patient cells or tissues in vivo or in vitro.

In another embodiment, an oligonucleotide targets a natural antisense sequence of a Pancreatic Developmental gene polynucleotide, for example, nucleotides set forth in SEQ ID

2

NO: 6 to 12, and any variants, alleles, homologs, mutants, derivatives, fragments and complementary sequences thereto. Examples of antisense oligonucleotides are set forth as SEQ ID NOS: 13 to 45.

Another embodiment provides a method of modulating function and/or expression of a Pancreatic Developmental gene polynucleotide in patient cells or tissues in vivo or in vitro comprising contacting said cells or tissues with an antisense oligonucleotide 5 to 30 nucleotides in length wherein said oligonucleotide has at least 50% sequence identity to a reverse component of the antisense of the Pancreatic Developmental gene polynucleotide; thereby modulating function and/or expression of the Pancreatic Developmental gene polynucleotide in patient cells or tissues in vivo or in vitro.

Another embodiment provides a method of modulating function and/or expression of a Pancreatic Developmental gene polynucleotide in patient cells or tissues in vivo or in vitro comprising contacting said cells or tissues with an antisense oligonucleotide 5 to 30 nucleotides in length wherein said oligonucleotide has at least 50% sequence identity to an antisense oligonucleotide to a Pancreatic Developmental gene antisense polynucleotide; thereby modulating function and/or expression of the Pancreatic Developmental gene polynucleotide in patient cells or tissues in vivo or in vitro.

In one embodiment, a composition comprises one or more antisense oligonucleotides which bind to sense and/or antisense Pancreatic Developmental gene polynucleotides.

In another embodiment, the oligonucleotides comprise one or more modified or substituted nucleotides.

In another embodiment, the oligonucleotides comprise one or more modified bonds.

In yet another embodiment, the modified nucleotides comprise modified bases comprising phosphorothioate, methylphosphonate, peptide nucleic acids, 2'-O-methyl, fluoro- or carbon, methylene or other locked nucleic acid (LNA) molecules. Preferably, the modified nucleotides are locked nucleic acid molecules, including  $\alpha$ -L-LNA.

In another embodiment, the oligonucleotides are administered to a patient subcutaneously, intramuscularly, intravenously or intraperitoneally.

In another embodiment, the oligonucleotides are administered in a pharmaceutical composition. A treatment regimen comprises administering the antisense compounds at least once to patient; however, this treatment can be modified to include multiple doses over a period of time. The treatment can be combined with one or more other types of therapies.

In another embodiment, the oligonucleotides are encapsulated in a liposome or attached to a carrier molecule (e.g. cholesterol, TAT peptide).

Other aspects are described infra.

## **BRIEF DESCRIPTION OF THE DRAWINGS**

FIG. 1 is a graph of real time PCR results showing die fold change+standard deviation in NEUROD1 mRNA after treatment of HepG2 cells with phosphorothioate oligonucleotides introduced using Lipofectamine 2000, as compared to control. Real time PCR results show that the levels of the NEUROD1 mRNA in HepG2 cells are significantly increased 48 h after treatment with one of the oligos designed to NEUROD1 antisense Steedo.aApr07. Bars denoted as CUR-1373, CUR-1374, CUR-1375 and CUR-1376 correspond to samples treated with SEQ ID NOS: 13 to 16 respectively.

FIG. 2 is a graph of real time PCR results showing the fold change+standard deviation in HNF4A mRNA after treatment of 518A2 cells with phosphorothioate oligonucleotides intro-

duced using Lipofectamine 2000, as compared to control. Bars denoted as CUR-1194, CUR-1195, CUR-1193, CUR-1192, CUR-191, CUR-1190, CUR-1188, CUR-1189, CUR-1187, CUR-1186, CUR-1182, CUR-1183, CUR-1185, CUR-1184, CUR-1181 correspond to samples treated with SEQ ID NOS: 17 to 31 respectively.

FIG. 3 is a graph of real time PCR results showing the fold change+standard deviation in MAFA mRNA after treatment of HepG2 cells with phosphorothioate oligonucleotides introduced using Lipofectamine 2000, as compared to control. Real time PCR results show that the levels of MAFA mRNA in HepG2 cells are significantly increased 48 h after treatment with one of the oligos designed to MAFA antisense BM127748. Bars denoted as CUR-1207, CUR-1209, CUR-1208, CUR-1210 and CUR-1211 correspond to samples treated with SEQ ID NOS: 32 to 36 respectively.

FIG. 4 is a graph of real time PCR results showing the fold change+standard deviation in PDX1 mRNA after treatment of HepG2 cells with phosphorothioate oligonucleotides introduced using Lipofectamine 2000, as compared to control. Real time PCR results show that the levels of PDX1 mRNA are significantly increased in HepG2 cells 48 h after treatment with two of the oligos designed to PDX1 antisense Hs.416201. Bars denoted as CUR-1388, CUR-1389, CUR-1390, CUR-1391 and CUR-1392 correspond to samples treated with SEQ ID NOS: 37 to 41 respectively.

FIG. 5 is a graph of real time PCR results showing the fold change+standard deviation in NKX6-1 mRNA after treatment of MCF-7 cells with phosphorothioate oligonucleotides introduced using Lipofectamine 2000, as compared to control. Bars denoted as CUR-1501 to CUR-1504 correspond to samples treated with SEQ ID NOS: 42 to 45 respectively.

#### SEQUENCE LISTING DESCRIPTION

SEQ ID NO: 1: *Homo sapiens* neurogenic differentiation 1 (NEUROD1), mRNA (NCBI Accession No.: NM\_002500). SEQ ID NO: 2: *Homo sapiens* hepatocyte nuclear factor 4, alpha (HNF4A), transcript variant 2, mRNA (NCBI Accession No.: NM\_000457). SEQ ID NO: 3: *Homo sapiens* v-maf musculoaponeurotic fibrosarcoma oncogene homolog A (avian) (MAFA), mRNA (NCBI Accession No.: NM\_201589). SEQ ID NO: 4: *Homo sapiens* pancreatic and duodenal homeobox 1 (PDX1), mRNA (NCBI Accession No.: NM\_000209). SEQ ID NO: 5: *Homo sapiens* NK6 homobox 1 (NKX6-1), mRNA, (NCBI Accession No.: NM\_006168). SEQ ID NOS: 6 to 12: SEQ ID NO: 6: Natural NEUROD1 antisense sequence (Steedo.aApr07); SEQ ID NO: 7: Natural HNF4A antisense sequence (AF143870); SEQ ID NO: 8: Natural HNF4A antisense sequence (BC071794). SEQ ID NO: 9: Natural HNF4A antisense sequence (BX099913); SEQ ID NO: 10: Natural MAFA antisense sequence (BM127748); SEQ ID NO: 11: Natural PDX1 antisense sequence (Hs.416201) and SEQ ID NO: 12: Natural NKX6-1 antisense sequence (torsnaby.aApr07-unspliced) SEQ ID NOS: 13 to 45; Antisense oligonucleotides, \* indicates phosphothioate bond.

#### DETAILED DESCRIPTION

Several aspects of the invention are described below with reference to example applications for illustration. It should be understood that numerous specific details, relationships, and methods are set forth to provide a full understanding of the invention. One having ordinary skill in the relevant art, however, will readily recognize that the invention can be practiced without one or more of the specific details or with other

methods. The present invention is not limited by the ordering of acts or events, as some acts may occur in different orders and/or concurrently with other acts or events. Furthermore, not all illustrated acts or events are required to implement a methodology in accordance with the present invention.

All genes, gene names, and gene products disclosed herein are intended to correspond to homologs from any species for which the compositions and methods disclosed herein are applicable. Thus, the terms include, but are not limited to genes and gene products from humans and mice. It is understood that when a gene or gene product from a particular species is disclosed, this disclosure is intended to be exemplary only, and is not to be interpreted as a limitation unless the context in which it appears clearly indicates. Thus, for example, for the genes disclosed herein, which in some embodiments relate to mammalian nucleic acid and amino acid sequences are intended to encompass homologous and/or orthologous genes and gene products from other animals including, but not limited to other mammals, fish, amphibians, reptiles, and birds. In embodiments, the genes or nucleic acid sequences are human.

#### Definitions

The terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention. As used herein, the singular forms “a”, “an” and “the” are intended to include the plural forms as well, unless the context clearly indicates otherwise. Furthermore, to the extent that the terms “including”, “includes”, “having”, “has”, “with”, or variants thereof are used in either the detailed description and/or the claims, such terms are intended to be inclusive in a manner similar to the term “comprising.”

The term “about” or “approximately” means within an acceptable error range for the particular value as determined by one of ordinary skill in the art, which will depend in part on how the value is measured or determined, i.e., the limitations of the measurement system. For example, “about” can mean within 1 or more than 1 standard deviation, per the practice in the art. Alternatively, “about” can mean a range of up to 20%, preferably up to 10%, more preferably up to 5%, and more preferably still up to 1% of a given value. Alternatively, particularly with respect to biological systems or processes, the term can mean within an order of magnitude, preferably within 5-fold, and more preferably within 2-fold, of a value. Where particular values are described in the application and claims, unless otherwise stated the term “about” meaning within an acceptable error range for the particular value should be assumed.

As used herein, the term “mRNA” means the presently known mRNA transcript(s) of a targeted gene, and any further transcripts which may be elucidated.

By “antisense oligonucleotides” or “antisense compound” is meant an RNA or DNA molecule that binds to another RNA or DNA (target RNA, DNA). For example, if it is an RNA oligonucleotide it binds to another RNA target by means of RNA-RNA interactions and alters the activity of the target RNA. An antisense oligonucleotide can upregulate or down-regulate expression and/or function of a particular polynucleotide. The definition is meant to include any foreign RNA or DNA molecule which is useful from a therapeutic, diagnostic, or other viewpoint. Such molecules include, for example, antisense RNA or DNA molecules, interference RNA (RNAi), micro RNA, decoy RNA molecules, siRNA, enzymatic RNA, therapeutic editing RNA, and agonist and antagonist RNA, antisense oligomeric compounds, antisense oligonucleotides external guide sequence (EGS) oligonucleotides, alternate splicers, primers, probes, and other oligo-

meric compounds that hybridize to at least a portion of the target nucleic acid. As such, these compounds may be introduced in the form of single-stranded, double-stranded, partially single-stranded, or circular oligomeric compounds.

In the context of this invention, the term “oligonucleotide” refers to an oligomer or polymer of ribonucleic acid (RNA) or deoxyribonucleic acid (DNA) or mimetics thereof. The term “oligonucleotide”, also includes linear or circular oligomers of natural and/or modified monomers or linkages, including deoxyribonucleosides, ribonucleosides, substituted and alpha-anomeric forms thereof, peptide nucleic acids (PNA), locked nucleic acids (LNA), phosphorothioate, methylphosphonate, and the like. Oligonucleotides are capable of specifically binding to a target polynucleotide by way of a regular pattern of monomer-to-monomer interactions, such as Watson-Crick type of base pairing, Hoogsteen or reverse Hoogsteen types of base pairing, or the like.

The oligonucleotide may be “chimeric”, that is, composed of different regions. In the context of this invention “chimeric” compounds are oligonucleotides, which contain two or more chemical regions, for example, DNA region(s), RNA region(s), PNA region(s) etc. Each chemical region is made up of at least one monomer unit, i.e., a nucleotide in the case of an oligonucleotides compound. These oligonucleotides typically comprise at least one region wherein the oligonucleotide is modified in order to exhibit one or more desired properties. The desired properties of the oligonucleotide include, but are not limited, for example, to increased resistance to nuclease degradation, increased cellular uptake, and/or increased binding affinity for the target nucleic acid. Different regions of the oligonucleotide may therefore have different properties. The chimeric oligonucleotides of the present invention can be formed as mixed structures of two or more oligonucleotides, modified oligonucleotides, oligonucleosides and/or oligonucleotide analogs as described above.

The oligonucleotide can be composed of regions that can be linked in “register” that is, when the monomers are linked consecutively, as in native DNA, or linked via spacers. The spacers are intended to constitute a covalent “bridge” between the regions and have in cases a length not exceeding about 100 carbon atoms. The spacers may carry different functionalities, for example, having positive or negative charge, carry special nucleic acid binding properties (intercalators, groove binders, toxins, fluorophors etc.), being lipophilic, inducing special secondary structures like, for example, alanine containing peptides that induce alpha-helices.

As used herein “Pancreatic Developmental genes” and “Pancreatic Developmental gene” are inclusive of all family members, mutants, alleles, fragments, species, coding and noncoding sequences, sense and antisense polynucleotide strands, etc.

As used herein, the words ‘Neurogenic differentiation 1’, ‘Neurogenic differentiation factor 1’, NEUROD1, BETA2, BHF-1, bHLHa3, NeuroD, NEUROD, NeuroD1, are considered the same in the literature and are used interchangeably in the present application.

As used herein, the words Hepatocyte nuclear factor 4, alpha; Hepatocyte nuclear factor 4.alpha.; HNF4.alpha.; HNF4A, HNF-4alpha, MODY, MODY1, NR2A1, NR2A21, TCF, TCF14, Transcription factor-14, APF, LFB1 and HP1 are considered the same in the literature and are used interchangeably in the present application.

As used herein, the words ‘v-maf musculoaponeurotic fibrosarcoma oncogene homolog A’, MAFA, hMafA, v-maf, mafA, Pancreatic beta-cell-specific transcriptional activator,

RIPE3b1, Transcription factor MafA, Transcription factor RIPE3b1, V-maf musculoaponeurotic fibrosarcoma oncogene homolog A (avian), are considered the same in the literature and are used interchangeably in the present application.

As used herein, the words ‘Pancreatic and duodenal homeobox 1’, PDX1, PDX-1, Glucose-sensitive factor, GSF, IDX-1, Insulin promoter factor 1, Insulin upstream factor 1, IPF1, IPF-1, Islet/duodenum homeobox-1, IUF1, IUF-1, MODY4, Pancreas/duodenum homeobox protein 1, Somatostatin-transactivating factor 1, STF-1 are considered the same in the literature and are used interchangeably in the present application.

As used herein, the words NK6 homeobox 1, NKX6-1, Homeobox protein NK-6 homolog A, Homeobox protein Nkx-6.1, Nkx6.1, NKX6.1 and NKX6A are considered the same in the literature and are used interchangeably in the present application.

As used herein, the term “oligonucleotide specific for” or “oligonucleotide which targets” refers to an oligonucleotide having a sequence (i) capable of forming a stable complex with a portion of the targeted gene, or (ii) capable of forming a stable duplex with a portion of a mRNA transcript of the targeted gene. Stability of the complexes and duplexes can be determined by theoretical calculations and/or in vitro assays. Exemplary assays for determining stability of hybridization complexes and duplexes are described in the Examples below.

As used herein, the term “target nucleic acid” encompasses DNA, RNA (comprising premRNA and mRNA) transcribed from such DNA, and also cDNA derived from such RNA, coding, noncoding sequences, sense or antisense polynucleotides. The specific hybridization of an oligomeric compound with its target nucleic acid interferes with the normal function of the nucleic acid. This modulation of function of a target nucleic acid by compounds, which specifically hybridize to it, is generally referred to as “antisense”. The functions of DNA to be interfered include, for example, replication and transcription. The functions of RNA to be interfered, include all vital functions such as, for example, translocation of the RNA to the site of protein translation, translation of protein from the RNA, splicing of the RNA to yield one or more mRNA species, and catalytic activity which may be engaged in or facilitated by the RNA. The overall effect of such interference with target nucleic acid function is modulation of the expression of an encoded product or oligonucleotides.

RNA interference “RNAi” is mediated by double stranded RNA (dsRNA) molecules that have sequence-specific homology to their “target” nucleic acid sequences. In certain embodiments of the present invention, the mediators are 5-25 nucleotide “small interfering” RNA duplexes (siRNAs). The siRNAs are derived from the processing of dsRNA by an RNase enzyme known as Dicer siRNA duplex products are recruited into a multi-protein siRNA complex termed RISC (RNA Induced Silencing Complex). Without wishing to be bound by any particular theory, a RISC is then believed to be guided to a target nucleic acid (suitably mRNA), where the siRNA duplex interacts in a sequence-specific way to mediate cleavage in a catalytic fashion. Small interfering RNAs that can be used in accordance with the present invention can be synthesized and used according to procedures that are well known in the art and that will be familiar to the ordinarily skilled artisan. Small interfering RNAs for use in the methods of the present invention suitably comprise between about 1 to about 50 nucleotides (nt). In examples of non limiting embodiments, siRNAs can comprise about 5 to about 40 nt,

about 5 to about 30 nt, about 10 to about 30 nt, about 15 to about 25 nt, or about 20-25 nucleotides.

Selection of appropriate oligonucleotides is facilitated by using computer programs that automatically align nucleic acid sequences and indicate regions of identity or homology. Such programs are used to compare nucleic acid sequences obtained, for example, by searching databases such as Genbank or by sequencing PCR products. Comparison of nucleic acid sequences from a range of species allows the selection of nucleic acid sequences that display an appropriate degree of identity between species. In the case of genes that have not been sequenced, Southern blots are performed to allow a determination of the degree of identity between genes in target species and other species. By performing Southern blots at varying degrees of stringency, as is well known in the art, it is possible to obtain an approximate measure of identity. These procedures allow the selection of oligonucleotides that exhibit a high degree of complementarity to target nucleic acid sequences in a subject to be controlled and a lower degree of complementarity to corresponding nucleic acid sequences in other species. One skilled in the art will realize that there is considerable latitude in selecting appropriate regions of genes for use in the present invention.

By "enzymatic RNA" is meant an RNA molecule with enzymatic activity. Enzymatic nucleic acids (ribozymes) act by first binding to a target RNA. Such binding occurs through the target binding portion of an enzymatic nucleic acid which is held in close proximity to an enzymatic portion of the molecule that acts to cleave the target RNA. Thus, the enzymatic nucleic acid first recognizes and then binds a target RNA through base pairing, and once bound to the correct site, acts enzymatically to cut the target RNA.

By "decoy RNA" is meant an RNA molecule that mimics the natural binding domain for a ligand. The decoy RNA therefore competes with natural binding target for the binding of a specific ligand. For example, it has been shown that over-expression of HIV trans-activation response (TAR) RNA can act as a "decoy" and efficiently binds HIV tat protein, thereby preventing it from binding to TAR sequences encoded in the HIV RNA. This is meant to be a specific example. Those in the art will recognize that this is but one example, and other embodiments can be readily generated using techniques generally known in the art.

As used herein, the term "monomers" typically indicates monomers linked by phosphodiester bonds or analogs thereof to form oligonucleotides ranging in size from a few monomeric units, e.g., from about 3-4, to about several hundreds of monomeric units. Analogs of phosphodiester linkages include: phosphorothioate, phosphorodithioate, methylphosphonates, phosphoroselenoate, phosphoramidate, and the like, as more fully described below.

The term "nucleotide" covers naturally occurring nucleotides as well as nonnaturally occurring nucleotides. It should be clear to the person skilled in the art that various nucleotides which previously have been considered "non-naturally occurring" have subsequently been found in nature. Thus, "nucleotides" includes not only the known purine and pyrimidine heterocycles-containing molecules, but also heterocyclic analogues and tautomers thereof. Illustrative examples of other types of nucleotides are molecules containing adenine, guanine, thymine, cytosine, uracil, purine, xanthine, diaminopurine, 8-oxo-N6-methyladenine, 7-deazaxanthine, 7-deazaguanine, N4,N4-ethanocytosine, N6,N6-ethano-2,6-diaminopurine, 5-methylcytosine, 5-(C3-C6)-alkynylcytosine, 5-fluorouracil, 5-bromouracil, pseudoisocytosine, 2-hydroxy-5-methyl-4-triazolopyridin, isocytosine, isoguanin, inosine and the "non-naturally occurring" nucleotides

described in U.S. Pat. No. 5,432,272. The term "nucleotide" is intended to cover every and all of these examples as well as analogues and tautomers thereof. Especially interesting nucleotides are those containing adenine, guanine, thymine, cytosine, and uracil, which are considered as the naturally occurring nucleotides in relation to therapeutic and diagnostic application in humans. Nucleotides include the natural 2'-deoxy and 2'-hydroxyl sugars, e.g., as described in Kornberg and Baker, *DNA Replication*, 2nd Ed. (Freeman, San Francisco, 1992) as well as their analogs.

"Analog" in reference to nucleotides includes synthetic nucleotides having modified base moieties and/or modified sugar moieties. Such analogs include synthetic nucleotides designed to enhance binding properties, e.g., duplex or triplex stability, specificity, or the like.

As used herein, "hybridization" means the pairing of substantially complementary strands of oligomeric compounds. One mechanism of pairing involves hydrogen bonding, which may be Watson-Crick, Hoogsteen or reversed Hoogsteen hydrogen bonding, between complementary nucleoside or nucleotide bases (nucleotides) of the strands of oligomeric compounds. For example, adenine and thymine are complementary nucleotides which pair through the formation of hydrogen bonds. Hybridization can occur under varying circumstances.

An antisense compound is "specifically hybridizable" when binding of the compound to the target nucleic acid interferes with the normal function of the target nucleic acid to cause a modulation of function and/or activity, and there is a sufficient degree of complementarity to avoid non-specific binding of the antisense compound to non-target nucleic acid sequences under conditions in which specific binding is desired, i.e., under physiological conditions in the case of in vivo assays or therapeutic treatment, and under conditions in which assays are performed in the case of in vitro assays.

As used herein, the phrase "string nt hybridization conditions" or "stringent conditions" refers to conditions under which a compound of the invention will hybridize to its target sequence, but to a minimal number of other sequences. Stringent conditions are sequence-dependent and will be different in different circumstances and in the context of this invention, "stringent conditions" under which oligomeric compounds hybridize to a target sequence are determined by the nature and composition of the oligomeric compounds and the assays in which they are being investigated. In general, stringent hybridization conditions comprise low concentrations (<0.15M) of salts with inorganic cations such as Na<sup>++</sup> or K<sup>++</sup> (i.e., low ionic strength), temperature higher than 20° C.-25° C. below the T<sub>m</sub> of the oligomeric compound target sequence complex, and the presence of denaturants such as formamide, dimethylformamide, dimethyl sulfoxide, or the detergent sodium dodecyl sulfate (SDS). For example, the hybridization rate decreases 1.1% for each 1% formamide. An example of a high stringency hybridization condition is 0.1× sodium chloride-sodium citrate buffer (SSC)/0.1% (w/v) SDS at 60° C. for 30 minutes.

"Complementary," as used herein, refers to the capacity for precise pairing between two nucleotides on one or two oligomeric strands. For example, if a nucleobase at a certain position of an antisense compound is capable of hydrogen bonding with a nucleobase at a certain position of a target nucleic acid, said target nucleic acid being a DNA, RNA, or oligonucleotide molecule, then the position of hydrogen bonding between the oligonucleotide and the target nucleic acid is considered to be a complementary position. The oligomeric compound and the further DNA, RNA, or oligonucleotide molecule are complementary to each other when a sufficient

number of complementary positions in each molecule are occupied by nucleotides which can hydrogen bond with each other. Thus, "specifically hybridizable" and "complementary" are terms which are used to indicate a sufficient degree of precise pairing or complementarity over a sufficient number of nucleotides such that stable and specific binding occurs between the oligomeric compound and a target nucleic acid.

It is understood in the art that the sequence of an oligomeric compound need not be 100% complementary to that of its target nucleic acid to be specifically hybridizable. Moreover, an oligonucleotide may hybridize over one or more segments such that intervening or adjacent segments are not involved in the hybridization event (e.g., a loop structure, mismatch or hairpin structure). The oligomeric compounds of the present invention comprise at least about 70%, or at least about 75%, or at least about 80%, or at least about 85%, or at least about 90%, or at least about 95%, or at least about 99% sequence complementarity to a target region within the target nucleic acid sequence to which they are targeted. For example, an antisense compound in which 18 of 20 nucleotides of the antisense compound are complementary to a target region, and would therefore specifically hybridize, would represent 90 percent complementarity. In this example, the remaining noncomplementary nucleotides may be clustered or interspersed with complementary nucleotides and need not be contiguous to each other or to complementary nucleotides. As such, an antisense compound which is 18 nucleotides in length having 4 (four) noncomplementary nucleotides which are flanked by two regions of complete complementarity with the target nucleic acid would have 77.8% overall complementarity with the target nucleic acid and would thus fall within the scope of the present invention. Percent complementarity of an antisense compound with a region of a target nucleic acid can be determined routinely using BLAST programs (basic local alignment search tools) and PowerBLAST programs known in the art. Percent homology, sequence identity or complementarity, can be determined by, for example, the Gap program (Wisconsin Sequence Analysis Package, Version 8 for Unix, Genetics Computer Group, University Research Park, Madison Wis.), using default settings, which uses the algorithm of Smith and Waterman (*Adv. Appl. Math.*, (1981) 2, 482-489).

As used herein, the term "Thermal Melting Point (T<sub>m</sub>)" refers to the temperature, under defined ionic strength, pH, and nucleic acid concentration, at which 50% of the oligonucleotides complementary to the target sequence hybridize to the target sequence at equilibrium. Typically, stringent conditions will be those in which the salt concentration is at least about 0.01 to 1.0 M Na ion concentration (or other salts) at pH 7.0 to 8.3 and the temperature is at least about 30° C. for short oligonucleotides (e.g., 10 to 50 nucleotide). Stringent conditions may also be achieved with the addition of destabilizing agents such as formamide.

As used herein, "modulation" means either an increase (stimulation) or a decrease (inhibition) in the expression of a gene.

The term "variant," when used in the context of a polynucleotide sequence, may encompass a polynucleotide sequence related to a wild type gene. This definition may also include, for example, "allelic," "splice," "species," or "polymorphic" variants. A splice variant may have significant identity to a reference molecule, but will generally have a greater or lesser number of polynucleotides due to alternate splicing of exons during mRNA processing. The corresponding polypeptide may possess additional functional domains or an absence of domains. Species variants are polynucleotide sequences that vary from one species to another. Of particular

utility in the invention are variants of wild type gene products. Variants may result from at least one mutation in the nucleic acid sequence and may result in altered mRNAs or in polypeptides whose structure or function may or may not be altered. Any given natural or recombinant gene may have none, one, or many allelic forms. Common mutational changes that give rise to variants are generally ascribed to natural deletions, additions, or substitutions of nucleotides. Each of these types of changes may occur alone, or in combination with the others, one or more times in a given sequence.

The resulting polypeptides generally will have significant amino acid identity relative to each other. A polymorphic variant is a variation in the polynucleotide sequence of a particular gene between individuals of a given species. Polymorphic variants also may encompass "single nucleotide polymorphisms" (SNPs) or single base mutations in which the polynucleotide sequence varies by one base. The presence of SNPs may be indicative of, for example, a certain population with a propensity for a disease state, that is susceptibility versus resistance.

Derivative polynucleotides include nucleic acids subjected to chemical modification, for example, replacement of hydrogen by an alkyl, acyl, or amino group. Derivatives, e.g., derivative oligonucleotides, may comprise non-naturally-occurring portions, such as altered sugar moieties or inter-sugar linkages. Exemplary among these are phosphorothioate and other sulfur containing species which are known in the art. Derivative nucleic acids may also contain labels, including radionucleotides, enzymes, fluorescent agents, chemiluminescent agents, chromogenic agents, substrates, cofactors, inhibitors, magnetic particles and the like.

A "derivative" polypeptide or peptide is one that is modified, for example, by glycosylation, pegylation, phosphorylation, sulfation, reduction/alkylation, acylation, chemical coupling, or mild formalin treatment. A derivative may also be modified to contain a detectable label, either directly or indirectly, including, but not limited to, a radioisotope, fluorescent, and enzyme label.

As used herein, the term "animal" or "patient" is meant to include, for example, humans, sheep, elks, deer, mule deer, minks, mammals, monkeys, horses, cattle pigs, goats, dogs, cats, rats, mice, birds, chicken, reptiles, fish, insects and arachnids.

"Mammal" covers warm blooded mammals that are typically under medical care (e.g., humans and domesticated animals). Examples include feline, canine, equine, bovine, and human, as well as just human.

"Treating" or "treatment" covers the treatment of a disease-state in a mammal, and includes: (a) preventing the disease-state from occurring in a mammal, in particular, when such mammal is predisposed to the disease-state but has not yet been diagnosed as having it; (b) inhibiting the disease-state, e.g., arresting its development; and/or (c) relieving the disease-state, e.g., causing regression of the disease state until a desired endpoint is reached. Treating also includes the amelioration of a symptom of a disease (e.g., lessen the pain or discomfort), wherein such amelioration may or may not be directly affecting the disease (e.g., cause, transmission, expression, etc.).

As used herein, "cancer" refers to all types of cancer or neoplasm or malignant tumors found in mammals, including, but not limited to: leukemias, lymphomas, melanomas, carcinomas and sarcomas. The cancer manifests itself as a "tumor" or tissue comprising malignant cells of the cancer. Examples of tumors include sarcomas and carcinomas such as, but not limited to: fibrosarcoma, myxosarcoma, liposar-

coma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, seminoma embryonal carcinoma, Wilms' tumor, cervical cancer, testicular tumor, lung carcinoma, small cell lung carcinoma, bladder carcinoma, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, meningioma, melanoma, neuroblastoma, and retinoblastoma. Additional cancers which can be reared by the disclosed composition according to the invention include but not limited to, for example, Hodgkin's Disease, Non-Hodgkin's Lymphoma, multiple myeloma, neuroblastoma, breast cancer, ovarian cancer, lung cancer, rhabdomyosarcoma, primary thrombocytosis, primary macroglobulinemia, small-cell lung tumors, primary brain tumors, stomach cancer, colon cancer, malignant pancreatic insulinoma, malignant carcinoid, urinary bladder cancer, premalignant skin lesions, testicular cancer, lymphomas, thyroid cancer, neuroblastoma, esophageal cancer, genitourinary tract cancer, malignant hypercalcemia, cervical cancer, endometrial cancer, adrenal cortical cancer, and prostate cancer.

"Neurological disease or disorder" refers to any disease or disorder of the nervous system and/or visual system. "Neurological disease or disorder" include disease or disorders that involve the central nervous system (brain, brainstem and cerebellum), the peripheral nervous system (including cranial nerves), and the autonomic nervous system (parts of which are located in both central and peripheral nervous system). Examples of neurological disorders include but are not limited to, headache, stupor and coma, dementia, seizure, sleep disorders, trauma, infections, neoplasms, neuroophthalmology, movement disorders, demyelinating diseases, spinal cord disorders, and disorders of peripheral nerves, muscle and neuromuscular junctions. Addiction and mental illness, include, but are not limited to, bipolar disorder and schizophrenia, are also included in the definition of neurological disorder. The following is a list of several neurological disorders, symptoms, signs and syndromes that can be treated using compositions and methods according to the present invention: acquired epileptiform aphasia; acute disseminated encephalomyelitis; adrenoleukodystrophy; age-related macular degeneration; agenesis of the corpus callosum; agnosia; Aicardi syndrome; Alexander disease; Alpers' disease; alternating hemiplegia; Vascular dementia; amyotrophic lateral sclerosis; anencephaly; Angelman syndrome; angiomatosis; anoxia; aphasia; apraxia; arachnoid cysts; arachnoiditis; Anronl-Chiari malformation; arteriovenous malformation; Asperger syndrome; ataxia telegiectasia; attention deficit hyper activity disorder; autism; autonomic dysfunction; back pain; Batten disease; Behcet's disease; Bell's palsy; benign essential blepharospasm; benign focal; amyotrophy; benign intracranial hypertension; Binswanger's disease; blepharospasm; Bloch Sulzberger syndrome; brachial plexus injury; brain abscess; brain injury; brain tumors (including glioblastoma multiforme); spinal tumor; Brown-Sequard syndrome; Canavan disease; carpal tunnel syndrome; causalgia; central pain syndrome; central pontine myelinolysis; cephalic disorder; cerebral aneurysm; cerebral

arteriosclerosis; cerebral atrophy; cerebral gigantism; cerebral palsy; Charcot-Marie-Tooth disease; chemotherapy-induced neuropathy and neuropathic pain; Chiari malformation; chorea; chronic inflammatory demyelinating polyneuropathy; chronic pain; chronic regional pain syndrome; Coffin Lowry syndrome; coma, including persistent vegetative state; congenital facial diplegia; corticobasal degeneration; cranial arteritis; craniosynostosis; Creutzfeldt-Jakob disease; cumulative trauma disorders; Cushing's syndrome; cytomegalic inclusion body disease; cytomegalovirus infection; dancing eyes-dancing feet syndrome; Dandy Walker syndrome; Dawson disease; De Mosier's syndrome; Dejerine-Klumpke palsy; dementia, dermatomyositis; diabetic neuropathy; diffuse sclerosis; dysautonomia; dysgraphia; dyslexia; dystonias; early infantile epileptic encephalopathy; empty sella syndrome; encephalitis; encephaloceles; encephalotrigeminal angiomatosis; epilepsy; Erb's palsy; essential tremor; Fabry's disease; Fahr's syndrome; fainting; familial spastic paralysis; febrile seizures; Fisher syndrome; Friedreich's ataxia; fronto-temporal dementia and other "tauopathies"; Gaucher's disease; Gerstmann's syndrome; giant cell arteritis; giant cell inclusion disease; globoid cell leukodystrophy; Guillain-Barre syndrome; HTLV-1-associated myelopathy; Hallervorden-Spatz disease; head injury headache; hemifacial spasm; hereditary spastic paraplegia; hereditary ataxia; polyneuriformis; herpes zoster ophthalmicus; herpes zoster; Hirayama syndrome; HIV associated dementia and neuropathy (also neurological manifestations of AIDS); holoprosencephaly; Huntington's disease and other polyglutamine repeat diseases; hydranencephaly; hydrocephalus; hypercortisolism; hypoxia; immune-mediated encephalomyelitis; inclusion body myositis; incontinentia pigmenti; infantile phytanic acid storage disease; infantile reflux disease; infantile spasms; inflammatory myopathy; intracranial cyst; intracranial hypertension; Joubert syndrome; Kearns-Sayre syndrome; Kennedy disease Kinsbourne syndrome; Klippel Feil syndrome; Krabbe disease; Kugelberg-Welander disease; kuru; Lafora disease; Lambert-Eaton myasthenic syndrome; Landau-Kleffner syndrome; lateral medullary (Wallenberg) syndrome; learning disabilities; Leigh's disease; Lennox-Gustaut syndrome; Lesch-Nyhan syndrome; leukodystrophy; Lewy body dementia; Lissencephaly; locked-in syndrome; Lou Gehrig's disease (i.e., motor neuron disease or amyotrophic lateral sclerosis); lumbar disc disease; Lyme disease-neurological sequelae; Machado-Joseph disease; macrocephaly; megalencephaly; Melkersson-Rosenthal syndrome; Meniers disease; meningitis; Menkes disease; metachromatic leukodystrophy; microencephaly; migraine; Miller Fisher syndrome; mini-strokes; mitochondrial myopathies; Mobius syndrome; monomelic amyotrophy; motor neuron disease; Moyamoya disease; mucopolysaccharidosis; multi-infarct dementia; multifocal motor neuropathy; multiple sclerosis and other demyelinating disorders; multiple system atrophy with postural hypotension; p muscular dystrophy; myasthenia gravis; myelinoclastic diffuse sclerosis; myoclonic encephalopathy of infants; myoclonus; myopathy; myotonia congenital; narcolepsy; neurofibromatosis; neuroleptic malignant syndrome; neurological manifestations of AIDS; neurological sequelae of lupus; neuromyotonia; neuronal ceroid lipofuscinosis; neuronal migration disorders Niemann-Pick disease; O'Sullivan-McLeod syndrome; occipital neuralgia; occult spinal dysraphism sequence; Ohtahara syndrome; olivopontocerebellar atrophy; opsoclonus myoclonus; optic neuritis; orthostatic hypotension; overuse syndrome; paresthesia; Neurodegenerative disease or disorder (Parkinson's disease, Huntington's disease, Alzheimer's disease, amyotrophic lateral sclerosis (ALS),



## 13

dementia, multiple sclerosis and other diseases and disorders associated with neuronal cell death): paramyotonia congenital; paraneoplastic diseases; paroxysmal attacks; Parry Romberg syndrome; Pelizaeus-Merzbacher disease; periodic paralyses; peripheral neuropathy; painful neuropathy and neuropathic pain; persistent vegetative state; pervasive developmental disorders; photic sneeze reflex; phytanic acid storage disease; Pick's disease; pinched nerve; pituitary tumors; polymyositis; porencephaly; post-polio syndrome; postherpetic neuralgia; post infectious encephalomyelitis; postural hypotension; Prader-Willi syndrome; primary lateral sclerosis; prion diseases; progressive hemifacial atrophy; progressive multifocal leukoencephalopathy; progressive sclerosing poliodystrophy; progressive supranuclear palsy; pseudotumor cerebri, Ramsay-Hunt syndrome (types I and II); Rasmussen's encephalitis; reflex sympathetic dystrophy syndrome; Refsum disease; repetitive motion disorders; repetitive stress injuries; restless legs syndrome; retrovirus-associated myelopathy; Rett syndrome; Reye's syndrome; Saint Vitus dance; Sandhoff disease; Schilder's disease; schizencephaly; septo-optic dysplasia; shaken baby syndrome; shingles; Shy-Drager syndrome; Sjogren's syndrome; sleep apnea; Soto's syndrome; spasticity; spina bifida; spinal cord injury; spinal cord tumors; spinal muscular atrophy; Stiff-Person syndrome; stroke; Sturge-Weber syndrome; subacute sclerosing panencephalitis; subcortical arteriosclerotic encephalopathy; Sydenham chorea; syncope; syringomyelia; tardive dyskinesia; Tay-Sachs disease; temporal arteritis; tethered spinal cord syndrome; Thomsen disease; thoracic outlet syndrome; Tic Douloureux; Todd's paralysis; Tourette syndrome; transit ischemic attack; transmissible spongiform encephalopathies; transverse myelitis; traumatic brain injury; tremor; trigeminal neuralgia; tropical spastic paraparesis; tuberous sclerosis; vascular dementia (multi-infarct dementia); vasculitis including temporal arteritis; Von Hippel-Lindau disease; Waltzenberg's syndrome; Werdnig-Hoffman disease; West syndrome; whiplash; Williams syndrome; Wildon's disease; and Zellweger syndrome.

An "Inflammation" refers to systemic inflammatory conditions and conditions associated locally with migration and attraction of monocytes, leukocytes and/or neutrophils. Examples of inflammation include, but are not limited to, inflammation resulting from infection with pathogenic organisms (including gram-positive bacteria, gram-negative bacteria, viruses, fungi, and parasites such as protozoa and helminths), transplant rejection (including rejection of solid organs such as kidney, liver, heart, lung or cornea, as well as rejection of bone marrow transplants including graft-versus-host disease (GVHD)), or from localized chronic or acute autoimmune or allergic reactions. Autoimmune diseases include acute glomerulonephritis; rheumatoid or reactive arthritis; chronic glomerulonephritis inflammatory bowel diseases such as Crohn's disease, ulcerative colitis and necrotizing enterocolitis; granulocyte transfusion associated syndromes; inflammatory dermatoses such as contact dermatitis, atopic dermatitis, psoriasis; systemic lupus erythematosus (SLE), autoimmune thyroiditis, multiple sclerosis, and some forms of diabetes, or any other autoimmune state where attack by the subject's own immune system results in pathologic tissue destruction. Allergic reactions include allergic asthma, chronic bronchitis, acute and delayed hypersensitivity. Systemic inflammatory disease states include inflammation associated with trauma, burns, reperfusion following ischemic events (e.g. thrombotic events in heart brain, intestines or peripheral vasculature, including myocardial infarction and stroke), sepsis, ARDS or multiple organ dysfunction syndrome. Inflammatory cell recruitment also occurs in ath-

## 14

erosclerotic plaques. Inflammation includes, but is not limited to, Non-Hodgkin's lymphoma, Wegener's granulomatosis, Hashimoto's thyroiditis, hepatocellular carcinoma, thymus atrophy, chronic pancreatitis, rheumatoid arthritis, reactive lymphoid hyperplasia, osteoarthritis, ulcerative colitis, papillary carcinoma, Crohn's disease, ulcerative colitis, acute cholecystitis, chronic cholecystitis, cirrhosis, chronic sialadenitis, peritonitis, acute pancreatitis, chronic pancreatitis, chronic Gastritis, adenomyosis, endometriosis, acute cervicitis, chronic cervicitis, lymphoid hyperplasia, multiple sclerosis, hypertrophy secondary to idiopathic thrombocytopenic purpura, primary IgA nephropathy, systemic lupus erythematosus, psoriasis, pulmonary emphysema, chronic pyelonephritis, and chronic cystitis.

A cardiovascular disease or disorder includes those disorders that can either cause ischemia or are caused by reperfusion of the heart. Examples include, but are not limited to, atherosclerosis, coronary artery disease, granulomatous myocarditis, chronic myocarditis (non-granulomatous), primary hypertrophic cardiomyopathy, peripheral artery disease (PAD), stroke, angina pectoris, myocardial infarction, cardiovascular tissue damage caused by cardiac arrest, cardiovascular tissue damage caused by cardiac bypass, cardiogenic shock, and related conditions that would be known by those of ordinary skill in the art or which involve dysfunction of or tissue damage to the heart or vasculature, especially, but not limited to, tissue damage related to a Pancreatic Developmental gene activation. CVS diseases include, but are not limited to, atherosclerosis, granulomatous myocarditis, myocardial infarction, myocardial fibrosis secondary to valvular heart disease, myocardial fibrosis without infarction, primary hypertrophic cardiomyopathy, and chronic myocarditis (non-granulomatous).

A "Metabolic disease or disorder" refers to a wide range of diseases and disorders of the endocrine system including, for example, insulin resistance, diabetes, obesity, impaired glucose tolerance, high blood cholesterol, hyperglycemia, hyperinsulinemia, dyslipidemia and hyperlipidemia.

Polynucleotide and Oligonucleotide Compositions and Molecules  
Targets

In one embodiment, the targets comprise nucleic acid sequences of a Pancreatic Developmental gene, including without limitation sense and/or antisense noncoding and/or coding sequences associated with a Pancreatic Developmental gene.

In one embodiment, the targets comprise nucleic acid sequences of NEUROD1, including without limitation sense and/or antisense noncoding and/or coding sequences associated with NEUROD1 gene.

In one embodiment, the targets comprise nucleic acid sequences of HNF4A, including without limitation sense and/or antisense noncoding and/or coding sequences associated with HNF4A gene.

In one embodiment, the targets comprise nucleic acid sequences of MAFA, including without limitation sense and/or antisense noncoding and/or coding sequences associated with MAFA gene.

In one embodiment, the targets comprise nucleic acid sequences of PDX1, including without limitation sense and/or antisense noncoding and/or coding sequences associated with PDX1 gene.

In one embodiment, the targets comprise nucleic acid sequences of NKX6, including without limitation sense and/or antisense noncoding and/or coding sequences associated with NKX6 gene.

BETA2/NeuroD1 is a tissue-specific basic helix-loop-helix transcription factor with ability to up-regulate insulin gene expression. NeuroD1/BETA2 is a key regulator of pancreatic islet morphogenesis and insulin hormone gene transcription in islet beta cells. It was cloned as a gene required for neuronal differentiation, named NeuroD; we now refer to the gene as BETA2/NeuroD1. Like many bHLH family members that play important roles in regulating various developmental systems, BETA2/NeuroD1 is essential for development of the pancreas and brain.

HNF4A encodes a transcription factor with an important role in hepatocyte and pancreatic transcriptional regulation. An orphan nuclear receptor and hepatic activator, hepatic nuclear factor-4 (HNF-4), is a central regulator of transcriptional networks in the liver and pancreatic  $\beta$ -cells. The two promoters, P1 and P2, are located 45.5 kb apart on chromosome 20q. While HNF4A transcripts in the liver are primarily of P1 origin, the P2 promoter drives expression in the pancreas, where it regulates genes involved in insulin secretion and glucose homeostasis.

MAFA is the  $\beta$ -cell-specific nuclear factor bound to a conserved cis-regulatory element called RIPE3b1 in the insulin gene enhancer region and functions as an important transactivator for the insulin gene. MAFA is a basic-leucine zipper (bLZ) transcription factor that controls  $\beta$ -cell-specific expression of the insulin gene through a cis-regulatory element called RIPE3b1 and functions as potent transactivator of insulin gene. MAFA cooperates synergistically with NEUROD1 and PDX1. Phosphorylation by GSK3 increases its transcriptional activity and is required for its oncogenic activity.

Pancreatic-duodenal homeobox 1 (PDX1) is a transcription factor of homeobox genes family important in differentiation and development of the pancreas, duodenum and antrum. Pancreatic duodenal homeobox 1 (PDX-1) is a transcription factor with a critical role in pancreatic development. PDX-1 regulates pancreatic cell proliferation and differentiation, and increased expression of this transcription factor has been described in human Pancreatic adenocarcinoma and cell lines. Pdx1 is also necessary for  $\beta$ -cell maturation: developing  $\beta$ -cells co-express Pdx1, Nkx6-1, and insulin, a process that results in the silencing of MafB and the expression of MafA, a necessary switch in maturation of  $\beta$ -cells. Pdx 1 appears to also play a role in the fattening of endocrine cells,

encoding for insulin and somatostatin, two pancreatic endocrine products, while repressing glucagon. Thus, Pdx1 expression apparently favors the production of insulin+ $\beta$ -cells and somatostatin+ $\Delta$ -cells rather than glucagon+ $\alpha$ -cells.

Nkx6.1 is recognized as the most beta-cell specific transcription factor in the pancreas. Nkx6 homeodomain transcription factors have important developmental roles in the CNS and the pancreas. Nkx1 is essential for proper motoneuron and oligodendrocyte development and the development and maintenance of insulin-producing pancreatic beta cells.

Nkx-6.1 is expressed in ventral neural progenitor cells and subsequently in the median half of the lateral motor neuron column (LMCm) and in mesenchymal tissues surrounding Shh-expressing cells; ventral spinal meninges, esophageal mesenchyme, and dorsal tracheal mesenchyme. Nkx6.1 is required for ventral regional patterning and neuronal fate determination in the vertebrate CNS. Nkx6.1 controls motor neuron and ventral interneuron fates Nkx6.1 controls migration and axon pathfinding of cranial branchio-motoneurons and it is required for the early specification of somatic motoneuron progenitors in the spinal cord. Early specification of branchio-motoneurons (hindbrain) is independent of Nkx6.1 function, but it is required for their subsequent development. Nkx6.1 is required for the development of postmitotic motoneurons, and the control of branchio-motoneuron migration. The status of Nkx6.1 expression in certain motor neuron pools regulates muscle nerve formation, and the pattern of innervation of individual muscles.

Table 1 shows a list of some Pancreatic Developmental genes

It should be appreciated that in the Table 1 below, an indicated gene means the gene and all currently known variants thereof, including the different mRNA transcripts that the gene and its variants can give rise to, any further gene variants which may be elucidated, and antisense sequences. The list also includes the non-coding RNA molecules or the portions of polynucleotides. In general, however, such variants will have significant sequence identity to a sequence of any polynucleotide in Table 1 below, e.g., a variant will have at least about 70 percent sequence identity to a sequence of the Table 1 below, typically as least about 75, 80, 85, 90, 95, 97, 98 or 99 percent sequence identity to a sequence of the below Table 1. Sequence identity of variant can be determined by any number of standard techniques such as BLAST program (ncbi.nlm.nih.gov/blast/).

TABLE 1

| Gene Symbol | Accession Number | Function   |
|-------------|------------------|--|
| VEGFA       | NM_001025366     | Induces angiogenesis, vasculogenesis and endothelial cell growth, promotes cell migration, and inhibits apoptosis.   |
| TCF7L2      | NM_001146274     | Blood glucose homeostasis  |
| SST         | NM_001048        | Inhibits the release of numerous secondary hormones by binding to high-affinity G-protein-coupled somatostatin receptors   |
| SOX9        | NM_000346        | Maintenance of pancreatic progenitor cells   |
| SOX17       | NM_022454        | Pancreas development   |
| SLC2A2      | NM_000340        | Mediates facilitated bidirectional glucose transport   |
| RBPJL       | NM_014276        | Pancreas development—formation of ascinar structures   |
| RBPJ        | NM_005349        | Pancreas development—formation of ascinar structures   |
| PYY         | NM_004160        | Inhibits pancreatic secretion and mobility in the gut  |
| PTF1A       | NM_178161        | Determines whether cells allocated to the pancreatic buds continue towards pancreatic organogenesis or revert back to duodenal fates. The protein is thought to be involved in the maintenance of exocrine pancreas-specific gene expression including clastase 1 and amylase. |
| PPY         | NM_002722        | Acts as a regulator of pancreatic and gastrointestinal functions and may be important in the regulation of food intake.  |
| POU3F4      | NM_000307        | Expressed in the pancreatic anlage of the mouse foregut at e10 in the alpha cells and transactivates glucagon gene expression  |

TABLE 1-continued

| Gene Symbol | Accession Number                            | Function  |
|-------------|---|---|
| PDX1        | NM_000209                                   | Transcriptional activator of several genes, including insulin, somatostatin, glucokinase, islet amyloid polypeptide, and glucose transporter type 2. The encoded nuclear protein is involved in the early development of the pancreas and plays a major role in glucose-dependent regulation of insulin gene expression.  |
| PBX1        | NM_002585                                   | PBX1 regulates the activity of PDX1 in pancreatic development. Regulates proglucagon expression by serving as a co-factor for Cdx-2   |
| PAX 6       | NM_000280                                   | Glucose homeostasis, regulates beta and alpha cell differentiation  |
| PAX4        | NM_006193                                   | Involved in pancreatic islet development and differentiation of insulin-producing beta cells  |
| ONECUT1     | NM_004498                                   | Transcriptional regulator of pancreatic duct development. Serves as a coactivator protein to enhance FoxA2 transcription  |
| Nodal       | NM_018055                                   | pancreas development  |
| NKX6-1      | NM_006168                                   | Required for the development of beta cells and is a potent bifunctional transcription regulator that binds to AT-rich sequences within the promoter region of target genes  |
| NKX2-2      | NM_002509                                   | Regulates NKX6.1, regulates differentiation of beta cells   |
| NEUROG3     | NM_020999                                   | Critical for the development of alpha and beta cells  |
| NEUROD1     | NM_002500                                   | Regulates expression of the insulin gene  |
| MYT1        | NM_004535                                   | Initiates endocrine differentiation in pancreatic islet cells, positively regulates NGF3  |
| MYC         | NM_002467                                   | Induces cell proliferation  |
| MNX1        | NM_001165255                                | Transcriptional activator protein expressed early in pancreas development   |
| MIXL1       | NM_031944                                   | Transcription factor that regulates cell fate during development  |
| MAFB        | NM_005461                                   | Activator of glucagon gene expression in alpha and beta cells   |
| MAFA        | NM_201589                                   | Regulates pancreatic beta cell-specific expression of the insulin gene  |
| KRT19       | NM_002276                                   | Pancreas development—duct formation   |
| ISL2        | NM_145805                                   | Pancreas development—bud formation  |
| ISL1        | NM_002202                                   | The encoded protein binds to the enhancer region of the insulin gene, among others, and may play an important role in regulating insulin gene expression. The encoded protein is central to the development of pancreatic cell lineages and may also be required for motor neuron generation.   |
| INSM1       | NM_002196                                   | Pancreatic beta cell development  |
| Ins2        | NM_000207,<br>NM_001185097,<br>NM_001185098 | Insulin—stimulates glucose uptake   |
| Ins1        | NM_000207,<br>NM_001185097,<br>NM_001185098 | Insulin—stimulates glucose uptake   |
| INHBB       | NM_002193                                   | Inhibins and activins inhibit and activate, respectively, the secretion of follitropin by the pituitary gland. Inhibins/activins are involved in regulating a number of diverse functions such as hypothalamic and pituitary hormone secretion, gonadal hormone secretion, germ cell development and maturation, erythroid differentiation, insulin secretion, nerve cell survival, embryonic axial development or bone growth, depending on their subunit composition. Inhibins appear to oppose the functions of activins |
| HNF4A       | NM_000457.3                                 | Regulates expression of HNF1a   |
| HNF1B       | NM_000458.2                                 | Regulates expression of HNF4a   |
| HHEX        | NM_002729.4                                 | Recognizes the DNA sequence 5'-ATTAA-3'. Transcriptional repressor. May play a role in hematopoietic differentiation. Establishes anterior identity at two levels; acts early to enhance canonical WNT-signaling by repressing expression of TLE4, and acts later to inhibit NODAL-signaling by directly targeting NODAL  |
| HES1        | NM_005524                                   | Represses the expression of Ngn preventing neuronal differentiation in cells adjacent to developing neuroblasts.  |
| GHRL        | NM_001134941                                | Ghrelin is an endogenous ligand for the growth hormone secretagogue receptor and is involved in regulating growth hormone release.  |
| Gdf11       | NM_005811                                   | promotes beta-cell differentiation, modulates NGN3  |
| GCG         | NM_002054                                   | Glucagon, is a pancreatic hormone that counteracts the glucose-lowering action of insulin by stimulating glycogenolysis and gluconeogenesis   |
| GATA6       | NM_005257                                   | interacts with Nkx2.2   |
| Gata4       | NM_002052                                   | Transcriptional activator. Binds to the consensus sequence 5'-AGATAG-3'. Acts as a transcriptional activator of ANF in cooperation with NKX2-5  |
| FST         | NM_006350                                   | Binds directly to activin and functions as an activin antagonist. Specific inhibitor of the biosynthesis and secretion of pituitary follicle stimulating hormone (FSH)  |
| FOXA2       | NM_021784                                   | regulation of Pdx1  |
| FOXA1       | NM_004496                                   | regulation of Pdx1  |
| FGF2        | NM_002006                                   | Induction of pancreatic islet cluster   |
| FGF10       | NM_004465                                   | Maintains the pancreatic progenitor cell state  |
| CPA1        | NM_001868                                   | Carboxypeptidase A1 is a monomeric pancreatic exopeptidase. It is involved in zymogen inhibition  |
| ARX         | NM_139058                                   | The ARX gene provides instructions for producing a protein that regulates the activity of other genes. On the basis of this action, the ARX protein is called a transcripion factor. The ARX gene is part of a larger family of homeobox genes, which act during early embryonic development to control the formation of many body structures. Specifically, the ARX protein is believed to be involved in the development of the pancreas, gastrointestinal tract, testes, and brain.                                      |

TABLE 1-continued

| Gene Symbol | Accession Number | Function  |
|-------------|------------------|---|
| AMY1        | NM_001008221     | This gene encodes an amylase isoenzyme produced by the salivary gland. Alternative splicing results in multiple transcript variants encoding the same protein.  |
| ACVR2B      | NM_001106        | On ligand binding, forms a receptor complex consisting of two type II and two type I transmembrane serine/threonine kinases. Type II receptors phosphorylate and activate type I receptors which autophosphorylate, then bind and activate SMAD transcriptional regulators. Receptor for activin A, activin B and inhibin A |
| ACVR2A      | NM_001616        | On ligand binding, forms a receptor complex consisting of two type II and two type I transmembrane serine/threonine kinases. Type II receptors phosphorylate and activate type I receptors which autophosphorylate, then bind and activate SMAD transcriptional regulators. Receptor for activin A, activin B and inhibin A |

In some embodiments, antisense oligonucleotides are used to prevent or treat diseases or disorders associated with Pancreatic Developmental gene family members. Exemplary Pancreatic Developmental gene mediated diseases and disorders which can be treated with cell/tissues regenerated from stem cells obtained using the antisense compounds comprise: a disease or disorder associated with abnormal function and/or expression of a Pancreatic Developmental gene, a disease or disorder associated with abnormal function and/or expression of any of the genes listed in Table 1, a cardiovascular disease or disorder (e.g., congestive heart failure, myocardial infarction, an Ischemic disease, an atrial or ventricular arrhythmia, a hypertensive vascular disease, a peripheral vascular disease, and atherosclerosis etc.), inflammation, a gastrointestinal disease or disorder (e.g., a disorder of the esophagus, achalasia, vigorous achalasia, dysphagia, cricopharyngeal incoordination, pre-esophageal dysphagia, diffuse esophageal spasm, globus sensation, Barrett's metaplasia, gastroesophageal reflux etc.), a disease or disorder of the stomach and/or duodenum (e.g., functional dyspepsia, inflammation of the gastric mucosa, gastritis, stress gastritis, chronic erosive gastritis, atrophy of gastric glands, metaplasia of gastric tissues, gastric ulcers, duodenal ulcers, a neoplasm of the stomach), a disease or disorder of the pancreas (e.g., acute or chronic pancreatitis, insufficiency of the exocrine or endocrine tissues of the pancreas like steatorrhea, diabetes etc.), a neoplasm of the exocrine or endocrine pancreas (e.g., multiple endocrine neoplasia syndrome, ductal adenocarcinoma, cystadenocarcinoma, an islet cell tumor, insulinoma, gastrinoma, carcinoid tumors, glucagonoma, Zollinger-Ellison syndrome, Vipoma syndrome, malabsorption syndrome etc.), a disease or disorder of the bowel (e.g., chronic inflammatory disease of the bowel, Crohn's disease, ileus, diarrhea and constipation, colonic inertia, megacolon, malabsorption syndrome, ulcerative colitis, a functional bowel disorder, irritable bowel syndrome etc.), a neoplasm of the bowel (e.g., familial polyposis, adenocarcinoma, primary malignant lymphoma, carcinoid tumors, Kaposi's sarcoma, polyps, cancer of the colon and rectum); a hepatic disease or disorder (e.g., bilirubin metabolism disorder, jaundice, syndroms of Gilbert's, Crigler-Najjar, Dubin-Johnson and Rotor; intrahepatic cholestasis, hepatomegaly, portal hypertension, ascites, Budd-Chiari syndrome, portal-systemic encephalopathy, fatty liver, psittacosis, Reye's syndrome, a liver disease due to alcohol, alcoholic hepatitis or cirrhosis, fibrosis, cirrhosis etc.), fibrosis and/or cirrhosis of the liver due to inborn errors of metabolism or exogenous substances, a storage disease or disorder, syndrome of Gauche's, Zellweger's, Wilson's-disease, acute or chronic hepatitis, viral hepatitis and its variants; an inflammatory condition of the liver due to virus, bacteria, fungi, protozoa, helminth; a drug induced disease or disorder

15

of the liver, a chronic liver disease like primary sclerosing cholangitis, alpha1-antitrypsin-deficiency, primary biliary cirrhosis, a postoperative liver disorder like postoperative intrahepatic cholestasis, a hepatic granuloma, a vascular liver disease or disorder associated with systemic disease, a benign or malignant neoplasm of the liver, a disturbance of liver metabolism in the new-born or prematurely born, a musculoskeletal Disease (e.g., osteoporosis, postmenopausal osteoporosis, senile osteoporosis, secondary osteoporosis, idiopathic juvenile osteoporosis, Paget's disease of the bone, osteochondroma, osteocartilaginous exostose, etc.), a tumor of the bone (e.g., benign chondromas, chondroblastoma, chondromyxoid fibromas, osteoid osteomas, a giant cell tumor of the bone, multiple myeloma, osteosarcoma (osteogenic sarcoma), fibrosarcoma, malignant fibrous histiocytoma, chondrosarcoma, Ewing's tumor (Ewing's sarcoma), malignant lymphoma of bone (reticulum cell sarcoma, metastatic tumors of the bone), osteoarthritis, and gout and Pseudogout; a disorder of joint and connective tissue (e.g., rheumatoid arthritis, psoriatic arthritis, discoid lupus erythematosus, systemic lupus erythematosus, scleroderma (systemic sclerosis), Sjogren's syndrome, connective tissue disease, polymyositis and dermatomyositis, relapsing polychondritis, vasculitis, polyarthritis nodosa, polymyalgia rheumatica, temporal arteritis, Wegener's granulomatosis, Reiter's syndrome, Behcet's syndrome, ankylosing spondylitis, or Charcot's joints (neuropathic joint disease) etc.); a bone and joint infection (e.g., osteomyelitis, and infectious arthritis); a disease or disorder of muscles, bursas, and/or tendons (e.g., spasmodic torticollis, fibromyalgia syndromes (myofascial pain syndromes, fibromyositis), bursitis, tendinitis and tenosynovitis), foot problem (e.g., ankle sprain, foot fractures, heel spurs, Sever's disease, posterior achilles tendon bursitis, anterior achilles tendon bursitis, posterior tibial neuralgia, pain in the ball of the foot (caused by damage to the nerves between the toes or to the joints between the toes and foot), onychomycosis, or nail discoloration), cancer, an inflammatory disease or disorder such as: hypersensitivity reactions of type I-IV (e.g., a hypersensitivity disease of the lung including asthma, atopic diseases, allergic rhinitis or conjunctivitis, angioedema of the lids, hereditary angioedema, antireceptor hypersensitivity reactions and autoimmune diseases, Hashimoto's thyroiditis, systemic lupus erythematosus, Goodpasture's syndrome, pemphigus, myasthenia gravis, Grave's and Raynaud's disease, type B insulin-resistant diabetes, rheumatoid arthritis, psoriasis, Crohn's disease, scleroderma, mixed connective tissue disease, polymyositis, sarcoidosis, glomerulonephritis, acute or chronic host versus graft reactions); a pulmonary disease or disorder such as: Chronic obstructive pulmonary disease (COPD); a urinary system disorder such as: malign disorders

of the organs constituting the genitourinary system of female and male, a renal disease or disorder like acute or chronic renal failure, immunologically mediated renal diseases like renal transplant rejection, lupus nephritis, immune complex renal diseases, glomerulopathies, nephritis, toxic nephropathy, an obstructive uropathy like benign prostatic hyperplasia (BPH), neurogenic bladder syndrome, urinary incontinence like urge-, stress-, or overflow incontinence, pelvic pain, and erectile dysfunction, a disease or a disorder associated with defective endocrine pancreatic development (e.g., type 2 diabetes mellitus); a disease or a disorder associated with defective neurogenesis; a neurodegenerative disease or disorder (e.g. Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis etc.); a disease or a disorder associated with defective development of the vestibular and/or auditory system, a disease or a disorder associated with photoreceptor cell degeneration (e.g., loss of vision, age-related macular degeneration etc.), obesity, a disease or a disorder associated with defective functioning of liver (e.g., liver failure), pulverulent cataract, cerulean cataract, non-syndromic congenital cataract, congenital cataract-microcornea syndrome, a pancreatic disease or a disorder (e.g., diabetes, MODY syndrome, Partial pancreas agenesis, chronic hyperglycemia, pancreatic beta cell failure, glucose toxicity, Glucose Intolerance, Metabolic syndrome X etc.), Crohn's disease, myocardial infarction, hypercholesterolemia, intercranial arteriosclerosis, cerebral infarction, herpesviral infection, a disease or disorder associated with impaired lipid metabolism, a disease or disorder associated with insulin production, a disease or disorder associated with serotonin production (e.g., depression and obesity), a neurological disease or disorder (including disorders associated with neural defects (e.g., defects in motor neurons, serotonin-producing neurons, dopamine neurons, and developmental defects in the forebrain, midbrain, hindbrain, and spinal cord) etc.), a disease of the reproductive System and a metabolic disease or disorder such as diabetes (e.g., type 2 diabetes: non-insulin dependent diabetes mellitus).

In another embodiment, the antisense oligonucleotides modulate the expression, in vivo amounts and/or function of a Pancreatic Developmental gene in patients suffering from or at risk of developing diseases or disorders associated with Pancreatic Developmental genes.

In one embodiment, the oligonucleotides are specific for polynucleotides of a Pancreatic Developmental gene, which includes, without limitation noncoding regions. The Pancreatic Developmental gene targets comprise variants of a Pancreatic Developmental gene; mutants of a Pancreatic Developmental gene, including SNPs: noncoding sequences of a Pancreatic Developmental gene; alleles, fragments and the like. Preferably the oligonucleotide is an antisense RNA molecule.

In accordance with embodiments of the invention, the target nucleic acid molecule is not limited to Pancreatic Developmental gene polynucleotides alone but extends to any of the isoforms, receptors, homologs, non-coding regions and the like of a Pancreatic Developmental gene.

In another embodiment, an oligonucleotide targets a natural antisense sequence (natural antisense to the coding and non-coding regions) of a Pancreatic Developmental gene targets, including, without limitation, variants, alleles, homologs, mutants, derivatives, fragments and complementary sequences thereto. Preferably the oligonucleotide is an antisense RNA or DNA molecule.

In another embodiment, the oligomeric compounds of the present invention also include variants in which a different base is present at one or more of the nucleotide positions in the compound. For example, if the first nucleotide is an

adenine, variants may be produced which contain thymidine, guanosine, cytidine or other natural or unnatural nucleotides at this position. This may be done at any of the positions of the antisense compound.

In some embodiments, homology, sequence identity or complementarity, between the antisense compound and target is from about 50% to about 60%. In some embodiments, homology, sequence identity or complementarity, is from about 60% to about 70%. In some embodiments, homology, sequence identity or complementarity, is from about 70% to about 80%. In some embodiments, homology, sequence identity or complementarity, is from about 80% to about 90%. In some embodiments, homology, sequence identity or complementarity, is about 90%, about 92%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99% or about 100%.

An antisense compound is specifically hybridizable when binding of the compound to the target nucleic acid interferes with the normal function of the target nucleic acid to cause a loss of activity, and there is a sufficient degree of complementarity to avoid non-specific binding of the antisense compound to non-target nucleic acid sequences under conditions in which specific binding is desired. Such conditions include, i.e., physiological conditions in the case of in vivo assays or therapeutic treatment, and conditions in which assays are performed in the case of in vitro assays.

An antisense compound, whether DNA, RNA, chimeric, substituted etc, is specifically hybridizable when binding of the compound to the target DNA or RNA molecule interferes with the normal function of the target DNA or RNA to cause a loss of utility, and there is a sufficient degree of complementarity to avoid non-specific binding of the antisense compound to non-target sequences under conditions in which specific binding is desired, i.e., under physiological conditions in the case of in vivo assays or therapeutic treatment, and in the case of in vitro assays, under conditions in which the assays are performed.

In another embodiment, targeting of a Pancreatic Developmental gene including without limitation, antisense sequences which are identified and expanded, using for example, PCR, hybridization etc., one or more of the sequences set forth as SEQ ID NO: 6 to 12, and the like, modulate the expression or function of a Pancreatic Developmental gene. In one embodiment, expression or function is up-regulated as compared to a control. In another embodiment, expression or function is down-regulated as compared to a control.

In another embodiment, oligonucleotides comprise nucleic acid sequences set forth as SEQ ID NOS: 13 to 45 including antisense sequences which are identified and expanded, using for example, PCR, hybridization etc. These oligonucleotides can comprise one or more modified nucleotides, shorter or longer fragments, modified bands and the like. Examples of modified bonds or internucleotide linkages comprise phosphorothionate, phosphorodithioate or the like. In another embodiment, the nucleotide comprise a phosphorus derivative. The phosphorus derivative (or modified phosphate group) which may be attached to the sugar or sugar analog moiety in the modified oligonucleotides of the present invention may be a monophosphate, diphosphate, triphosphate, alkylphosphate, alkanephosphate, phosphorothioate and the like. The preparation of the above-noted phosphate analogs, and their incorporation into nucleotides, modified nucleotides and oligonucleotides, per se, is also known and need not be described here.

The specificity and sensitivity of antisense is also harnessed by those of skill in the art for therapeutic uses. Anti-

sense oligonucleotides have been employed as therapeutic moieties in the treatment of disease states in animals and man. Antisense oligonucleotides have been safely and effectively administered to humans and numerous clinical trials are presently underway. It is thus established that oligonucleotides can be useful therapeutic modalities that can be configured to be useful in treatment regimes for treatment of cells, tissues and animals, especially humans.

In embodiments of the present invention oligomeric antisense compounds, particularly oligonucleotides, bind to target nucleic acid molecules and modulate the expression and/or function of molecules encoded by a target gene. The functions of DNA to be interfered comprise, for example, replication and transcription. The functions of RNA to be interfered comprise all vital functions such as, for example, translocation of the RNA to the site of protein translation, translation of protein from the RNA, splicing of the RNA to yield one or more mRNA species, and catalytic activity which may be engaged in or facilitated by the RNA. The functions may be up-regulated or inhibited depending on the functions desired.

The antisense compounds, include, antisense oligomeric compounds, antisense oligonucleotides, external guide sequence (EGS) oligonucleotides, alternate splicers primers, probes, and other oligomeric compounds that hybridize to at least a portion of the target nucleic acid. As such, these compounds may be introduced in the form of single-stranded, double-stranded, partially single-stranded, or circular oligomeric compounds.

Targeting an antisense compound to a particular nucleic acid molecule, in the context of this invention, can be a multistep process. The process usually begins with the identification of a target nucleic acid whose function is to be modulated. This target nucleic acid may be, for example, a cellular gene (or mRNA transcribed from the gene) whose expression is associated with a particular disorder or disease state, or a nucleic acid molecule from an infectious agent. In the present invention, the target nucleic acid encodes a Pan-

creatic Developmental gene. The targeting process usually also includes determination of at least one target region, segment, or site within the target nucleic acid for the antisense interaction to occur such that the desired effect, e.g., modulation of expression, will result. Within the context of the present invention, the term "region" is defined as a portion of the target nucleic acid having at least one identifiable structure, function, or characteristic. Within regions of target nucleic acids are segments. "Segments" are defined as smaller or sub-portions of regions within a target nucleic acid. "Sites," as used in the present invention, are defined as positions within a target nucleic acid.

In one embodiment, the antisense oligonucleotides bind to the natural antisense sequences of a Pancreatic Developmental gene and modulate the expression and/or function of a Pancreatic Developmental gene (SEQ ID NO: 1 to 5). Examples of antisense sequences include SEQ ID NOS: 6 to 45.

In another embodiment, the antisense oligonucleotides bind to one or more segments of a Pancreatic Developmental gene polynucleotide and modulate the expression and/or function of a Pancreatic Developmental gene. The segments comprise at least five consecutive nucleotides of a Pancreatic Developmental gene sense or antisense polynucleotides.

In another embodiment, the antisense oligonucleotides are specific for natural antisense sequences of a Pancreatic Developmental gene wherein binding of the oligonucleotides

to the natural antisense sequences of a Pancreatic Developmental gene modulate expression and/or function of a Pancreatic Developmental gene.

In another embodiment, oligonucleotide compounds comprise sequences set forth as SEQ ID NOS: 13 to 45, antisense sequences which are identified and expanded, using for example, PCR, hybridization etc. These oligonucleotides can comprise one or more modified nucleotides, shorter or longer fragments, modified bonds and the like. Examples of modified bonds or internucleotide linkages comprise phosphorothioate, phosphorodithioate or the like. In another embodiment, the nucleotides comprise a phosphorus derivative. The phosphorus derivative (or modified phosphate group) which may be attached to the sugar or sugar analog moiety in the modified oligonucleotides of the present invention may be a monophosphate, diphosphate, triphosphate, alkylphosphate, alkanephosphate, phosphorothioate and the like. The preparation of the above-noted phosphate analogs, and their incorporation into nucleotides, modified nucleotides and oligonucleotides, per se, is also known and need not be described here.

Since, as is known in the art, the translation initiation codon is typically 5'-AUG (in transcribed mRNA molecules: 5'-ATG in the corresponding DNA molecule), the translation initiation codon is also referred to as the "AUG codon," the "start codon" or the "AUG start codon". A minority of genes has a translation initiation codon having the RNA sequence 5'-GUG, 5'-UUG or 5'-CUG; and 5'-AUA, 5'-ACG and 5'-CUG have been shown to function in vivo. Thus, the terms "translation initiation codon" and "star codon" can encompass many codon sequences, even though the initiator amino acid in each instance is typically methionine (in eukaryotes) or formylmethionine (in prokaryotes). Eukaryotic and prokaryotic genes may have two or more alternative start codons, any one of which may be preferentially utilized for translation initiation in a particular cell type or tissue, or under a particular set of conditions. In the context of the invention, "start codon" and "translation initiation codon" refer to the codon or codons that are used in vivo to initiate translation of an mRNA transcribed from a gene encoding a Pancreatic Developmental gene, regardless of the sequence(s) of such codons. A translation termination codon (or "stop codon") of a gene may have one of three sequences, i.e., 5'-UAA, 5'-UAG and 5'-UGA (the corresponding DNA sequences are 5'-TAA, 5'-TAG and 5'-TGA, respectively).

The terms "start codon region" and "translation initiation codon region" refer to a portion of such an mRNA or gene that encompasses from about 25 to about 50 contiguous nucleotides in either direction (i.e., 5' or 3') from a translation initiation codon. Similarly, the terms "stop codon region" and "translation termination codon region" refer to a portion of such an mRNA or gene that encompasses from about 25 to about 50 contiguous nucleotides in either direction (i.e. 5' or 3') from a translation termination codon. Consequently, the "star codon region" (or "translation initiation codon region") and the "stop codon region" (or "translation termination codon region") are all regions that may be targeted effectively with the antisense compounds of the present invention.

The open reading frame (ORF) or "coding region," which is known in the art to refer to the region between the translation initiation codon and the translation termination codon, is also a region which may be targeted effectively. Within the context of the present invention, a targeted region is the intragenic region encompassing the translation initiation or termination codon of the open reading frame (ORF) of a gene.

Another target region includes the 5' untranslated region (5'UTR), known in the art to refer to the portion of an mRNA

in the 5' direction from the translation initiation codon, and thus including nucleotides between the 5' cap site and the translation initiation codon of an mRNA (or corresponding nucleotides on the gene). Still another target region includes the 3' untranslated region (3'UTR), known in the art to refer to the portion of an mRNA in the 3' direction from the translation termination codon, and thus including nucleotides between the translation termination codon and 3' end of an mRNA (or corresponding nucleotides on the gene). The 5' cap site of an mRNA comprises an N7-methylated guanosine residue joined to the 5'-most residue of the mRNA via a 5'-5' triphosphate linkage. The 5' cap region of an mRNA is considered to include the 5' cap structure itself as well as the first 50 nucleotides adjacent to the cap site. Another target region for this invention is the 5' cap region.

Although some eukaryotic mRNA transcripts are directly translated, many contain one or more regions, known as "introns," which are excised from a transcript before it is translated. The remaining (and therefore translated) regions are known as "exons" and are spliced together to form a continuous mRNA sequence. In one embodiment, targeting splice sites, i.e., intron-exon junctions or exon-intron junctions, is particularly useful in situations where aberrant splicing is implicated in disease, or where an overproduction of a particular splice product is implicated in disease. An aberrant fusion junction due to rearrangement or deletion is another embodiment of a target site. mRNA transcripts produced via the process of splicing of two (or more) mRNAs from different gene sources are known as "fusion transcripts". Introns can be effectively targeted using antisense compounds targeted to, for example, DNA or pre-mRNA.

In another embodiment, the antisense oligonucleotides bind to coding and/or non-coding regions of a target polynucleotide and modulate the expression and/or function of the target molecule.

In another embodiment, the antisense oligonucleotides bind to natural antisense polynucleotides and modulate the expression and/or function of the target molecule.

In another embodiment, the antisense oligonucleotides bind to sense polynucleotides and modulate the expression and/or function of the target molecule.

Alternative RNA transcripts can be produced from the same genomic region of DNA. These alternative transcripts are generally known as "variants". More specifically, "pre-mRNA variants" are transcripts produced from the same genomic DNA that differ from other transcripts produced from the same genomic DNA in either their start or stop position and contain both intronic and exonic sequence.

Upon excision of one or more exon or intron regions, or portions thereof during splicing, pre-mRNA variants produce smaller "mRNA variants". Consequently, mRNA variants are processed pre-mRNA variants and each unique pre-mRNA variant must always produce a unique mRNA variant as a result of splicing. These mRNA variants are also known as "alternative splice variants". If no splicing of the pre-mRNA variant occurs then the pre-mRNA variant is identical to the mRNA variant.

Variants can be produced through the use of alternative signals to start or stop transcription. Pre-mRNAs and mRNAs can possess more than one start codon or stop codon. Variants that originate from a pre-mRNA or mRNA that use alternative start codons are known as "alleviative start variants" of that pre-mRNA or mRNA. Those transcripts that use an alternative stop codon are known as "alternative stop variants" of that pre-mRNA or mRNA. One specific type of alleviative stop variant is the "polyA variant" in which the multiple transcripts produced result from the alternative selection of

one of the "polyA stop signals" by the transcription machinery, thereby producing transcripts that terminate at unique polyA sites. Within the context of the invention, the types of variants described herein are also embodiments of target nucleic acids.

The locations on the target nucleic acid to which the antisense compounds hybridize are defined as at least a 5-nucleotide long portion of a target region to which an active antisense compound is targeted.

While the specific sequences of certain exemplary target segments are set forth herein, one of skill in the art will recognize that these serve to illustrate and describe particular embodiments within the scope of the present invention. Additional target segments are readily identifiable by one having ordinary skill in the art in view of this disclosure.

Target segments 5-100 nucleotides in length comprising a stretch of at least five (5) consecutive nucleotides selected from within the illustrative target segments are considered to be suitable for targeting as well.

Target segments can include DNA or RNA sequences that comprise at least the 5 consecutive nucleotides from the 5'-terminus of one of the illustrative target segments (the remaining nucleotides being a consecutive stretch of the same DNA or RNA beginning immediately upstream of the 5'-terminus of the target segment and continuing until the DNA or RNA contains about 5 to about 100 nucleotides). Similarly target segments are represented by DNA or RNA sequences that comprise at least the 5 consecutive nucleotides from the 3'-terminus of one of the illustrative target segments (the remaining nucleotides being a consecutive stretch of the same DNA or RNA beginning immediately downstream of the 3'-terminus of the target segment and continuing until the DNA or RNA contains about 5 to about 100 nucleotides). One having skill in the art armed with the target segments illustrated herein will be able, without undue experimentation, to identify further target segments.

Once one or more target regions, segments or sites have been identified, antisense compounds are chosen which are sufficiently complementary to the target, i.e., hybridize sufficiently well and with sufficient specificity, to give the desired effect.

In embodiments of the invention the oligonucleotides bind to an antisense strand of a particular target. The oligonucleotides are at least 5 nucleotides in length and can be synthesized so each oligonucleotide targets overlapping sequences such that oligonucleotides are synthesized to cover the entire length of the target polynucleotide. The targets also include coding as well as non coding regions.

In one embodiment, specific nucleic acids are targeted by antisense oligonucleotides. Targeting an antisense compound to a particular nucleic acid, is a multistep process. The process usually begins with the identification of a nucleic acid sequence whose function is to be modulated. This may be, for example, a cellular gene (or mRNA transcribed from the gene) whose expression is associated with a particular disorder or disease state, or a non coding polynucleotide such as for example, non coding RNA (ncRNA).

RNAs can be classified into (1) messenger RNAs (mRNAs), which are translated into proteins, and (2) non-protein-coding RNAs (ncRNAs). ncRNAs comprise microRNAs, antisense transcripts and other Transcriptional Units (TU) containing a high density of stop codons and lacking any extensive "Open Reading Frame". Many ncRNAs appear to start from initiation sites in 3' untranslated regions (3'UTRs) of protein-coding loci, ncRNAs are often rare and at least half of the ncRNAs that have been sequenced by the FANTOM consortium seem not to be polyadenylated. Most researchers

have for obvious reasons focused on polyadenylated mRNAs that are processed and exported to the cytoplasm. Recently, it was shown that the set of non-polyadenylated nuclear RNAs may be very large, and that many such transcripts arise from intergenic regions. The mechanism by which ncRNAs may regulate gene expression is by base pairing with target transcripts. The RNAs that function by base pairing can be grouped into (1) cis encoded RNAs that are encoded at the same genetic location, but on the opposite strand to the RNAs they act upon and therefore display perfect complementarity to their target, and (2) trans-encoded RNAs that are encoded at a chromosomal location distinct from the RNAs they act upon and generally do not exhibit perfect base-pairing potential with their targets.

Without wishing to be bound by theory, perturbation of an antisense polynucleotide by the antisense oligonucleotides described herein can alter the expression of the corresponding sense messenger RNAs. However, this regulation can either be discordant (antisense knockdown results in messenger RNA elevation) or concordant (antisense knockdown results in concomitant messenger RNA reduction). In these cases, antisense oligonucleotides can be targeted to overlapping or non-overlapping parts of the antisense transcript resulting in its knockdown or sequestration. Coding as well as non-coding antisense can be targeted in an identical manner and that either category is capable of regulating the corresponding sense transcripts—either in a concordant or discordant manner. The strategies that are employed in identifying new oligonucleotides for use against a target can be based on the knockdown of antisense RNA transcripts by antisense oligonucleotides or any other means of modulating the desired target.

Strategy 1: In the case of discordant regulation, knocking down the antisense transcript elevates the expression of the conventional (sense) gene. Should that later gene encode for a known or putative drug target, then knockdown of its antisense counterpart could conceivably mimic the action of a receptor agonist or an enzyme stimulant.

Strategy 2: In the case of concordant regulation, one could concomitantly knock down both antisense and sense transcripts and thereby achieve synergistic reduction of the conventional (sense) gene expression. If, for example, an antisense oligonucleotide is used to achieve knockdown, then this strategy can be used to apply one antisense oligonucleotide targeted to the sense transcript and another antisense oligonucleotide to the corresponding antisense transcript, or a single energetically symmetric antisense oligonucleotide that simultaneously targets overlapping sense and antisense transcripts.

According to the present invention, antisense compounds include antisense oligonucleotides, ribozymes, external guide sequence (EGS) oligonucleotides, siRNA compounds, single- or double-stranded RNA interference (RNAi) compounds such as siRNA compounds, and other oligomeric compounds which hybridize to at least a portion of the target nucleic acid and modulate its function. As such, they may be DNA, RNA, DNA-like, RNA-like, or mixtures thereof, or may be mimetics of one or more of these. These compounds may be single-stranded, doublestranded, circular hairpin oligomeric compounds and may contain structural elements such as internal or terminal bulges, mismatches or loops. Antisense compounds are routinely prepared linearly but can be joined or otherwise prepared to be circular and/or branched. Antisense compounds can include constructs such as, for example, two strands hybridized to form a wholly or partially double-stranded compound or a single strand with sufficient self-complementarity to allow for hybridization

and formation of a fully or partially double-stranded compound. The two strands can be linked internally leaving free 3' or 5' termini or can be linked to form a continuous hairpin structure or loop. The hairpin structure may contain an overhang on either the 5' or 3' terminus producing an extension of single stranded character. The double stranded compounds optionally can include overhangs on the ends. Further modifications can include conjugate groups attached to one of the termini, selected nucleotide positions, sugar positions or to one of the internucleoside linkages. Alternatively, the two strands can be linked via a non-nucleic acid moiety or linker group. When formed from only one strand, dsRNA can take the form of a self-complementary hairpin-type molecule that doubles back on itself to form a duplex. Thus, the dsRNAs can be fully or partially double stranded. Specific modulation of gene expression can be achieved by stable expression of dsRNA hairpins in transgenic cell lines, however, in some embodiments, the gene expression or function is up regulated. When formed from two strands, or a single strand that takes the form of a self-complementary hairpin-type molecule doubled back on itself to form a duplex, the two strands (or duplex-forming regions of a single strand) are complementary RNA strands that base pair in Watson-Crick fashion.

Once introduced to a system, the compounds of the invention may elicit the action of one or more enzymes or structural proteins to effect cleavage or other modification of the target nucleic acid or may work via occupancy-based mechanisms. In general, nucleic acids (including oligonucleotides) may be described as “DNA-like” (i.e. generally having one or more 2'-deoxy sugars and generally, T rather than U bases) or “RNA-like” (i.e., generally having one or more 2'-hydroxyl or 2'-modified sugars and, generally U rather than T bases). Nucleic acid helices can adopt more than one type of structure, most commonly the A- and B-forms. It is believed that, in general, oligonucleotides which have B-form-like structure are “DNA-like” and those which have A-form like structure are “RNA-like.” In some (chimeric) embodiments, an antisense compound may contain both A- and B-form regions.

In another embodiment, the desired oligonucleotides or antisense compounds, comprise at least one of antisense RNA, antisense DNA, chimeric antisense oligonucleotides, antisense oligonucleotides comprising modified linkages, interference RNA (RNAi), short interfering RNA (siRNA); a micro, interfering RNA (miRNA); a small, temporal RNA (stRNA); or a short, hairpin RNA (shRNA); small RNA-induced gene activation (RNAa); small activating RNAs (saRNAs), or combinations thereof.

dsRNA can also activate gene expression, a mechanism that has been termed “small RNA-induced gene activation” or RNAa. dsRNAs targeting gene promoters induce potent transcriptional activation of associated genes. RNAa was demonstrated in human cells using synthetic dsRNAs, termed “small activating RNAs” (saRNAs).

Small double-stranded RNA (dsRNA), such as small interfering RNA (siRNA) and microRNA (miRNA), have been found to be the trigger of an evolutionary conserved mechanism known as RNA interference (RNAi), RNAi invariably leads to gene silencing. However, in instances described in detail in the examples section which follows, oligonucleotides are shown to increase the expression and/or function of the Pancreatic Developmental gene polynucleotides and encoded products thereof. dsRNAs may also act as small activating RNAs (saRNA). Without wishing to be bound by theory, by targeting sequences in gene promoters, saRNAs



would induce target gene expression in a phenomenon referred to as dsRNA-induced transcriptional activation (RNAa).

In a further embodiment, the “target segments” identified herein may be employed in a screen for additional compounds that modulate the expression of a Pancreatic Developmental gene polynucleotide. “Modulators” are those compounds that decrease or increase the expression of a nucleic acid molecule encoding a Pancreatic Developmental gene and which comprise at least a 5-nucleotide portion that is complementary to a target segment. The screening method comprises the steps of contacting a target segment of a nucleic acid molecule encoding sense or natural antisense polynucleotides of a Pancreatic Developmental gene with one or more candidate modulators, and selecting for one or more candidate modulators which decrease or increase the expression of a nucleic acid molecule encoding a Pancreatic Developmental gene polynucleotide, e.g. SEQ ID NOS: 13 to 45. Once it is shown that the candidate modulator or modulators are capable of modulating (e.g. either decreasing or increasing) the expression of a nucleic acid molecule encoding a Pancreatic Developmental gene polynucleotide, the modulator may then be employed in further investigative studies of the function of a Pancreatic Developmental gene polynucleotide, or for use as a research, diagnostic, or therapeutic agent in accordance with the present invention.

Targeting the natural antisense sequence modulates the function of the target gene. For example, the Pancreatic Developmental gene (e.g. accession numbers NM\_001025366, NM\_001146274, NM\_001048, NM\_000346, NM\_022454, NM\_000340, NM\_014276, NM\_005349, NM\_004160, NM\_178161, NM\_002722, NM\_000307, NM\_000209, NM\_002585, NM\_000280, NM\_006193, NM\_004498, NM\_018055, NM\_006168, NM\_002509, NM\_020999, NM\_002500, NM\_004535, NM\_002467, NM\_001165255, NM\_031944, NM\_005461, NM\_201589, NM\_002276, NM\_145805, NM\_002202, NM\_002196, NM\_000207, NM\_001185097, NM\_001185098, NM\_000207, NM\_001185097, NM\_001185098, NM\_002193, NM\_000457.3, NM\_000458.2, NM\_002729.4, NM\_005524, NM\_001134941, NM\_005811, NM\_002054, NM\_005257, NM\_002052, NM\_006350, NM\_021784, NM\_004496, NM\_002006, NM\_004465, NM\_001868, NM\_139058, NM\_00108221, NM\_001106, NM\_001616). In an embodiment, the target is an antisense polynucleotide of the Pancreatic Developmental gene. In an embodiment, an antisense oligonucleotide targets sense and/or natural antisense sequences of a Pancreatic Developmental gene polynucleotide (e.g. accession numbers NM\_001025366, NM\_001146274, NM\_001048, NM\_000346, NM\_022454, NM\_000340, NM\_014276, NM\_005349, NM\_004160, NM\_178161, NM\_002722, NM\_000307, NM\_000209, NM\_002585, NM\_002580, NM\_006193, NM\_004498, NM\_018055, NM\_006168, NM\_002509, NM\_020999, NM\_002500, NM\_004535, NM\_002467, NM\_001165255, NM\_031944, NM\_005461, NM\_201589, NM\_002276, NM\_145805, NM\_002202, NM\_002196, NM\_000207, NM\_001185097, NM\_001185098, NM\_000207, NM\_001185097, NM\_001185098, NM\_002193, NM\_000457.3, NM\_000458.2, NM\_002729.4, NM\_005524, NM\_001134941, NM\_005811, NM\_002054, NM\_005257, NM\_002052, NM\_006350, NM\_021784, NM\_004496, NM\_002006, NM\_004465, NM\_001868, NM\_139058, NM\_00108221, NM\_001106, NM\_001616), variants, alleles, isoforms,

homologs, mutants, derivatives, fragments and complementary sequences thereto. Preferably the oligonucleotide is an antisense molecule and the targets include coding and non-coding regions of antisense and/or sense Pancreatic Developmental gene polynucleotides.

The target segments of the present invention may be also be combined with their respective complementary antisense compounds of the present invention to form stabilized double-stranded (duplexed) oligonucleotides.

Such double stranded oligonucleotide moieties have been shown in the art to modulate target expression and regular translation as well as RNA processing via an antisense mechanism. Moreover, the double-stranded moieties may be subject to chemical modifications. For example, such double-stranded moieties have been shown to inhibit the target by the classical hybridization of antisense strand of the duplex so the target, thereby triggering enzymatic degradation of the target.

In an embodiment, an antisense oligonucleotide targets Pancreatic Developmental gene polynucleotides (e.g. accession numbers NM\_001025366, NM\_001146274, NM\_001048, NM\_000346, NM\_022454, NM\_000340, NM\_014276, NM\_005349, NM\_004160, NM\_178161, NM\_002722, NM\_000307, NM\_000209, NM\_002585, NM\_000280, NM\_006193, NM\_004498, NM\_018055, NM\_006168, NM\_002509, NM\_020999, NM\_002500, NM\_004535, NM\_002467, NM\_001165255, NM\_031944, NM\_005461, NM\_201589, NM\_002276, NM\_145805, NM\_002202, NM\_002196, NM\_000207, NM\_001185097, NM\_001185098, NM\_000207, NM\_001185097, NM\_001185098, NM\_002193, NM\_000457.3, NM\_000458.2, NM\_002729.4, NM\_005524, NM\_001134941, NM\_005811, NM\_002054, NM\_005257, NM\_002052, NM\_006350, NM\_021784, NM\_004496, NM\_002006, NM\_004465, NM\_001868, NM\_139058, NM\_00100221, NM\_001106, NM\_001616, variants, alleles, isoforms, homologs mutants, derivatives, fragments and complementary sequences thereto. Preferably the oligonucleotide is an antisense molecule.

In accordance with embodiments of the invention the target nucleic acid molecule is not limited to Pancreatic Developmental gene alone but extends to any of the isoforms, receptors, homologs and the like of a Pancreatic Developmental gene molecule.

In another embodiment, an oligonucleotide targets a natural antisense sequence of a Pancreatic Developmental gene polynucleotide, for example, polynucleotides set forth as SEQ ID NO: 6 to 12, and any variants, alleles, homologs, mutants, derivatives, fragments and complementary sequence thereto. Example of antisense oligonucleotides are set forth as SEQ ID NOS: 13 to 45.

In one embodiment, the oligonucleotides are complementary to or bind to nucleic acid sequences of a Pancreatic Developmental gene antisense, including without limitation noncoding sense and/or antisense sequences associated with a Pancreatic Developmental gene polynucleotide and modulate expression and/or function of a Pancreatic Developmental gene molecule.

In another embodiment, the oligonucleotides are complementary to or bind to nucleic acid sequences of a Pancreatic Developmental gene natural antisense, set forth as SEQ ID NO: 6 to 12 and modulate expression and/or function of a Pancreatic Developmental gene molecule.

In an embodiment, oligonucleotides comprise sequences of at least 5 consecutive nucleotides of SEQ ID NOS: 13 to 45 and modulate expression and/or function of a Pancreatic Developmental gene molecule.

The polynucleotide targets comprise Pancreatic Developmental gene, including family members thereof, variants of a Pancreatic Developmental gene, mutants of a Pancreatic Developmental gene, including SNPs; noncoding sequences of a Pancreatic Developmental gene; alleles of a Pancreatic Developmental gene; species variants, fragments and the like. Preferably the oligonucleotide is an antisense molecule.

In another embodiment, the oligonucleotide targeting Pancreatic Developmental gene polynucleotides, comprise: antisense RNA, interference RNA (RNAi), short interfering RNA (siRNA); micro interfering RNA (miRNA); a small, temporal RNA (stRNA); or a short, hairpin RNA (shRNA); small RNA-induced gene activation (RNAa); or, small activating RNA (saRNA).

In another embodiment targeting of a Pancreatic Developmental gene polynucleotide, e.g. SEQ ID NO: 6 to 12 modulate the expression or function of these targets. In one embodiment, expression or function is up-regulated as compared to a control. In another embodiment, expression or function is down-regulated as compared to a control.

In another embodiment, antisense compounds comprise sequences set forth as SEQ ID NOS: 13 to 45. These oligonucleotides can comprise one or more modified nucleotides, shorter or longer fragments, modified bonds and the like.

In another embodiment, SEQ ID NOS: 13 to 45 comprise one or more LNA nucleotides.

The modulation of a desired target nucleic acid can be carried out in several ways known in the art. For example, antisense oligonucleotides, siRNA etc. Enzymatic nucleic acid molecules (e.g., ribozymes) are nucleic acid molecules capable of catalyzing one or more of a variety of reactions, including the ability to repeatedly cleave other separate nucleic acid molecules in a nucleotide base sequence-specific manner. Such enzymatic nucleic acid molecules can be used, for example, to target virtually any RNA transcript.

Because of their sequence-specificity, trans-cleaving enzymatic nucleic acid molecules show promise as therapeutic agents for human disease. Enzymatic nucleic acid molecules can be designed to cleave specific RNA targets within the background of cellular RNA. Such a cleavage event renders the mRNA non-functional and abrogates protein expression from that RNA. In this manner, synthesis of a protein associated with a disease state can be selectively inhibited.

In general, enzymatic nucleic acids with RNA cleaving activity act by first binding to a target RNA. Such binding occurs through the target binding portion of a enzymatic nucleic acid which is held in close proximity to an enzymatic portion of the molecule that acts to cleave the target RNA. Thus, the enzymatic nucleic acid first recognizes and then binds a target RNA through complementary base pairing, and one bound to the connect site, acts enzymatically to cut the target RNA. Strategic cleavage of such a target RNA will destroy its ability to direct synthesis of an encoded protein. After an enzymatic nucleic acid has bound and cleaved its RNA target, it is released from that RNA to search for another target and can repeatedly bind and cleave new targets.

Several approaches such as in vitro selection (evolution) strategies have been used to evolve new nucleic acid catalysts capable of catalyzing a variety of reactions, such as cleavage and ligation of phosphodiester linkages and amide linkages.

The development of ribozymes that are optimal for catalytic activity would contribute significantly to any strategy that employs RNA-cleaving ribozymes for the purpose of regulating gene expression. The hammerhead ribozyme, for example, functions with a catalytic rate (kcat) of about 1 min<sup>-1</sup> in the presence of saturating (10 mM) concentrations of Mg<sup>2+</sup> cofactor. An artificial "RNA ligase" ribozyme has

been shown to catalyze the corresponding self-modification reaction with a rate of about 100 min<sup>-1</sup>. In addition, it is known that certain modified hammerhead ribozymes that have substrate binding arms made of DNA catalyze RNA cleavage with multiple turn-over rates that approach 100 min<sup>-1</sup>. Finally, replacement of a specific residue within the catalytic core of the hammerhead with certain nucleotide analogues gives modified ribozymes that show as much as a 10-fold improvement in catalytic rate. These findings demonstrate that ribozymes can promote chemical transformations with catalytic rates that are significantly greater than those displayed in vitro by most natural self-cleaving ribozymes. It is then possible that the structures of certain self-cleaving ribozymes may be optimized to give maximal catalytic activity, or that entirely new RNA motifs can be made that display significantly faster rates for RNA phosphodiester cleavage.

Intermolecular cleavage of an RNA substrate by an RNA catalyst that fits the "hammerhead" model was first shown in 1987. The RNA catalyst was recovered and reacted with multiple RNA molecules, demonstrating that it was truly catalytic.

Catalytic RNAs designed based on the "hammerhead" motif have been used to cleave specific target sequences by making appropriate base changes in the catalytic RNA to maintain necessary base pairing with the target sequences. This has allowed use of the catalytic RNA to cleave specific target sequences and indicates that catalytic RNAs designed according to the "hammerhead" model may possibly cleave specific substrate RNAs in vivo.

RNA interference (RNAi) has become a powerful tool for modulating gene expression in mammals and mammalian cells. This approach requires the delivery of small interfering RNA (siRNA) either as RNA itself or as DNA, using an expression plasmid or virus and the coding sequence for small hairpin RNAs that are processed to siRNAs. This system enables efficient transport of the pre-siRNAs to the cytoplasm where they are active and permit the use of regulated and tissue specific promoters for gene expression.

In one embodiment, an oligonucleotide or antisense compound comprises an oligomer or polymer of ribonucleic and (RNA) and/or deoxyribonucleic acid (DNA), or a mimetic, chimera, analog or homolog thereof. This term includes oligonucleotides composed of naturally occurring nucleotides, sugars and covalent internucleoside (backbone) linkages as well as oligonucleotides having non-naturally occurring portions which function similarly. Such modified or substituted oligonucleotides are often desired over native forms because of desirable properties such as, for example, enhanced cellular uptake, enhanced affinity for a target nucleic acid and increased stability in the presence of nucleases.

According to the present invention, the oligonucleotides or "antisense compounds" include antisense oligonucleotides (e.g. RNA, DNA, mimetic, chimera, analog or homolog thereof), ribozymes, external guide sequence (EGS) oligonucleotides, siRNA compounds, single- or double-stranded RNA interference (RNAi) compounds such as siRNA compounds, saRNA, aRNA, and other oligomeric compounds which hybridize to at least a portion of the target nucleic acid and modulate its function. As such, they may be DNA, RNA, DNA-like, RNA-like, or mixtures thereof, or may be mimetics of one or more of these. These compounds may be single-stranded, double-stranded, circular or hairpin oligomeric compounds and may contain structural elements such as internal or terminal bulges, mismatches or loops. Antisense compounds are routinely prepared linearly but can be joined or otherwise prepared to be circular and/or branched. Anti-

sense compounds can include constructs such as, for example, two strands hybridized to form a wholly or partially double-stranded compound or a single strand with sufficient self-complementarity to allow for hybridization and formation of a fully or partially double-stranded compound. The two strands can be linked internally leaving free 3' or 5' termini or can be linked to form a continuous hairpin structure or loop. The hairpin structure may contain an overhang on either the 5' or 3' terminus producing an extension of single stranded character. The double stranded compounds optionally can include overhangs on the ends. Further modifications can include conjugate groups attached to one of the termini, selected nucleotide positions, sugar positions or to one of the internucleoside linkages. Alternatively, the two strands can be linked via a non-nucleic acid moiety or linker group. When formed from only one strand, dsRNA can take the form of a self-complementary hairpin-type molecule that doubles back on itself to form a duplex. Thus, the dsRNAs can be fully or partially double stranded. Specific modulation of gene expression can be achieved by stable expression of dsRNA hairpins in transgenic cell lines. When formed from two strands, or a single strand that takes the form of a self-complementary hairpin-type molecule doubled back on itself to form a duplex, the two strands (or duplex-forming regions of a single strand) are complementary RNA strands that base pair in Watson-Crick fashion.

Once introduced to a system, the compounds of the invention may elicit the action of one or more enzymes or structural proteins to effect cleavage or other modification of the target nucleic acid or may work via occupancy-based mechanisms. In general, nucleic acids (including oligonucleotides) may be described as "DNA-like" (i.e. generally having one or more 2'-deoxy sugars and, generally, T rather than U bases) or "RNA-like" (i.e., generally having one or more 2'-hydroxyl or 2'-modified sugars and, generally U rather than T bases). Nucleic acid helices can adopt more than one type of structure, most commonly the A- and B-forms. It is believed that, in general, oligonucleotides which have B-form-like structure are "DNA-like" and those which have A-formlike structure are "RNA-like." In some (chimeric) embodiments, an antisense compound may contain both A- and B-form regions.

The antisense compounds in accordance with this invention can comprise an antisense portion from about 5 to about 80 nucleotides (i.e. from about 5 to about 80 linked nucleosides) in length. This refers to the length of the antisense strand or portion of the antisense compound. In other words, a single-stranded antisense compound of the invention comprises from 5 to about 80 nucleosides, and a double-stranded antisense compound of the invention (such as a dsRNA, for example) comprises a sense and an antisense strand or portion of 5 to about 80 nucleotides in length. One of ordinary skill in the art will appreciate that this comprehends antisense portions of 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 3, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, or 80 nucleotides in length, or any range therewithin.

In one embodiment, the antisense compounds of the invention have antisense portions of 10 to 50 nucleotides in length. One having ordinary skill in the art will appreciate that this embodies oligonucleotides having antisense portions of 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44,

45, 46, 47, 48, 49, or 50 nucleotides in length, or any range therewithin. In some embodiments, the oligonucleotides are 15 nucleotides in length.

In one embodiment, the antisense or oligonucleotide compounds of the invention have antisense portions of 12 or 13 to 30 nucleotides in length. One having ordinary skill in the art will appreciate that this embodies antisense compounds having antisense portions of 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 nucleotides in length, or any range therewithin.

In another embodiment, the oligomeric compounds of the present invention also include variants in which a different base is present at one or more of the nucleotide positions in the compound. For example, if the first nucleotide is an adenosine, variants may be produced which contain thymidine, guanosine or citidine at this position. This may be done at any of the positions of the antisense or dsRNA compounds. These compounds are then tested using the methods described herein to determine their ability to inhibit expression of a target nucleic acid.

In some embodiments, homology, sequence identity or complementarity, between the antisense compound and target is from about 40% to about 60%. In some embodiments, homology, sequence identity or complementarity, is from about 60% to about 70%. In some embodiments, homology, sequence identity or complementarity, is from about 70% to about 80%. In some embodiments, homology, sequence identity or complementarity, is from about 80% to about 90%. In some embodiments, homology, sequence identity or complementarity, is about 90%, about 92%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99% or about 100%.

In another embodiment, the antisense oligonucleotides, such as for example, nucleic acid molecules set forth in SEQ ID NOS: 6 to 45 comprise one or more substitutions or modifications. In one embodiment, the nucleotides are substituted with locked nucleic acids (LNA).

In another embodiment, the oligonucleotides target one or more regions of the nucleic acid molecules sense and/or antisense of coding and/or non-coding sequences associated with Pancreatic Developmental gene and the sequences set forth as SEQ ID NOS: 1 to 12. The oligonucleotides are also targeted to overlapping regions of SEQ ID NOS: 1 to 12.

Certain oligonucleotides of this invention are chimeric oligonucleotides. "Chimeric oligonucleotides" or "chimeras," in the context of this invention, are oligonucleotides which contain two or more chemically distinct regions, each made up of at least one nucleotide. These oligonucleotides typically contain at least one region of modified nucleotides that confers one or more beneficial properties (such as, for example, increased nuclease resistance, increased uptake into cells, increased binding affinity for the target) and a region that is a substrate for enzymes capable of cleaving RNA:DNA or RNA:RNA hybrids. By way of example, RNase H is a cellular endonuclease which cleaves the RNA strand of an RNA:DNA duplex. Activation of RNase H, therefore, results in cleavage of the RNA target, thereby greatly enhancing the efficiency of antisense modulation of gene expression. Consequently, comparable results can often be obtained with shorter oligonucleotides when chimeric oligonucleotides are used, compared to phosphorothioate deoxyoligonucleotides hybridizing to the same target region. Cleavage of the RNA target can be routinely detected by gel electrophoresis and, if necessary, associated nucleic acid hybridization techniques known in the art. In one embodiment, a chimeric oligonucleotide comprises at least one region modified to increase target binding affinity, and, usually, a region that acts as a substrate for

35

RNAse H. Affinity of an oligonucleotide for its target (in this case, a nucleic acid encoding ras) is routinely determined by measuring the  $T_m$  of an oligonucleotide/target pair, which is the temperature at which the oligonucleotide and target dissociate; dissociation is detected spectrophotometrically. The higher the  $T_m$ , the greater is the affinity of the oligonucleotide for the target.

Chimeric antisense compounds of the invention may be formed as composite structures of two or more oligonucleotides, modified oligonucleotides, oligonucleosides and/or oligonucleotides mimetics as described above. Such compounds have also been referred to in the art as hybrids or gapmers. Representative United States patents that teach the preparation of such hybrid structures comprise, but are not limited to, U.S. Pat. Nos. 5,013,830; 5,149,797; 5,220,007; 5,256,775; 5,366,878; 5,403,711; 5,491,133; 5,565,350; 5,623,065; 5,652,355; 5,652,356; and 5,700,922, each of which is herein incorporated by reference.

In another embodiment, the region of the oligonucleotide which is modified comprises at least one nucleotide modified at the 2' position of the sugar, most preferably a 2'-O-alkyl, 2'-O-alkyl-O-alkyl or 2'-fluoro-modified nucleotide. In other embodiments, RNA modifications include 2'-fluoro, 2'-amino and 2'-O-methyl modifications on the ribose of pyrimidines, abasic residues or an inverted base at the 3' end of the RNA. Such modifications are routinely incorporated into oligonucleotides and these oligonucleotides have been shown to have a higher  $T_m$  (i.e., higher target binding affinity) than; 2'-deoxyoligonucleotides against a given target. The effect of such increased affinity is to greatly enhance RNAi oligonucleotide inhibition of gene expression. RNAse H is a cellular endonuclease that cleaves the RNA strand of RNA: DNA duplexes; activation of this enzyme therefore results in cleavage of the RNA target, and thus can greatly enhance the efficiency of RNAi inhibition. Cleavage of the RNA target can be routinely demonstrated by gel electrophoresis. In another embodiment, the chimeric oligonucleotide is also modified to enhance nuclease resistance. Cells contain a variety of exo- and endo-nucleases which can degrade nucleic acids. A number of nucleotide and nucleoside modifications have been shown to make the oligonucleotide into which they are incorporated more resistant to nuclease digestion than the native oligodeoxynucleotide. Nuclease resistance is routinely measured by incubating oligonucleotides with cellular extracts or isolated nuclease solutions and measuring the extent of intact oligonucleotide remaining over time, usually by gel electrophoresis. Oligonucleotides which have been modified to enhance their nuclease resistance survive intact for a longer time than unmodified oligonucleotides. A variety of oligonucleotide modifications have been demonstrated to enhance or confer nuclease resistance. Oligonucleotides which contain at least one phosphorothioate modification are presently more preferred. In some cases, oligonucleotide modifications which enhance target binding affinity are also, independently, able to enhance nuclease resistance. Some desirable modifications can be found in De Mesmacker et al. (1995) *Acc. Chem. Res.*, 28:366-374.

Specific examples of some oligonucleotides envisioned for this invention include those comprising modified backbones, for example, phosphorothioates, phosphotriesters, methyl phosphonates, short chain alkyl or cycloalkyl intersugar linkages or short chain heteroatomic or heterocyclic intersugar linkages. Most are oligonucleotides with phosphorothioate backbones and those with heteroatom backbones, particularly  $\text{CH}_2-\text{NH}-\text{O}-\text{CH}_2$ ,  $\text{CH}_2-\text{N}(\text{CH}_3)-\text{O}-\text{CH}_2$  [known as a methylene(methylimino) or MMI backbone],  $\text{CH}_2-\text{O}-\text{N}(\text{CH}_3)-\text{CH}_2$ ,  $\text{CH}_2-\text{N}(\text{CH}_3)-\text{N}(\text{CH}_3)-$

36

$\text{CH}_2$  and  $\text{O}-\text{N}(\text{CH}_3)-\text{CH}_2-\text{CH}_2$  backbones, wherein the native phosphodiester backbone is represented as  $\text{O}-\text{P}-\text{O}-\text{CH}$ . The amide backbones disclosed by De Mesmacker et al. (1995) *Acc. Chem. Rev.* 28:366-374 are also preferred. Also are oligonucleotides having morpholino backbone structures (Summerton and Weller, U.S. Pat. No. 5,034,506). In other embodiments, such as the peptide nucleic acid (PNA) backbone, the phosphodiester backbone of the oligonucleotide is replaced with a polyamide backbone, the nucleotides being bound directly or indirectly to the aza nitrogen atoms of the polyamide backbone. Oligonucleotides may also comprise one or more substituted sugar moieties, oligonucleotides comprise one of the following at the 2' position: OH, SH, SCH<sub>3</sub>, F, OCN, OCH<sub>3</sub>, OCH<sub>3</sub>, OCH<sub>3</sub> O(CH<sub>2</sub>)<sub>n</sub> CH<sub>3</sub>, O(CH<sub>2</sub>)<sub>n</sub> NH<sub>2</sub> or O(CH<sub>2</sub>)<sub>n</sub> CH<sub>3</sub> where n is from 1 to about 10; C1 to C10 lower alkyl, alkoxyalkoxy, substituted lower alkyl, alkaryl or aralkyl; Cl; Br; CN; CF<sub>3</sub>; OCF<sub>3</sub>; O—, S—, or N-alkyl; O—, S—, or N-alkenyl; SOCH<sub>3</sub>; SO<sub>2</sub> CH<sub>3</sub>; ONO<sub>2</sub>; NO<sub>2</sub>; N<sub>3</sub>; NH<sub>2</sub>; heterocycloalkyl; heterocycloalkaryl; aminoalkylamino; polyalkylamino; substituted silyl; an RNA cleaving group; a reporter group; an intercalator; a group for improving the pharmacokinetic properties of an oligonucleotide; or a group for improving the pharmacodynamic properties of an oligonucleotide and other substituents having similar properties. A modification includes 2'-methoxyethoxy[2'-O—CH<sub>2</sub> CH<sub>2</sub> OCH<sub>3</sub>, also known as 2'-O-(2-methoxyethyl)]. Other modifications include 2'-methoxy(2'-O—CH<sub>3</sub>), 2'-propoxy(2'-OCH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>) and 2-fluoro(2'-F). Similar modifications may also be made at other positions on the oligonucleotide, particularly the 3' position of the sugar on the 3' terminal nucleotide and the 5' position of 5' terminal nucleotide. Oligonucleotides may also have sugar mimetics such as cyclobutyl in place of the pentofuranosyl group.

Oligonucleotides may also include, additionally or alternatively, nucleobase (often referred to in the art simply as "base") modifications or substitutions. As used herein, "unmodified" or "natural" nucleotides include adenine (A), guanine (G), thymine (T), cytosine (C) and uracil (U). Modified nucleotides include nucleotides found only infrequently or transiently in natural nucleic acids. e.g., hypoxanthine, 6-methyladenine, 5-Me pyrimidines, particularly 5-methylcytosine (also referred to as 5-methyl-2'-deoxycytosine and often referred to in the art as 5-Me-C), 5-hydroxymethylcytosine (HMC), glycosyl HMC and gentobiosyl HMC, as well as synthetic nucleosides. e.g., 2-aminoadenine, 2-(methylamino)adenine, 2-(imidazolylalkyl)adenine, 2-(aminoalkylamino)adenine or other heterosubstituted alkyladenines, 2-thiouracil, 2-thiothymine, 5-bromouracil, 5-hydroxymethyluracil, 8-azaguanine, 7-deazaguanine, N<sub>6</sub>(6-amino-hexyl)adenine and 2,6-diaminopurine. A "universal" base known in the art, e.g., inosine, may be included, S-Me-C substitutions have been shown to increase nucleic acid duplex stability by 0.6-1.2° C. (Sanghvi, Y. S., in Crooke, S. T. and Lebleu, B., eds., *Antisense Research and Applications*, CRC Press, Boca Raton, 1993, pp. 276-278) and are presently base substitutions.

Another modification of the oligonucleotides of the invention involves chemically linking to the oligonucleotide one or more moieties or conjugates which enhance the activity or cellular uptake of the oligonucleotide. Such moieties include but are not limited to lipid moieties such as a cholesterol moiety, a cholesteryl moiety, a thioether, e.g., hexyl-S-tritylthiol a thiocholesterol, an aliphatic chain, e.g., dodecanol or undecyl residues, a phospholipid, e.g., di-hexadecyl-rac-glycerol or triethylammonium 1,2-di-O-hexadecyl-rac-glycerol-3-H-phosphonate, a polyamine or a polyethylene glycol

chain or adamantane acetic acid. Oligonucleotides comprising lipophilic moieties, and methods for preparing such oligonucleotides are known in the art, for example, U.S. Pat. Nos. 5,138,045, 5,218,105 and 5,459,255.

It is not necessary for all positions in a given oligonucleotide to be uniformly modified, and in fact more than one of the aforementioned modifications may be incorporated in a single oligonucleotide or even at within a single nucleoside within an oligonucleotide. The present invention also includes oligonucleotides which are chimeric oligonucleotides as hereinbefore defined.

In another embodiment, the nucleic acid molecule of the present invention is conjugated with another moiety including but not limited to abasic nucleotides, polyether, polyamine, polyamides peptides, carbohydrates, lipid, or polyhydrocarbon compounds. Those skilled in the art will recognize that these molecules can be linked to one or more of any nucleotides comprising the nucleic acid molecule at several positions on the sugar, base or phosphate group.

The oligonucleotides used in accordance with this invention may be conveniently and routinely made through the well-known technique of solid phase synthesis. Equipment for such synthesis is sold by several vendors including Applied Biosystems. Any other means for such synthesis may also be employed; the actual synthesis of the oligonucleotides is well within the talents of one of ordinary skill in the art. It is also well known to use similar techniques to prepare other oligonucleotides such as the phosphorothioates and alkylated derivatives. It is also well known to use similar techniques and commercially available modified amidites and controlled-pore glass (CPG) products such as biotin, fluorescein, acridine or psoralen-modified amidites and/or CPG (available from Glen Research, Sterling Va.) to synthesize fluorescently labeled, biotinylated or other modified oligonucleotides such as cholesterol-modified oligonucleotides.

In accordance with the invention, use of modifications such as the use of LNA monomers to enhance the potency, specificity and duration of action and broaden the routes of administration of oligonucleotides comprised of current chemistries such as MOE, ANA, FANA, PS etc. This can be achieved by substituting some of the monomers in the current oligonucleotides by LNA monomers. The LNA modified oligonucleotide may have a size similar to the parent compound or may be larger or preferably smaller. It is that such LNA-modified oligonucleotides contain less than about 70%, more preferably less than about 60%, most preferably less than about 50% LNA monomers and that their sizes are between about 5 and 25 nucleotides, more preferably between about 12 and 20 nucleotides.

Modified oligonucleotide backbones comprise, but are not limited to, phosphorothioates, chiral phosphorothioates, phosphordithioates, phosphotriesters, aminoalkylphosphotriesters, methyl and other alkyl phosphonates comprising 3'alkylene phosphonates and chiral phosphonates, phosphinates, phosphoramidates comprising 3'-amino phosphoramidate and aminoalkylphosphoramidates, thionophosphoramidates, thionoalkylphosphonates, thionoalkylphosphotriesters, and boranophosphates having normal 3'-5' linkages, 2'-5' linked analogs of these, and those having inverted polarity wherein the adjacent pairs of nucleoside units are linked 3'-5' to 5'-3' or 2'-5' to 5'-2'. Various salts, mixed salts and free acid forms are also included.

Representative United States patents that teach the preparation of the above phosphorus containing linkages comprise, but are not limited to, U.S. Pat. Nos. 3,687,808; 4,469,863; 4,476,301; 5,023,243; 5,177,196; 5,188,897; 5,264,423; 5,276,019; 5,278,302; 5,286,717; 5,321,131; 5,399,676;

5,405,939; 5,453,496; 5,455,233; 5,466,677; 5,476,925; 5,519,126; 5,536,821; 5,541,306; 5,550,111; 5,563,253; 5,571,799; 5,587,361; and 5,625,050, each of which is herein incorporated by reference.

Modified oligonucleotide backbones that do not include a phosphorus atom therein have backbones that are formed by short chain alkyl or cycloalkyl internucleoside linkages, mixed heteroatom and alkyl or cycloalkyl internucleoside linkages, or one or more short chain heteroatomic or heterocyclic internucleoside linkages. These comprise those having morpholino linkages (formed in part from the sugar portion of a nucleoside); siloxane backbones; sulfide, sulfoxide and sulfone backbones; formacetyl and thioformacetyl backbones; methylene formacetyl and thioformacetyl backbones; alkene containing backbones; sulfamate backbones; methyleneimino and methylenehydrazino backbones; sulfonate and sulfonamide backbones; amide backbones; and others having mixed N, O, S and CH<sub>2</sub> component parts.

Representative United States patents that teach the preparation of the above oligonucleosides comprise, but are not limited to, U.S. Pat. Nos. 5,034,506; 5,166,315; 5,185,444; 5,214,134; 5,216,141; 5,235,033; 5,264,562; 5,264,564; 5,405,938; 5,434,257; 5,466,677; 5,470,967; 5,489,677; 5,541,307; 5,561,225; 5,596,086; 5,602,240; 5,610,289; 5,602,240; 5,608,046; 5,610,289; 5,618,704; 5,623,070; 5,663,312; 5,633,360; 5,677,437; and 5,677,439, each of which is herein incorporated by reference.

In other oligonucleotide mimetics, both the sugar and the internucleoside linkage, i.e., the backbone, of the nucleotide units are replaced with novel groups. The base units are maintained for hybridization with an appropriate nucleic acid target compound. One such oligomeric compound, an oligonucleotide mimetic that has been shown to have excellent hybridization properties, is referred to as a peptide nucleic acid (PNA). In PNA compounds, the sugar-backbone of an oligonucleotide is replaced with an amide containing backbone, in particular an aminoethylglycine backbone. The nucleobases are retained and are bound directly or indirectly to aza nitrogen atoms of the amide portion of the backbone. Representative United States patents that teach the preparation of PNA compounds comprise, but are not limited to, U.S. Pat. Nos. 5,539,082; 3,714,331; and 5,719,262, each of which is herein incorporated by reference. Further teaching of PNA compounds can be found in Nielsen, et al. (1991) *Science* 254, 1497-1500.

In another embodiment of the invention the oligonucleotides with phosphorothioate backbones and oligonucleosides with heteroatom backbones, and in particular —CH<sub>2</sub>—NH—O—CH<sub>2</sub>—, —CH<sub>2</sub>—N(CH<sub>3</sub>)—O—CH<sub>2</sub>— known as a methylene(methylimino) or MMI backbone. —CH<sub>2</sub>—O—N(CH<sub>3</sub>)—CH<sub>2</sub>—, —CH<sub>2</sub>N(CH<sub>3</sub>)—N(CH<sub>3</sub>)CH<sub>2</sub>— and —O—N(CH<sub>3</sub>)—CH<sub>2</sub>—CH<sub>2</sub>— wherein the native phosphodiester backbone is represented as —O—P—O—CH<sub>2</sub>— of the above referenced U.S. Pat. No. 5,489,677, and the amide backbones of the above referenced U.S. Pat. No. 5,602,240. Also are oligonucleotides having morpholino backbone structures of the above-referenced U.S. Pat. No. 5,034,506.

Modified oligonucleotides may also contain one or more substituted sugar moieties, oligonucleotides comprise one of the following at the 2' position: OH; F; O—, S—, or N-alkyl; O—, S—, or N-alkenyl; O—, S— or N-alkynyl; or O alkyl-O-alkyl, wherein the alkyl, alkenyl and alkynyl may be substituted or unsubstituted C to CO alkyl or C<sub>2</sub> to CO alkenyl and alkynyl. Particularly are O(CH<sub>2</sub>)<sub>n</sub> OmCH<sub>3</sub>, O(CH<sub>2</sub>)<sub>n</sub>, OCH<sub>3</sub>, O(CH<sub>2</sub>)<sub>n</sub>NH<sub>2</sub>, O(CH<sub>2</sub>)<sub>n</sub>CH<sub>3</sub>, O(CH<sub>2</sub>)<sub>n</sub>ONH<sub>2</sub>, and O(CH<sub>2</sub>)<sub>n</sub>ON(CH<sub>2</sub>)<sub>n</sub>CH<sub>3</sub>)<sub>2</sub> where n and m can be from 1 to about 10. Other oligonucleotides comprise one of the follow-

ing at the 2' position: C to CO, (lower alkyl, substituted lower alkyl, alkaryl, aralkyl, O-alkaryl or O-aralkyl, SH, SCH<sub>3</sub>, OCN, Cl, Br, CN, CF<sub>3</sub>, OCF<sub>3</sub>, SOCH<sub>3</sub>, SO<sub>2</sub>CH<sub>3</sub>, ONO<sub>2</sub>, NO<sub>2</sub>, N<sub>3</sub>, NH<sub>2</sub>, heterocycloalkyl, heterocycloalkaryl, aminoalkylamino, polyalkylamino, substituted silyl, an RNA cleaving group, a reporter group, an intercalator, a group for improving the pharmacokinetic properties of an oligonucleotide, or a group for improving the pharmacodynamic properties of an oligonucleotide, and other substituents having similar properties. A modification comprises 2'-methoxyethoxy(2'-O—CH<sub>2</sub>CH<sub>2</sub>OCH<sub>3</sub>, also known as 2'-O-(2-methoxyethyl) or 2'-MOE) i.e., an alkoxyalkoxy group. A further modification comprises 2'-dimethylaminooxyethoxy, i.e., a O(CH<sub>2</sub>)<sub>2</sub>ON(CH<sub>3</sub>)<sub>2</sub> group, also known as 2'-DMAOE, as described in examples herein below, and 2'-dimethylaminoethoxyethyl or 2'-DMAEOE), i.e., 2'-O—CH<sub>2</sub>O—CH<sub>2</sub>N(CH<sub>2</sub>)<sub>2</sub>.

Other modifications comprise 2'-methoxy(2'-O CH<sub>3</sub>), 2'-aminopropoxy(2'-O CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>NH<sub>2</sub>) and 2'-fluoro (2'-F). Similar modifications may also be made at other positions on the oligonucleotide, particularly the 3' position of the sugar on the 3' terminal nucleotide or in 2'-5' linked oligonucleotides and the 5' position of 5' terminal nucleotide. Oligonucleotides may also have sugar mimetics such as cyclobutyl moieties in place of the pentofuranosyl sugar. Representative United States patents that teach the preparation of such modified sugar structures comprise, but are not limited to, U.S. Pat. Nos. 4,981,957; 5,118,800; 5,319,080; 5,359,044; 5,393,878; 5,446,137; 5,466,786; 5,514,785; 5,519,134; 5,567,811; 5,576,427; 5,591,722; 5,597,909; 5,610,300; 5,627,053; 5,639,873; 5,646,265; 5,658,873; 5,670,633; and 5,700,920, each of which is herein incorporated by reference.

Oligonucleotides may also comprise nucleobase (often referred to in the art simply as "base") modifications or substitutions. As used herein, "unmodified" or "natural" nucleotides comprise the purine bases adenine (A) and guanine (G), and the pyrimidine bases thymine (T), cytosine (C) and uracil (U). Modified nucleotides comprise other synthetic and natural nucleotides such as 5-methylcytosine (5-me-C), 5-hydroxymethyl cytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 2-thiouracil, 2-thiothymine and 2-thiocytosine, 5-halouracil and cytosine, 5-propynyl uracil and cytosine, 6-azo uracil, cytosine and thymine, 5-uracil (pseudo-uracil), 4-thiouracil, 8-halo, 8-amino, 8-thiol, 8-thioalkyl, 8-hydroxyl and other 8-substituted adenines and guanines, 5-halo particularly 3-bromo, 5-trifluoromethyl and other 5-substituted uracils and cytosines, 7-methylguanine and 7-methyladenine, 8-azaguanine and 8-azaadenine, 7-deazaguanine and 7-deazaadenine and 3-deazaguanine and 3-deazaadenine.

Further, nucleotides comprise those disclosed in U.S. Pat. No. 3,687,808, those disclosed in 'The Concise Encyclopedia of Polymer Science And Engineering', pages 858-859, Kroschwitz, J. I. ed. John Wiley & Sons, 1990, those disclosed by Englisch et al., 'Angewandte Chemie., International Edition', 1991, 30, page 613, and those disclosed by Sanghvi, Y. S. Chapter 15, 'Antisense Research and Applications', pages 289-302, Crooke, S. T. and Lebleu, B. ea. CRC Press, 1993. Certain or these nucleotides are particularly useful for increasing the binding affinity of the oligomeric compounds of the invention. These comprise 5-substituted pyrimidines, 6-azapyrimidines and N-2, N-6 and 0-6 substituted purines, comprising 2-aminopropyladenine, 5-propynyluracil and 5-propynylcytosine, 5-methylcytosine substitutions

have been shown to increase nucleic acid duplex stability by 0.6-1.2° C. (Sanghvi, Y. S., Crooke, S. T. and Lebleu, B., eds, 'Antisense Research and Applications', CRC Press, Boca Raton, 1993, pp. 276-278) and are presently base substitutions, even more particularly when combined with 2'-O-methoxyethyl sugar modifications.

Representative United States patents that teach the preparation of the above noted modified nucleotides as well as other modified nucleotides comprise, but are not limited to, U.S. Pat. No. 3,687,808, as well as U.S. Pat. Nos. 4,845,205; 5,130,302; 5,134,066; 5,175,273; 5,367,066; 5,432,272; 5,457,187; 5,459,255; 5,484,908; 5,502,177; 5,525,711; 5,552,540; 5,387,469; 5,596,091; 5,614,617; 5,750,692, and 5,681,941, each of which is herein incorporated by reference.

Another modification of the oligonucleotides of the invention involves chemically linking to the oligonucleotide one or more moieties or conjugates, which enhance the activity, cellular distribution, or cellular uptake of the oligonucleotide.

Such moieties comprise but are not limited to, lipid moieties such as a cholesterol moiety, cholic acid, a thioether, e.g., hexyl-S-tritylthiol, a thiocholesterol, an aliphatic chain, e.g., dodecandiol or undecyl residues, a phospholipid, e.g., di-hexadecyl-rac-glycerol or triethylammonium 1,2-di-O-hexadecyl-rac-glycero-3-H-phosphonate, a polyamine or a polyethylene glycol chain, or adamantane acetic acid, a palmitoyl moiety, or an octadecylamine or hexylamino-carbonyl-t oxycholesterol moiety.

Representative United States patents that teach the preparation of such oligonucleotides conjugates comprise, but are not limited to, U.S. Pat. Nos. 4,828,979; 4,948,882; 5,218,105; 5,525,465; 5,541,313; 5,545,730; 5,552,538; 5,714,717; 5,580,731; 5,580,731; 5,591,584; 5,109,124; 5,118,802; 5,138,045; 5,414,077; 5,486,603; 5,512,439; 5,578,718; 5,608,046; 4,587,044; 4,605,735; 4,667,025; 4,762,779; 4,789,737; 4,824,941; 4,835,263; 4,876,335; 4,904,582; 4,958,013; 5,082,830; 5,112,963; 5,214,136; 5,082,830; 5,112,963; 5,214,136; 5,245,022; 5,254,469; 5,258,506; 5,262,536; 3,272,250; 5,292,873; 5,317,098; 5,371,241; 5,391,723; 5,416,203; 5,451,463; 5,510,475; 5,512,667; 5,514,785; 5,565,552; 5,567,810; 5,574,142; 5,585,481; 5,587,371; 5,595,726; 5,597,696; 5,599,923; 5,599,928 and 5,688,941, each of which is herein incorporated by reference.

Drug Discovery: The compounds of the present invention can also be applied in the areas of drug discovery and target validation. The present invention comprehends the use of the compounds and target segments identified herein in drug discovery efforts to elucidate relationships that exist between a Pancreatic Developmental gene polynucleotide and a disease state, phenotype, or condition. These methods include detecting or modulating a Pancreatic Developmental gene polynucleotide comprising contacting a sample, tissue, cell or organism with the compounds of the present invention, measuring the nucleic acid or protein level of a Pancreatic Developmental gene polynucleotide and/or a related phenotype or chemical endpoint at some time after treatment, and optionally comparing the measured value to a non-treated sample or sample treated with a further compound of the invention. These methods can also be performed in parallel or in combination with other experiments to determine the function of unknown genes for the process of target validation or to determine the validity of a particular gene product as a target for treatment or prevention of a particular disease, condition, or phenotype.

Assessing Up-regulation or Inhibition of Gene Expression:

Transfer of an exogenous nucleic acid into a host cell or organism can be assessed by directly detecting the presence of the nucleic acid in the cell or organism. Such detection can

be achieved by several methods well known in the art. For example, the presence of the exogenous nucleic acid can be detected by Southern blot or by a polymerase chain reaction (PCR) technique using primers that specifically amplify nucleotide sequences associated with the nucleic acid. Expression of the exogenous nucleic acids can also be measured using conventional methods including gene expression analysis. For instance, mRNA produced from an exogenous nucleic acid can be detected and quantified using a Northern blot and reverse transcription PCR (RT-PCR).

Expression of RNA from the exogenous nucleic acid can also be detected by measuring an enzymatic activity or a reporter protein activity. For example, antisense modulatory activity can be measured indirectly as a decrease or increase in target nucleic acid expression as an indication that the exogenous nucleic acid is producing the effector RNA. Based on sequence conservation, primers can be designed and used to amplify coding regions of the target genes. Initially, the most highly expressed coding region from each gene can be used to build a model control gene, although any coding or non coding region can be used. Each control gene is assembled by inserting each coding region between a reporter coding region and its poly(A) signal. These plasmids would produce an mRNA with a reporter gene in the upstream portion of the gene and a potential RNAi target in the 3' non-coding region. The effectiveness of individual antisense oligonucleotides would be assayed by modulation of the reporter gene. Reporter genes useful in the methods of the present invention include acetohydroxyacid synthase (AHAS), alkaline phosphatase (AP), beta galactosidase (LacZ), beta glucuronidase (GUS), chloramphenicol acetyltransferase (CAT), green fluorescent protein (GFP), red fluorescent protein (RFP), yellow fluorescent protein (YFP), cyan fluorescent protein (CFP), horseradish peroxidase (HRP), luciferase (Luc), nopaline synthase (NOS), octopine synthase (OCS), and derivatives thereof. Multiple selectable markers are available that confer resistance to ampicillin, bleomycin, chloramphenicol, gentamycin, hygromycin, kanamycin, lincomycin, methotrexate, phosphinothricin, puromycin, and tetracycline. Methods to determine modulation of a reporter gene are well known in the art, and include, but are not limited to, fluorometric methods (e.g. fluorescence spectroscopy, Fluorescence Activated Cell Sorting (FACS), fluorescence microscopy), antibiotic resistance determination.

NEUROD1, HNF4A, MAFA, PDX1, NKX6-1 proteins and mRNA expression can be assayed using methods known to those of skill in the art and described elsewhere herein. For example, immunoassays such as the ELISA can be used to measure protein levels. Pancreatic Developmental gene antibodies for ELISAs are available commercially, e.g., from R&D Systems (Minneapolis, Minn.), Abcam, Cambridge, Mass.

In embodiments, NEUROD1, HNF4A, MAFA, PDX1, NKX6-1 expression (e.g., mRNA or protein) in a sample (e.g., cells or tissues in vivo or in vitro) treated using an antisense oligonucleotide of the invention is evaluated by comparison with Pancreatic Developmental gene expression in a control sample. For example, expression of the protein or nucleic acid can be compared using methods known to those of skill in the art with that in a mock-treated or untreated sample. Alternatively, comparison with a sample treated with a control antisense oligonucleotide (e.g., one having an altered or different sequence) can be made depending on the information desired. In another embodiment, a difference in the expression of the Pancreatic Developmental gene protein or nucleic acid in a treated vs. an untreated sample can be compared with the difference in expression of a different

nucleic acid (including any standard deemed appropriate by the researcher, e.g., a housekeeping gene) in a treated sample vs. an untreated sample.

Observed differences can be expressed as desired, e.g., in the form of a ratio or fraction, for use in a comparison with control. In embodiments, the level of a Pancreatic Developmental gene mRNA or protein, in a sample treated with an antisense oligonucleotide of the present invention, is increased or decreased by about 1.25-fold to about 10-fold or more relative to an untreated sample or a sample treated with a control nucleic acid. In embodiments, the level of a Pancreatic Developmental gene mRNA or protein is increased or decreased by at least about 1.25-fold, at least about 1.3-fold, at least about 1.4-fold, at least about 1.5-fold, at least about 1.6-fold, at least about 1.7-fold, at least about 1.8-fold, at least about 2-fold, at least about 2.5-fold, at least about 3-fold, at least about 3.5-fold, at least about 4-fold, at least about 4.5-fold, at least about 5-fold, at least about 5.5-fold, at least about 6-fold, at least about 6.5-fold, at least about 7-fold, at least about 7.5-fold, at least about 8-fold, at least about 8.5-fold, at least about 9-fold, at least about 9.5-fold, or at least about 10-fold or more.

Kits, Research Reagents, Diagnostics, and Therapeutics

The compounds of the present invention can be utilized for diagnostics, therapeutics, and prophylaxis, and as research reagents and components of kits. Furthermore, antisense oligonucleotides, which are able to inhibit gene expression with exquisite specificity, are often used by those of ordinary skill to elucidate the function of particular genes or so distinguish between functions of various members of a biological pathway.

For use in kits and diagnostics and in various biological systems, the compounds of the present invention, either alone or in combination with other compounds or therapeutics, are useful as tools in differential and/or combinatorial analyses to elucidate expression patterns of a portion or the entire complement of genes expressed within cells and tissues.

As used herein the term "biological system" or "system" is defined as any organism, cell, cell culture or tissue that expresses, or is made competent to express products of the Pancreatic Developmental genes. These include, but are not limited to, humans, transgenic animals, cells, cell cultures, tissues, xenografts, transplants and combinations thereof.

As one non limiting example, expression patterns within cells or tissues treated with one or more antisense compounds are compared to control cells or tissues not treated with antisense compounds and the patterns produced are analyzed for differential levels of gene expression as they pertain, for example, to disease association, signaling pathway, cellular localization, expression level, size, structure or function of the genes examined. These analyses can be performed on stimulated or unstimulated cells and in the presence or absence of other compounds that affect expression patterns.

Examples of methods of gene expression analysis known in the art include DNA arrays or microarrays (Brazma and Vilo, (2000) *FEBS Lett.*, 480, 17-24; Celis, et al. (2000) *FEBS Lett.*, 480, 2-16). SAGE (serial analysis of gene expression) (Madden, et al. (2000) *Drug Discov. Today*, 5, 415-425). READS (restriction enzyme amplification of digested cDNAs) (Prashar and Weissman, (1999) *Methods Enzymol.*, 303, 258-72). TOGA (total gene expression analysis) (Sutcliffe, et al., (2000) *Proc. Natl. Acad. Sci. U.S.A.* 97, 1976-81), protein arrays and proteomics (Celis, et al., (2000) *FEBS Lett.*, 480, 2-16; Jungblut, et al., *Electrophoresis*, 1999, 20, 2100-10), expressed sequence tag (EST) sequencing (Celis, et al., *FEBS Lett.*, 2000, 480, 2-16; Larsson, et al., *J. Biotechnol.*, 2000, 80, 143-57), subtractive RNA fingerprinting



(SuRF) (Fuchs, et al., (2000) *Anal. Biochem.* 286, 91-98; Larson, et al., (2000) *Cytometry* 41, 203-208), subtractive cloning, differential display (DD) (Jurecic and Belmont, (2000) *Curr. Opin. Microbiol.* 3, 316-21), comparative genomic hybridization (Carulli, et al., (1998) *J. Cell Biochem. Suppl.*, 31, 286-96), FISH (fluorescent in situ hybridization) techniques (Going and Gusterson, (1999) *Eur. J. Cancer*, 35, 1895-904) and mass spectrometry methods (To. Comb. (2000) *Chem. High Throughput Screen*, 3, 235-41).

The compounds of the invention are useful for research and diagnostics, because these compounds hybridize to nucleic acids encoding a Pancreatic Developmental gene. For example, oligonucleotides that hybridize with such efficiency and under such conditions as disclosed herein as to be effective Pancreatic Developmental gene modulators are effective primers or probes under conditions favoring gene amplification or detection, respectively. These primers and probes are useful in methods requiring the specific detection of nucleic acid molecules encoding a Pancreatic Developmental gene and in the amplification of said nucleic acid molecules for detection or for use in further studies of a Pancreatic Developmental gene. Hybridization of the antisense oligonucleotides, particularly the primers and probes, of the invention with a nucleic acid encoding a Pancreatic Developmental gene can be detected by means known in the art. Such means may include conjugation of an enzyme to the oligonucleotide, radiolabeling of the oligonucleotide, or any other suitable detection means. Kits using such detection means for detecting the level of a Pancreatic Developmental gene in a sample may also be prepared.

The specificity and sensitivity of antisense are also harnessed by those of skill in the art for therapeutic uses. Antisense compounds have been employed as therapeutic moieties in the treatment of disease states in animals, including humans. Antisense oligonucleotide drugs have been safely and effectively administered to humans and numerous clinical trials are presently underway. It is thus established that antisense compounds can be useful therapeutic modalities that can be configured to be useful in treatment regimes for the treatment of cells, tissues and animals, especially humans.

For therapeutics, an animal, preferably a human, suspected of having a disease or disorder which can be treated by modulating the expression of a Pancreatic Developmental gene polynucleotide is treated by administering antisense compounds in accordance with this invention. For example, in one non-limiting embodiment, the methods comprise the step of administering to the animal in need of treatment, a therapeutically effective amount of a Pancreatic Developmental gene modulator. The Pancreatic Developmental gene modulators of the present invention effectively modulate the activity of a Pancreatic Developmental gene or modulate the expression of a Pancreatic Developmental gene protein. In one embodiment, the activity or expression of a Pancreatic Developmental gene in an animal is inhibited by about 10% as compared to a control. Preferably, the activity or expression of a Pancreatic Developmental gene in an animal is inhibited by about 30%. More preferably, the activity or expression of a Pancreatic Developmental gene in an animal is inhibited by 50% or more. Thus, the oligomeric compounds modulate expression of a Pancreatic Developmental gene mRNA by at least 10%, by at least 50%, by at least 25%, by at least 30%, by at least 41%, by at least 50%, by at least 60%, by at least 70%, by at least 75%, by at least 80%, by at least 85%, by at least 90%, by at least 95%, by at least 98%, by at least 99%, or by 100% as compared to a control.

In one embodiment the activity or expression of a Pancreatic Developmental gene and/or in an animal is increased by

about 10% as compared to a control. Preferably, the activity or expression of a Pancreatic Developmental gene in an animal is increased by about 30%. More preferably, the activity or expression of a Pancreatic Developmental gene in an animal is increased by 50% or more. Thus, the oligomeric compounds modulate expression of a Pancreatic Developmental gene mRNA by at least 10%, by at least 50%, by at least 25%, by at least 30%, by at least 40%, by at least 50%, by at least 60%, by at least 70%, by at least 75%, by at least 80%, by at least 85%, by at least 90%, by at least 95%, by at least 98%, by at least 99%, or by 100% as compared to a control.

For example, the reduction of the expression of a Pancreatic Developmental gene may be measured in serum, blood, adipose tissue, liver or any other body fluid, tissue or organ of the animal. Preferably, the cells contained within said fluids, tissues or organs being analyzed contain a nucleic acid molecule encoding Pancreatic Developmental gene peptides and/or the Pancreatic Developmental gene protein itself.

The compounds of the invention can be utilized in pharmaceutical compositions by adding an effective amount of a compound to a suitable pharmaceutically acceptable diluent or carrier. Use of the compounds and methods of the invention may also be useful prophylactically.

Conjugates: Another modification of the oligonucleotides of the invention involves chemically linking to the oligonucleotide one or more moieties or conjugates that enhance the activity cellular distribution or cellular uptake of the oligonucleotide. These moieties or conjugates can include conjugate groups covalently bound to functional groups such as primary or secondary hydroxyl groups. Conjugate groups of the invention include intercalator, reporter molecules, polyamines, polyamides, polyethylene glycols, polyethers, groups that enhance the pharmacodynamic properties of oligomers and groups that enhance the pharmacokinetic properties of oligomers. Typical conjugate groups include cholesterol, lipids, phospholipids, biotin, phenazine, folate, phenanthridine, anthraquinone, acridine, fluoresceins, rhodamines, coumarins, and dyes. Groups that enhance the pharmacodynamic properties, in the context of this invention, include groups that improve uptake, enhance resistance to degradation, and/or strengthen sequence-specific hybridization with the target nucleic acid. Groups that enhance the pharmacokinetic properties, in the context of this invention, include groups that improve uptake, distribution, metabolism or excretion of the compounds of the present invention. Representative conjugate groups are disclosed in International Patent Application No. PCT/US92/09196, filed Oct. 23, 1992, and U.S. Pat. No. 6,287,860, which are incorporated herein by reference. Conjugate moieties include, but are not limited to, lipid moieties such as a cholesterol moiety, cholic acid, a thioether, e.g., hexyl-5-tritylthiol, a thiocholesterol, an aliphatic chain, e.g., dodecandiol or undecyl residues, a phospholipid, e.g., di-hexadecyl-rac-glycerol or triethylammonium 1,2-di-O-hexadecyl-rac-glycero-3-Hphosphonate a polyamine or a polyethylene glycol chain, or adamantane acetic acid, a palmityl moiety, or an octadecylamine or hexylamino-carbonyl-oxycholesterol moiety. Oligonucleotides of the invention may also be conjugated to active drug substances, for example, aspirin, warfarin, phenylbutazone, ibuprofen, suprofen, fenbufen, ketoprofen, (S)-(+)-pranoprofen, carprofen dansylsarcosine, 2,3,5-triiodobenzoic acid, flutemamic acid, folinic acid, a benzothiadiazide, chlorothiazide, a diazepam, indomethacin, a barbiturate, a cephalosporin, a sulfa drug, an antidiabetic, an antibacterial or an antibiotic.

Representative United States patents that teach the preparation of such oligonucleotides conjugates include, but are not limited to, U.S. Pat. Nos. 4,828,979; 4,948,882; 5,218,



105; 5,525,465; 5,541,313; 5,545,730; 5,552,538; 5,578,717; 5,580,731; 5,580,731; 5,591,584; 5,109,124; 5,118,802; 5,138,045; 5,414,077; 5,486,603; 5,512,439; 5,578,718; 5,608,046; 4,587,044; 4,605,735; 4,667,025; 4,762,779; 4,789,737; 4,824,941; 4,835,263; 4,876,335; 4,904,582; 4,958,013; 5,082,830; 5,112,963; 5,214,136; 5,082,830; 5,112,963; 5,214,136; 5,245,022; 5,254,469; 5,258,506; 5,262,536; 5,272,250; 5,292,873; 5,317,098; 5,371,241; 5,391,723; 5,416,203; 5,451,463; 5,510,475; 5,512,667; 5,514,785; 5,565,552; 5,567,810; 5,574,142; 5,585,481; 5,587,371; 5,595,726; 5,597,696; 5,599,923; 5,599,928 and 5,688,941.

Formulations: The compounds of the invention may also be admixed, encapsulated, conjugated or otherwise associated with other molecules, molecule structures or mixtures of compounds, as for example, liposomes, receptor-targeted molecules, oral, rectal, topical or other formulations, for assisting in uptake, distribution and/or absorption. Representative United States patents that teach the preparation of such uptake, distribution and/or absorption-assisting formulations include, but are not limited to, U.S. Pat. Nos. 5,108,921; 5,354,844; 5,416,016; 5,459,127; 5,521,291; 5,543,165; 5,547,932; 5,583,020; 5,591,721; 4,426,330; 4,534,899; 5,013,556; 5,108,921; 5,213,804; 5,227,170; 5,264,221; 5,356,633; 5,395,619; 5,416,016; 5,417,978; 5,462,854; 5,469,854; 5,512,295; 5,527,528; 5,534,259; 5,543,152; 5,556,948; 5,580,575; and 5,595,756, each of which is herein incorporated by reference.

Although, the antisense oligonucleotides do not need to be administered in the context of a vector in order to modulate a target expression and/or function, embodiments of the invention relates to expression vector constructs for the expression of antisense oligonucleotides, comprising promoters, hybrid promoter gene sequences and possess a strong constitutive promoter activity, or a promoter activity which can be induced in the desired case.

In an embodiment, invention practice involves administering at least one of the foregoing antisense oligonucleotides with a suitable nucleic acid delivery system. In one embodiment, that system includes a non-viral vector operably linked to the polynucleotide. Examples of such nonviral vectors include the oligonucleotide alone (e.g. any one or more of SEQ ID NOS: 13 to 45) or in combination with a suitable protein, polysaccharide or lipid formulation.

Additionally suitable nucleic acid delivery systems include viral vector, typically sequence from at least one of an adenovirus, adenovirus-associated virus (AAV), helper-dependent adenovirus, retrovirus, or hemagglutination virus of Japan-liposome (HVJ) complex. Preferably, the viral vector comprises a strong eukaryotic promoter operably linked to the polynucleotide e.g., a cytomegalovirus (CMV) promoter.

Additionally vectors include viral vectors, fusion proteins and chemical conjugates. Retroviral vectors include Moloney murine leukemia viruses and HIV-based viruses. One HIV-based viral vector comprises at least two vectors wherein the gag and pol genes are from an HIV genome and the env gene is from another virus. DNA viral vectors are preferred. These vectors include pox vectors such as orthopox or avipox vectors, herpesvirus vectors such as a herpes simplex I virus (HSV) vector, Adenovirus Vectors and Adeno-associated Virus Vectors).

The antisense compounds of the invention encompass any pharmaceutically acceptable salts, esters, or salts of such esters, or any other compound which, upon administration to an animal, including a human, is capable of providing (directly or indirectly) the biologically active metabolic or residue thereof.

The term "pharmaceutically acceptable salts" refers to physiologically and pharmaceutically acceptable salts of the compounds of the invention: i.e., salts that retain the desired biological activity of the parent compound and do not impart undesired toxicological effects thereto. For oligonucleotides, examples of pharmaceutically acceptable salts and their uses are further described in U.S. Pat. No. 6,287,860, which is incorporated herein by reference.

The present invention also includes pharmaceutical compositions and formulations that include the antisense compounds of the invention. The pharmaceutical compositions of the present invention may be administered in a number of ways depending upon whether local or systemic treatment is desired and upon the area to be treated. Administration may be topical (including ophthalmic and to mucous membranes including vaginal and rectal delivery), pulmonary, e.g., by inhalation or insufflation of powders or aerosols, including by nebulizer; intratracheal, intranasal, epidermal and transdermal), oral or parenteral. Parenteral administration includes intravenous, intraarterial, subcutaneous, intraperitoneal or intramuscular injection or infusion; or intracranial, e.g., intrathecal or intraventricular, administration.

For treating tissues in the central nervous system, administration can be made by, e.g., injection or infusion into the cerebrospinal fluid. Administration of antisense RNA into cerebrospinal fluid is described, e.g., in U.S. Pat. App. Pub. No. 2007/011772, "Methods for slowing familial ALS disease progression," incorporated herein by reference in its entirety.

When it is intended that the antisense oligonucleotide of the present invention be administered to cells in the central nervous system, administration can be with one or more agents capable of promoting penetration of the subject antisense oligonucleotide across the blood-brain barrier. Injection can be made, e.g., in the entorhinal cortex or hippocampus. Delivery of neurotrophic factors by administration of an adenovirus vector to motor neurons in muscle tissue is described in, e.g., U.S. Pat. No. 6,632,427, "Adenoviral-vector-mediated gene transfer into medullary motor neurons," incorporated herein by reference. Delivery of vectors directly to the brain, e.g., the striatum, the thalamus, the hippocampus, or the substantia nigra; is known in the art and described, e.g., in U.S. Pat. No. 6,756,523, "Adenovirus vectors for the transfer of foreign genes into cells of the central nervous system particularly in brain," incorporated herein by reference. Administration can be rapid as by injection or made over a period of time as by slow infusion or administration of slow release formulations.

The subject antisense oligonucleotides can also be linked or conjugated with agents that provide desirable pharmaceutical or pharmacodynamic properties. For example, the antisense oligonucleotide can be coupled to any substance, known in the art to promote penetration or transport across the blood-brain barrier, such as an antibody to the transferrin receptor, and administered by intravenous injection. The antisense compound can be linked with a viral vector, for example, that makes the antisense compound more effective and/or increases the transport of the antisense compound across the blood-brain barrier. Osmotic blood brain barrier disruption can also be accomplished by, e.g., infusion of sugars including, but not limited to, meso erythritol, xylitol, D(+) galactose, D(+) lactose, D(+) xylose, dulcitol, myo-inositol, L(-) fructose, D(-) mannitol, D(+) glucose, D(+) arabinose, D(-) arabinose, cellobiose, D(+) maltose, D(+) raffinose, L(+) rhamnose, D(+) melibiose, D(-) ribose, adonitol, D(+) arabitol, L(-) arabitol, D(+) fucose, L(-) fucose, D(-) lyxose, L(+) lyxose, and L(-) lyxose, or amino acids

including, but not limited to, glutamine, lysine, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glycine, histidine, leucine, methionine, phenylalanine, proline, serine, threonine, tyrosine, valine, and taurine. Methods and materials for enhancing blood brain barrier penetration are described, e.g., in U.S. Pat. No. 4,866,042, "Method for the delivery of genetic material across the blood brain barrier;" U.S. Pat. No. 6,294,520, "Material for passage through the blood-brain barrier;" and U.S. Pat. No. 6,936,589, "Parenteral delivery systems," all incorporated herein by reference in their entirety.

The subject antisense compounds may be admixed, encapsulated, conjugated or otherwise associated with other molecules, molecule structures or mixtures of compounds, for example, liposomes, receptor-targeted molecules, oral, rectal, topical or other formulations, for assisting in uptake, distribution and/or absorption. For example, cationic lipids may be included in the formulation to facilitate oligonucleotide uptake. One such composition shown to facilitate uptake is LIPOFECTIN (available from GIBCO-BRL, Bethesda, Md.).

Oligonucleotides with at least one 2'-O-methoxyethyl modification are believed to be particularly useful for oral administration. Pharmaceutical compositions and formulations for topical administration may include transdermal patches, ointments, lotions, creams, gels, drops, suppositories, sprays, liquids and powders. Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners and the like may be necessary or desirable. Coated condoms, gloves and the like may also be useful.

The pharmaceutical formulations of the present invention, which may conveniently be presented in unit dosage form, may be prepared according to conventional techniques well known in the pharmaceutical industry. Such techniques include the step of bringing into association the active ingredients with the pharmaceutical carrier(s) or excipient(s). In general, the formulations are prepared by uniformly and intimately bringing into association the active ingredients with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product.

The compositions of the present invention may be formulated into any of many possible dosage forms such as, but not limited to, tablets, capsules, gel capsules, liquid syrups, soft gels, suppositories, and enemas. The compositions of the present invention may also be formulated as suspensions in aqueous, non-aqueous or mixed media. Aqueous suspensions may further contain substances that increase the viscosity of the suspension including, for example, sodium carboxymethylcellulose, sorbitol and/or dextran. The suspension may also contain stabilizers.

Pharmaceutical compositions of the present invention include, but are not limited to, solutions, emulsions, foams and liposome-containing formulations. The pharmaceutical compositions and formulations of the present invention may comprise one or more penetration enhancers, carriers, excipients or other active or inactive ingredients.

Emulsions are typically heterogeneous systems of one liquid dispersed in another in the form of droplets usually exceeding 0.1  $\mu\text{m}$  in diameter. Emulsions may contain additional components in addition to the dispersed phases, and the active drug that may be present as a solution in either the aqueous phase, oily phase or itself as a separate phase. Microemulsions are included as an embodiment of the present invention. Emulsions and their uses are well known in the art and are further described in U.S. Pat. No. 6,287,860.

Formulations of the present invention include liposomal formulations. As used in the present invention, the term "lipo-

some" means a vesicle composed of amphiphilic lipids arranged in a spherical bilayer or bilayers. Liposomes are unilamellar or multilamellar vesicles which have a membrane formed from a lipophilic material and an aqueous interior that contains the composition to be delivered. Cationic liposomes are positively charged liposomes that are believed to interact with negatively charged DNA molecules to form a stable complex. Liposomes that are pH-sensitive or negatively-charged are believed to entrap DNA rather than complex with it. Both cationic and noncationic liposomes have been used to deliver DNA to cells.

Liposomes also include "sterically stabilized" liposomes, a term which, as used herein, refers to liposomes comprising one or more specialized lipids. When incorporated into liposomes, these specialized lipids result in liposomes with enhanced circulation lifetimes relative to liposome slacking such specialized lipids. Examples of sterically stabilized liposomes are those in which part of the vesicle-forming lipid portion of the liposome comprises one or more glycolipids or is derivatized with one or more hydrophilic polymers, such as a polyethylene glycol (PEG) moiety. Liposomes and their uses are further described in U.S. Pat. No. 6,287,860.

The pharmaceutical formulations and compositions of the present invention may also include surfactants. The use of surfactants in drug products, formulations and in emulsions is well known in the art. Surfactants and their uses are further described in U.S. Pat. No. 6,287,860, which is incorporated herein by reference.

In one embodiment, the present invention employs various penetration enhancers to effect the efficient delivery of nucleic acids, particularly oligonucleotides. In addition to adding the diffusion of non-lipophilic drugs across cell membranes, penetration enhancers also enhance the permeability of lipophilic drugs. Penetration enhancers may be classified as belonging to one of five broad categories, i.e., surfactants, fatty acids, bile salts, chelating agents, and non-chelating nonsurfactants. Penetration enhancers and their uses are further described in U.S. Pat. No. 6,287,860, which is incorporated herein by reference.

One of skill in the art will recognize that formulations are routinely designed according to their intended use, i.e. route of administration.

Formulations for topical administration include those in which the oligonucleotides of the invention are in admixture with a topical delivery agent such as lipids, liposomes, fatty acids, fatty acid esters, steroids, chelating agents and surfactants, lipids and liposomes include neutral (e.g. diolcoylphosphatidyl DOPE ethanolamine, dimyristoylphosphatidyl choline DMPC, distearoylphosphatidyl choline) negative (e.g. dimyristoylphosphatidyl glycerol DMPG) and cationic (e.g. dioleoylhexamethylaminopropyl DOTAP and diolcoylphosphatidyl ethanolamine DOTMA).

For topical or other administration, oligonucleotides of the invention may be encapsulated within liposomes or may form complexes thereto, in particular to cationic liposomes. Alternatively, oligonucleotides may be complexed to lipids, in particular to cationic lipids, fatty acids and esters, pharmaceutically acceptable salts thereof, and their uses are further described in U.S. Pat. No. 6,287,860.

Compositions and formulations for oral administration include powders or granules, microparticulates, nanoparticulates, suspensions or solutions in water or non-aqueous media, capsules, gel capsules, sachets, tablets or minitables. Thickeners, flavoring agents, diluents, emulsifiers, dispersing aids or binders may be desirable, oral formulations are those in which oligonucleotides of the invention are administered in conjunction with one or more penetration enhancers surfac-

tants and chelators, surfactants include fatty acids and/or esters or salts thereof, bile acids and/or salts thereof, bile acids/salts and fatty acids and their uses are further described in U.S. Pat. No. 6,287,860, which is incorporated herein by reference. Also are combinations of penetration enhancers, for example, fatty acids/salts in combination with bile acids/salts. A particularly combination is the sodium salt of lauric acid, capric acid and UDCA. Further penetration enhancers include polyoxyethylene-9-lauryl ether, polyoxyethylene-20-cetyl ether. Oligonucleotides of the invention may be delivered orally, in granular form including sprayed dried particles, or complexed to form micro or nanoparticles. Oligonucleotide complexing agents and their uses are further described in U.S. Pat. No. 6,287,860, which is incorporated herein by reference.

Compositions and formulations for parenteral, intrathecal or intraventricular administration may include sterile aqueous solutions that may also contain buffers, diluents and other suitable additives such as, but not limited to, penetration enhancers, carrier compounds and other pharmaceutically acceptable carriers or excipients.

Certain embodiments of the invention provide pharmaceutical compositions containing one or more oligomeric compounds and one or more other chemotherapeutic agents that function by a non-antisense mechanism. Examples of such chemotherapeutic agents include but are not limited to cancer chemotherapeutic drugs such as daunorubicin, daunomycin, dactinomycin, doxorubicin, epirubicin, idarubicin, esorubicin, bleomycin, mafosfamide, ifosfamide, cytosine arabinoside, bischloroethyl-nitrosurea, busulfan, mitomycin C, actinomycin D, mithramycin, prednisone, hydroxyprogesterone, testosterone, tamoxifen, dacarbazine, procarbazine, hexamethylmelamine, pentamethylmelamine, mitoxantrone, amsacrine, chlorambucil, methylcyclohexylnitrosurea, nitrogen mustards, melphalan, cyclophosphamide, 6-mercaptopurine, 6-thioguanine, cytarabine, 5-azacytidine, hydroxyurea, deoxycoformycin, 4-hydroxyperoxycyclo-phosphoramide, 5-fluorouracil (5-FU), 5-fluorodeoxyuridine (5-FUDR), methotrexate (MTX), colchicine, taxol, vincristine, vinblastine, etoposide (VP-16), trimetrexate, irinotecan, topotecan, gemcitabine, teniposide, cisplatin and diethylstilbestrol (DES). When used with the compounds of the invention, such chemotherapeutic agents may be used individually (e.g., 5-FU and oligonucleotide), sequentially (e.g., 5-FU and oligonucleotide for a period of time followed by MTX and oligonucleotide), or in combination with one or more other such chemotherapeutic agents (e.g., 5-FU, MTX and oligonucleotide, or 5-FU, radiotherapy and oligonucleotide). Anti-inflammatory drugs, including but not limited to nonsteroidal anti-inflammatory drugs and corticosteroids, and antiviral drugs, including but not limited to ribivirin, vidarabine, acyclovir and ganciclovir, may also be combined in compositions of the invention. Combinations of antisense compounds and other non-antisense drugs are also within the scope of this invention. Two or more combined compounds may be used together or sequentially.

In another related embodiment, compositions of the invention may contain one or more antisense compounds, particularly oligonucleotides, targeted to a first nucleic acid and one or more additional antisense compounds targeted to a second nucleic acid target. For example, the first target may be a particular antisense sequence of a Pancreatic Developmental gene, and the second target may be a region from another nucleotide sequence. Alternatively compositions of the invention may contain two or more antisense compounds targeted to different regions of the same Pancreatic Developmental gene nucleic acid target. Numerous examples of anti-

sense compounds are illustrated herein and others may be selected from among suitable compounds known in the art. Two or more combined compounds may be used together or sequentially.

#### Dosing:

The formulation of therapeutic compositions and their subsequent administration (dosing) is believed to be within the skill of those in the art. Dosing is dependent on severity and responsiveness of the disease state to be treated, with the course of treatment lasting from several days to several months, or until a cure is effected or a diminution of the disease state is achieved. Optimal dosing schedules can be calculated from measurements of drug accumulation in the body of the patient. Persons of ordinary skill can easily determine optimum dosages, dosing methodologies and repetition rates. Optimum dosages may vary depending on the relative potency of individual oligonucleotides, and can generally be estimated based on EC50s found to be effective in *in vitro* and *in vivo* animal models. In general, dosage is from 0.01  $\mu$ g to 100 g per kg of body weight, and may be given once or more daily, weekly, monthly or yearly, or even once every 2 to 20 years. Persons of ordinary skill in the art can easily estimate repetition rates for dosing based on measured residence times and concentrations of the drug in bodily fluids or tissues. Following successful treatment, it may be desirable to have the patient undergo maintenance therapy to prevent the recurrence of the disease state, wherein the oligonucleotide is administered in maintenance doses, ranging from 0.01  $\mu$ g to 100 g per kg of body weight, once or more daily, to once every 20 years.

In embodiments, a patient is treated with a dosage of drug that is at least about 1, at least about 2, at least about 3, at least about 4, at least about 5, at least about 6, at least about 7, at least about 8, at least about 9, at least about 10, at least about 15, at least about 20, at least about 25, at least about 30, at least about 35, at least about 40, at least about 45, at least about 50 at least about 60, at least about 70, at least about 80, at least about 90, or at least about 100 mg/kg body weight. Certain injected dosages of antisense oligonucleotides are described, e.g., in U.S. Pat. No. 7,563,884. "Antisense modulation of PTP1B expression," incorporated herein by reference in its entirety.

While various embodiments of the present invention have been described above, it should be understood that they have been presented by way of example only, and not limitation. Numerous changes to the disclosed embodiments can be made in accordance with the disclosure herein without departing from the spirit or scope of the invention. Thus, the breadth and scope of the present invention should not be limited by any of the above described embodiments.

All documents mentioned herein are incorporated herein by reference. All publications and patent documents cited in this application are incorporated by reference for all purposes to the same extent as if each individual publication or patent document were so individually denoted. By their citation of various references in this document, Applicants do not admit any particular reference is "prior art" to their invention. Embodiments of inventive compositions and methods are illustrated in the following examples.

#### EXAMPLES

The following non-limiting Examples serve to illustrate selected embodiments of the invention. It will be appreciated that variations in proportions and alternatives in elements of

the components shown will be apparent to those skilled in the art and are within the scope of embodiments of the present invention.

### Example 1

#### Design of Antisense Oligonucleotides Specific for a Nucleic Acid Molecule Antisense to a Pancreatic Developmental Gene and/or a Sense Strand of a Pancreatic Developmental Gene Polynucleotide

As indicated above the term “oligonucleotide specific for” or “oligonucleotide targets” refers to an oligonucleotide having a sequence (i) capable of forming a stable complex with a portion of the targeted gene, or (ii) capable of forming a stable duplex with a portion of an mRNA transcript of the targeted gene.

Selection of appropriate oligonucleotides is facilitated by using computer programs that automatically align nucleic acid sequences and indicate regions of identity or homology. Such programs are used to compare nucleic acid sequences obtained, for example, by searching databases such as GenBank or by sequencing PCR products. Comparison of nucleic acid sequences from a range of species allows the selection of nucleic acid sequences that display an appropriate degree of identity between species. In the case of genes that have not been sequenced. Southern blots are performed to allow a determination of the degree of identity between genes in target species and other species. By performing Southern blots at varying degrees of stringency, as is well known in the art, it is possible to obtain an approximate measure of identity. These procedures allow the selection of oligonucleotides that exhibit a high degree of complementarity to target nucleic acid sequences in a subject to be controlled and a lower degree of complementarity to corresponding nucleic acid sequences in other species. One skilled in the art will realize that there is considerable latitude in selecting appropriate regions of genes for use in the present invention.

An antisense compound is “specifically hybridizable” when binding of the compound to the target nucleic acid interferes with the normal function of the target nucleic acid to cause a modulation of function and/or activity, and there is a sufficient degree of complementarity to avoid non-specific binding of the antisense compound to non-target nucleic acid sequences under conditions in which specific binding is desired, i.e., under physiological conditions in the case of in vivo assays or therapeutic treatment, and under conditions in which assays are performed in the case of in vitro assays.

The hybridization properties of the oligonucleotides described herein can be determined by one or more in vitro assays as known in the art. For example, the properties of the oligonucleotides described herein can be obtained by determination of binding strength between the target natural antisense and a potential drug molecules using melting curve assay.

The binding strength between the target natural antisense and a potential drug molecule (Molecule) can be estimated using any of the established methods of measuring the strength of intermolecular interactions, for example, a melting curve assay.

Melting curve assay determines the temperature at which a rapid transition from double-stranded to single-stranded conformation occurs for the natural antisense/Molecule complex. This temperature is widely accepted as a reliable measure of the interaction strength between the two molecules.

A melting curve assay can be performed using a cDNA copy of the actual natural antisense RNA molecule or a syn-

thetic DNA or RNA nucleotide corresponding to the binding site of the Molecule. Multiple kits containing all necessary reagents to perform this assay are available (e.g. Applied Biosystems Inc. MeltDoctor kit). These kits include a suitable buffer solution containing one of the double strand DNA (dsDNA) binding dyes (such as ABI HRM dyes, SYBR Green, SYTO, etc.). The properties of the dsDNA dyes are such that they emit almost no fluorescence in free form, but are highly fluorescent when bound to dsDNA.

To perform the assay the cDNA or a corresponding oligonucleotide are mixed with Molecule in concentrations defined by the particular manufacturer’s protocols. The mixture is heated to 95° C. to dissociate all pre-formed dsDNA complexes, then slowly cooled to room temperature or other lower temperature defined by the kit manufacturer to allow the DNA molecules to anneal. The newly formed complexes are then slowly heated to 95° C. with simultaneous continuous collection of data on the amount of fluorescence that is produced by the reaction. The fluorescence intensity is inversely proportional to the amounts of dsDNA present in the reaction. The data can be collected using a real time PCR instrument compatible with the kit (e.g. ABI’s StepOne Plus Real Time PCR System or LightTyper instrument, Roche Diagnostics, Lewes, UK).

Melting peaks are constructed by plotting the negative derivative of fluorescence with respect to temperature ( $-d(\text{Fluorescence})/dT$ ) on the y-axis) against temperature (x-axis) using appropriate software (for example LightTyper (Roche) or SDS Dissociation Curve, ABI). The data is analyzed to identify the temperature of the rapid transition from dsDNA complex to single strand molecules. This temperature is called  $T_m$  and is directly proportional to the strength of interaction between the two molecules. Typically,  $T_m$  will exceed 40° C.

### Example 2

#### Modulation of a Pancreatic Developmental Gene Polynucleotide Treatment of HepG2 Cells with Antisense Oligonucleotides

HepG2 cells from ATCC (cat#HB-8065) were grown in growth media (MEM/EBSS (Hyclone cat #SH30024, or Mediatech cat #MT-10-010-CV)+10% FBS (Mediatech cat#MT35-011-CV)+penicillin/streptomycin (Mediatech cat#MT30-002-C1)) at 37° C. and 5% CO<sub>2</sub>. One day before the experiment the cells were replated at she density of 1.5x 10<sup>5</sup>/ml into 6 well plates and incubated at 37° C. and 5% CO<sub>2</sub>. On the day of the experiment the media in the 6 well plates was changed to fresh growth media. All antisense oligonucleotide were diluted to the concentration of 20 μM. Two μl of this solution was incubated with 400 μl of Opti-MEM media (Gibco cat#31985-070) and 4 μl of Lipofectamine 2000 (Invitrogen cat#11668019) at room temperature for 20 min and applied to each well of the 6 well plates with HepG2 cells. A Similar mixture including 2 μl of water instead of the oligonucleotide solution was used for the mock-transfected controls. After 3-18 h of incubation at 37° C. and 5% CO<sub>2</sub> the media was changed to fresh growth media, 48 h after addition of antisense oligonucleotides the media was removed and RNA was extracted from the cells using SV Total RNA Isolation System from Promega (cat #Z3105) or RNeasy Total RNA Isolation kit from Qiagen (cat#74181) following the manufacturer instructions. 600 ng of RNA was added to the reverse transcription reaction performed using Verso cDNA kit from Thermo Scientific (cat#AB1453B) or High Capacity cDNA Reverse Transcription Kit (cat#4368813) as described

in the manufacturer's protocol. The cDNA from this reverse transcription reaction was used to monitor gene expression by real time PCR using ABI Taqman Gene Expression Mix (cat#4369510) and primers/probes designed by ABI (Applied Biosystems Taqman Gene Expression Assay: Hs01922995\_s1, Hs01651425\_s1, and Hs00426216\_m1 by Applied Biosystems Inc. Foster City Calif.). The following PCR cycle was used: 50° C. for 2 min. 95° C. for 10 min. 40 cycles of (95° C. for 15 seconds, 60° C. for 1 min) using Mx4000 thermal cycler (Stratagene). Fold change in gene expression after treatment with antisense oligonucleotides was calculated based on the difference in 18S-normalized dCt values between treated and mock-transfected samples.

#### Results

Real time PCR results show that the fold change+standard deviation in NeuroD1 mRNA after treatment of HepG2 cells with phosphorothioate oligonucleotides introduced using Lipofectamine 2000, as compared to control (FIG. 1).

Real time PCR results show that the levels of MAFA mRNA in HepG2 cells are significantly increased 48 h after treatment with one of the oligos designed to MAFA antisense BM127748 (FIG. 3).

Real time PCR results show that the levels of PDX1 mRNA in HepG2 cells are significantly increased 48 h after treatment with one of the oligos designed to PDX1 antisense Hs.416201 (FIG. 4).

#### Treatment of 518A2 Cells with Antisense Oligonucleotides:

518A2 cells obtained from Albert Einstein-Montefiore Cancer Center, NY were grown in growth media (MEM/EBSS (Hyclone cat #SH30024, or Mediatech cat #MT-10-010-CV)+10% FBS (Mediatech cats MT35-011-CV)+penicillin/streptomycin (Mediatech cat#MT30-002-C1)) at 37° C. and 5% CO<sub>2</sub>. One day before the experiment the cells were replated at the density of 1.5x10<sup>5</sup>/ml into 6 well plates and incubated at 37° C. and 5% CO<sub>2</sub>. On the day of the experiment the media in the 6 well plates was changed to fresh growth media. All antisense oligonucleotides were diluted to the concentration of 20 µM. Two µl of this solution was incubated with 400 µl of Opti-MEM media (Gibco cat#31985-070) and 4 µl of Lipofectamine 2000 (Invitrogen cat#11668019) at room temperature for 20 min and applied to each well of the 6 well plates with 518A2 cells. Similar mixture including 2 µl of water instead of the oligonucleotide solution was used for the mock-transfected controls. After 3-18 h of incubation at 37° C. and 5% CO<sub>2</sub> the media was changed to fresh growth media. 48 h after addition of antisense oligonucleotides the media was removed and RNA was extracted from the cells using SV Total RNA Isolation System from Promega (cat #723105) or RNeasy Total RNA isolation kit from Qiagen (cat#74181) following the manufacturers' instructions. 600 ng of RNA was added to the reverse transcription reaction performed using Verso cDNA kit from Thermo Scientific (cat#AB1453B) or High Capacity cDNA Reverse Transcription Kit (cat#4368813 as described in the manufacturer's protocol. The cDNA from this reverse transcription reaction was used to monitor gene expression by real time PCR using ABI Taqman Gene Expression Mix (cat#4369510) and primers/probes designed by ABI (Applied Biosystems Taqman Gene Expression Assay: Hs01023298\_m1 by Applied Biosystems Inc., Foster City Calif.). The following PCR cycle was used: 50° C. for 2 min, 95° C. for 2 min, 95° C. for 10 min, 40 cycles of (95° C. for 15 seconds, 60° C. for 1 min) using StepOne Plus Real Time PCR Machine (Applied Biosystems). Fold change in gene expression after treatment with antisense oligonucleotides was calculated based on the difference in 18S-normalized dCt values between treated and mock-transfected samples.

Results: Real time PCR results show that the levels of HNF4A mRNA in 518A2 cells are significantly increased 48 h after treatment with oligos to HNF4A antisense transcripts BX099913, BC071794 and AF143870 (FIG. 2).

#### Treatment of MCF-7 Cells with Antisense Oligonucleotides:

MCF-7 cells from ATCC (cat#HTB-22) were grown in growth media (MEM/EBSS (Hyclone cat #SH30024, or Mediatech cat #MT-10-010-CV)+10% FBS (Mediatech cat#MT35-011-CV)+penicillin/streptomycin (Mediatech cat#MT30-002-C1)) at 37° C. and 5% CO<sub>2</sub>. One day before the experiment the cells were replated at the density of 1.5x10<sup>5</sup>/ml into 6 well plates and incubated at 37° C. and 5% CO<sub>2</sub>. On the day of the experiment the media in the 6 well plates was changed to fresh growth media. All antisense oligonucleotides were diluted to the concentration of 20 µM. Two µl of this solution was incubated with 400 µl of Opti-MEM media (Gibco cat#31985-070) and 4 µl of Lipofectamine 2000 (Invitrogen cat#11668019) at room temperature for 20 min and applied to each well of the 6 well plates with MCF-7 cells. Similar mixture including 2 µl of water instead of the oligonucleotide solution was used for the mock-transfected controls. After 3-18 h of incubation at 37° C. and 5% CO<sub>2</sub> the media was changed to fresh growth media 48 h after addition of antisense oligonucleotides the media was removed and RNA was extracted from the cells using SV Total RNA Isolation System from Promega (cat #Z3105) or RNeasy Total RNA Isolation kit from Qiagen (cat#74181) following the manufacturers instructions. 600 ng of RNA was added to the reverse transcription reaction performed using Verso cDNA kit from Thermo Scientific (cat#AB1453B) or High Capacity cDNA Reverse Transcription Kit (cat#4368813) as described in the manufacturer's protocol. The cDNA from this reverse transcription reaction was used to monitor gene expression by real time PCR using ABI Taqman Gene Expression Mix (cat#4369510) and primers/probes designed by ABI (Applied Biosystems Taqman Gene Expression Assay: Hs00232355\_m1. The following PCR cycle was used: 50° C. for 2 min. 95° C. for 10 min. 40 cycles of (95° C. for 15 seconds, 60° C. for 1 min) using StepOne Plus Real Time PCR Machine (Applied Biosystems).

Fold change in gene expression after treatment with antisense oligonucleotides was calculated based on the difference in 18S-normalized dCt values between treated and mock-transfected samples.

Results: Real time PCR results show that the levels of the NKX6-1 mRNA in MCF-7 cells are significantly increased 48 h after treatment with the oligos designed to NKX6-1 antisense torsnaby.aApr07-unsplined (FIG. 5).

Although the invention has been illustrated and described with respect to one or more implementations, equivalent alterations and modifications will occur to others skilled in the art upon the reading and understanding of this specification and the annexed drawings. In addition, while a particular feature of the invention may have been disclosed with respect to only one of several implementations, such feature may be combined with one or more other features of the other implementations as may be desired and advantageous for any given or particular application.

The Abstract of the disclosure will allow the reader to quickly ascertain the nature of the technical disclosure. It is submitted with the understanding that it will not be used to interpret or limit the scope or meaning of the following claims.

| CUR NO   | SEQ ID NO:    | SEQUENCE                                |
|----------|---------------|---|
| CUR-1373 | SEQ ID NO: 13 | T*C*C*T*C*T*T*C*T*C*A*A*C*C*A*C*T       |
| CUR-1374 | SEQ ID NO: 14 | T*G*T*C*T*C*G*G*C*T*C*T*C*A*C*T*C*T     |
| CUR-1375 | SEQ ID NO: 15 | C*A*T*T*C*T*T*C*A*A*A*T*T*C*G*C*T       |
| CUR-1376 | SEQ ID NO: 16 | G*T*T*C*T*C*C*G*T*G*C*T*T*A*G           |
| CUR-1194 | SEQ ID NO: 17 | A*C*C*T*A*T*A*G*T*A*C*A*G*C*C*A*G*C*A   |
| CUR-1195 | SEQ ID NO: 18 | G*C*T*T*C*T*G*C*C*A*G*G*T*G*A*C*A       |
| CUR-1193 | SEQ ID NO: 19 | C*A*G*C*A*A*G*T*G*T*C*A*G*A*T*C*C*A     |
| CUR-1192 | SEQ ID NO: 20 | A*G*T*G*T*C*A*G*A*T*C*C*A*G*C*T*C*A*G   |
| CUR-1191 | SEQ ID NO: 21 | G*G*A*G*T*T*G*G*T*T*G*G                 |
| CUR-1190 | SEQ ID NO: 22 | G*T*G*T*C*A*G*A*T*C*C*A*G*C*T*C*A*G     |
| CUR-1188 | SEQ ID NO: 23 | C*T*C*G*T*T*A*C*C*T*C*T*T*G*T*C*C*T*G*G |
| CUR-1189 | SEQ ID NO: 24 | A*G*T*C*G*G*A*G*G*C*T*G*G*T*T*A         |
| CUR-1187 | SEQ ID NO: 25 | C*C*C*T*G*C*T*T*C*C*T*T*G*T*G*T*C*T     |
| CUR-1186 | SEQ ID NO: 26 | G*C*C*A*C*C*T*G*C*T*T*C*C*T*T*G*T       |
| CUR-1182 | SEQ ID NO: 27 | T*C*C*T*G*C*T*T*C*C*T*G*G*C*T*C*T*A     |
| CUR-1183 | SEQ ID NO: 28 | C*C*T*C*C*A*T*G*T*C*T*G*C*C*T*C*A*A     |
| CUR-1185 | SEQ ID NO: 29 | T*C*C*G*T*C*T*C*C*T*C*A*T*A*G*T*C*A     |
| CUR-1184 | SEQ ID NO: 30 | T*C*C*G*T*C*T*C*C*T*C*A*T*A*G*T*C       |
| CUR-1181 | SEQ ID NO: 31 | G*T*C*C*G*T*T*C*C*T*C*A*T*A*G*T*C       |
| CUR-1207 | SEQ ID NO: 32 | C*T*A*C*C*A*G*C*A*T*C*A*C*T*C*A*A*C*C   |
| CUR-1209 | SEQ ID NO: 33 | A*G*T*T*C*G*A*G*G*T*G*A*A*G*G*A*G       |
| CUR-1208 | SEQ ID NO: 34 | C*G*C*T*G*G*A*G*A*T*C*T*G*T*A*C*T*G*G   |
| CUR-1210 | SEQ ID NO: 35 | C*C*T*G*A*T*G*A*A*G*T*T*G*A*G*G*T*G     |
| CUR-1211 | SEQ ID NO: 36 | G*T*A*C*G*T*C*A*A*G*A*C*T*T*C*G*A*C     |
| CUR-1388 | SEQ ID NO: 37 | G*C*A*A*T*T*G*A*A*G*C*T*G*T*C*T*C       |
| CUR-1389 | SEQ ID NO: 38 | C*G*G*C*A*G*A*G*A*A*C*A*G*A*G*G*T       |
| CUR-1390 | SEQ ID NO: 39 | T*T*T*C*A*G*G*A*G*A*T*G*G*C*G*C*T       |
| CUR-1391 | SEQ ID NO: 40 | G*G*A*G*A*G*C*A*A*T*C*T*G*A*G*A*G       |
| CUR-1392 | SEQ ID NO: 41 | G*C*C*T*C*T*A*A*G*T*C*A*G*A*G*C         |
| CUR-1501 | SEQ ID NO: 42 | T*C*T*C*A*G*T*C*T*A*A*T*C*T*C*T         |
| CUR-1502 | SEQ ID NO: 43 | G*T*T*A*C*A*G*T*C*A*C*T*C*C*A*A*G       |
| CUR-1503 | SEQ ID NO: 44 | G*C*T*A*T*G*C*T*G*C*A*C*A*T*C           |
| CUR-1504 | SEQ ID NO: 45 | T*T*t*C*C*T*C*C*A*AT*T*C*T*A*C          |

## SEQUENCE LISTING

&lt;160&gt; NUMBER OF SEQ ID NOS: 45

&lt;210&gt; SEQ ID NO 1

&lt;211&gt; LENGTH: 2641

&lt;212&gt; TYPE: DNA

&lt;213&gt; ORGANISM: Homo sapiens

-continued

&lt;300&gt; PUBLICATION INFORMATION:

&lt;308&gt; DATABASE ACCESSION NUMBER: NM\_002500

&lt;309&gt; DATABASE ENTRY DATE: 2010-12-26

&lt;313&gt; RELEVANT RESIDUES IN SEQ ID NO: (1) .. (2641)

&lt;400&gt; SEQUENCE: 1

```

gagaacgggg agcgcacagc ctggacgcgt gcgcaggcgt caggcgcata gacctgctag    60
ccccctcagct agcgggccccg cccgcgctta gcataactaa ctgggctata taacctgagc   120
gccccgcgcgg ccacgacacg aggaattcgc ccacgcagga ggccgcggcgt ccggaggccc   180
cagggttatg agactatcac tgctcaggac ctactaactaa caaaggaaat cgaacatga    240
ccaaatcgta cagcgagagt gggctgatgg gcgagcctca gcccgaaggc cctccaagct   300
ggacagacga gtgtctcagt tctcaggacg aggagcacga ggacagacaag aaggaggacg   360
acctcgaagc catgaacgca gaggaggact cactgaggaa cgggggagag gaggaggacg   420
aagatgagga cctggaagag gaggaagaag aggaagagga ggatgacgat caaaagccca   480
agagacgcgg ccccaaaaag aagaagatga ctaaggctcg cctggagcgt tttaaattga   540
gacgcatgaa ggctaacgcc cgggagcggg accgcatgca cggactgaac gcggcgctag   600
acaacctgcg caaggtgggtg ccttgctatt ctaagacgca gaagctgtcc aaaatcgaga   660
ctctgcgctt ggccaagaac tacatctggg ctctgtcggg gatcctgcgc tcaggcaaaa   720
gcccagacct ggtctccttc gttcagacgc ttgcaaggg cttatcccaa cccaccacca   780
acctgggttg cggctgcctg caactcaatc ctcgactttt tctgcctgag cagaaccagg   840
acatgcccc ccaactgcgc acggccagcg ctccctctcc tgtacacccc tactcctacc   900
agtgcctgg gctgcccagt ccgccttacg gtaccatgga cagctcccat gtcttcacg   960
ttaagcctcc gccgcacgcc tacagcgag cgctggagcc cttctttgaa agccctctga  1020
ctgattgcac cagcccttcc ttgatggac cctcagccc gccgctcagc atcaatggca  1080
acttctcttt caaacacgaa ccgtccgcgc agtttgagaa aaattatgcc tttaccatgc  1140
actatcctgc agcgacactg gcagggggccc aaagccacgg atcaatcttc tcaggcaccg  1200
ctgccccctc ctgcgagatc cccatagaca atattatgtc cttcgatagc cattcacatc  1260
atgagcgagt catgagtgcc cagctcaatg ccatatttca tgattagagg cagcgcagtt  1320
tcaccatttc cgggaaaacg acccactgtg cttacagtga ctgtcgtgtt tacaaaaggc  1380
agccctttgg gtactactgc tgcaaaagtgc aaatactcca agcttcaagt gatatatgta  1440
tttattgtca ttactgcctt tgaagaaaac aggggatcaa agttcctgtt caccttatgt  1500
attattttct atagctcttc tatttaaaaa ataaaaaaat acagtaaagt ttaaaaaata  1560
caccacgaat ttggtgtggc tgtattcaga tcgtattaat tatctgatcg ggataacaaa  1620
atcacagca ataattagga tctatgcaat ttttaacta gtaatgggccc aattaaaata  1680
tatataaata tatatttttc aaccagcatt ttactacttg ttacctttcc catgctgaat  1740
tattttgttg tgattttgta cagaattttt aatgactttt tataatgtgg atttcctatt  1800
ttaaaaccat gcagcttcat caatttttat acatatcaga aaagtagaat tatatcta  1860
ttatacaaaa taatttaact aatttaaac agcagaaaag tgcttagaaa gttattgtgt  1920
tgcttagca cttcttctct ctccaattgt aaaaaaaaa aaaaaaaaa aaaaaaaaa  1980
aaaattgcac aatttgagca attcatttca ctttaaagtc tttccgtctc cctaaaaata  2040
aaaccagaat cataattttc aagagaagaa aaaattaaga gatacattcc ctatcaaac  2100
atatcaattc aacacattac ttgcacaagc ttgtatatat atattataa taaatgccaa  2160

```

-continued

---

|   |      |
|---|------|
| catacccttc tttaaatcaa aagctgcttg actatcacat acaatttgca ctgttacttt | 2220 |
| ttagtctttt actcctttgc attccatgat ttacagaga atctgaagct attgatgttt  | 2280 |
| ccagaaaata taaatgcatg atttatata tagtcacaaa aatggtggtt tgcatatat   | 2340 |
| tcatgtaata aatctgagcc taaatcta atcaggttgta atgttggat ttatatctat   | 2400 |
| agtagtcaat tagtacagta gcttaaataa attcaaacca tttaatcat aattagaaca  | 2460 |
| atagctattg catgtaaaat gcagtcacaga ataagtctg tttgagatg gatgctggta  | 2520 |
| ccactggaat cgatctgtac tgtaattttg tttgtaatcc tgtatattat ggtgtaatgc | 2580 |
| acaatttaga aaacattcat ccagttgcaa taaaatagta ttgaaagtga aaaaaaaaaa | 2640 |
| a   | 2641 |

<210> SEQ ID NO 2  
 <211> LENGTH: 3239  
 <212> TYPE: DNA  
 <213> ORGANISM: Homo sapiens  
 <300> PUBLICATION INFORMATION:  
 <308> DATABASE ACCESSION NUMBER: NM\_000457.3  
 <309> DATABASE ENTRY DATE: 2010-12-20  
 <313> RELEVANT RESIDUES IN SEQ ID NO: (1) .. (3239)

<400> SEQUENCE: 2

|  |      |
|--|------|
| gggaggaggc agtgggaggg cggagggcgg gggccttcgg ggtgggcgcc cagggtaggg  | 60   |
| cagggtggcg cggcgtggag gcaggagaa tgcgactctc caaacccctc gtcgacatgg   | 120  |
| acatggccga ctacagtgt gcaactggacc cagcctacac caccctggaa ttgagaatg   | 180  |
| tgcagggtgt gacgatgggc aatgacacgt ccccatcaga aggcaccaac ctcaacgcgc  | 240  |
| ccaacagcct ggggtgtcagc gccctgtgtg ccatctgcgg ggaccgggcc acgggcaaac | 300  |
| actacgggtg ctcgagctgt gacggctgca agggcttctt ccggaggagc gtgcggaaga  | 360  |
| accacatgta ctctgcaga tttagccggc agtgcgtggt ggacaaagac aagaggaacc   | 420  |
| agtgcgccta ctgcaggctc aagaaatgct tccgggctgg catgaagaag gaagccgtcc  | 480  |
| agaatgagcg ggaccggatc agcactcgaa ggtcaagcta tgaggacagc agcctgccct  | 540  |
| ccatcaatgc gctcctgcag gcggaggtcc tgtcccgaca gatcacctcc cccgtctccg  | 600  |
| ggatcaacgg cgacattcgg gcgaagaaga ttgccagcat cgcagatgtg tgtgagtcca  | 660  |
| tgaaggagca gctgctggtt ctcggtgagt gggccaagta catccagct ttctgcgagc   | 720  |
| tccccctgga cgaccagggt gccctgctca gagcccatgc tggcgagcac ctgctgctcg  | 780  |
| gagccaccaa gagatccatg gtgttcaagg acgtgctgct cctaggcaat gactacattg  | 840  |
| tccctcgga ctgcccggag ctggcggaga tgagccgggt gtccatacgc atccttgacg   | 900  |
| agctgggtgt gcccttcag gagctgcaga tcgatgacaa tgagtatgcc tacctcaaag   | 960  |
| ccatcatctt ctttgaccca gatgccaagg ggctgagcga tccagggaag atcaagcggc  | 1020 |
| tgcgttccca ggtgcagggt agcttgaggg actacatcaa cgaccgccag tatgactcgc  | 1080 |
| gtggccgctt tggagagctg ctgctgctgc tgcccacctt gcagagcatc acctggcaga  | 1140 |
| tgatcgagca gatccagttc atcaagctct tcggcatggc caagattgac aacctgttgc  | 1200 |
| aggagatgct gctgggaggg tccccagcg atgcaccca tgcccaccac cccctgcacc    | 1260 |
| ctcacctgat gcaggaacat atgggaacca acgtcatcgt tgccaacaca atgcccactc  | 1320 |
| acctcagcaa cggacagatg tgtgagtggc cccgaccag gggacaggca gccaccctg    | 1380 |
| agacccca cccctcaccg ccaggtggct cagggtctga gccctataag ctctgcccgg    | 1440 |
| gagccgtcgc cacaatcgtc aagccctct ctgccatccc ccagccgacc atcaccaagc   | 1500 |



-continued

---

```

aggaagttat ctagcaagcc gctggggctt gggggctcca ctggctcccc ccagccccct 1560
aagagagcac ctggtgatca cgtggtcacg gcaaaggaag acgtgatgcc aggaccagtc 1620
ccagagcagg aatgggaagg atgaagggcc cgagaacatg gcctaagggc cacatcccac 1680
tgccaccctt gacgcctgc tctggataac aagactttga cttggggaga cctctactgc 1740
cttggaacaac ttttctcatg ttgaagccac tgccttcacc ttcaccttca tccatgtcca 1800
acccccgact tcataccaaa ggacagccgc ctggagatga cttgaggcct tacttaaacc 1860
cagctccctt ctccctagc ctggtgcttc tctctccta gccctgtca tgggtgtccag 1920
acagagccct gtgaggctgg gtccaattgt ggcacttggg gcaccttget cctccttctg 1980
ctgctgcccc cacctctget gcctccctct gctgtcacct tgetcagcca tcccgcttc 2040
tccaacacca cctctccaga ggccaaggag gccttggaac cgattcccc agtcattctg 2100
ggaacatgtt gtaagcactg actgggacca ggcaccaggc aggggtctaga aggctgtggt 2160
gaggggaagc gcctttctcc tccaacccaa cctcactctc cttcttcagg gacttgggtg 2220
ggtaacttggg tgaggatccc tgaaggcctt caacccgaga aaacaaaccc aggttggcga 2280
ctgcaacagg aacttgaggt ggagaggaag agcatcagaa agaggcagac catccaccag 2340
gcctttgaga aagggtagaa ttctggctgg tagagcaggt gagatgggac attccaaaga 2400
acagccttag ccaaggccta gtggtagtaa gaatctagca agaattgagg aagaatggtg 2460
tgaggagagg atgatgaaga gagagagggc ctgctggaga gcatagggtc tggaacacca 2520
ggctgaggtc ctgatcagct tcaaggagta tgcagggagc tgggcttcca gaaaatgaac 2580
acagcagttc tgcagaggac gggaggctgg aagctgggag gtcagggtgg gtggatgata 2640
taatgcgggt gagagtaatg aggcctgggg ctggagagga caagatgggt aaaccctcac 2700
atcagagtga catccaggag gaataagctc ccagggcctg tctcaagctc ttccttactc 2760
ccaggcactg tcttaaggca tctgacatgc atcatctcat ttaatcctcc cttcctccct 2820
attaacctag agattgtttt tgttttttat tctcctctc cctccccgcc ctcaccgcc 2880
ccactccctc ctaacctaga gattgttaca gaagctgaaa ttgcgttcta agagggtgaag 2940
tgattttttt tctgaaactc acacaactag gaagtggctg agtcaggact tgaacccagg 3000
tctccctgga tcagaacagg agctcttaac tacagtggct gaatagcttc tccaaaggct 3060
ccctgtgttc tcaccgtgat caagttgagg ggcttcgggc tcctttctac agcctcagaa 3120
accagactcg ttcttctggg aacctgccc actcccagga ccaagattgg cctgaggctg 3180
cactaaaatt cacttagggt cgagcatcct gtttgetgat aaatattaag gagaattca 3239

```

```

<210> SEQ ID NO 3
<211> LENGTH: 1062
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<300> PUBLICATION INFORMATION:
<308> DATABASE ACCESSION NUMBER: NM_201589
<309> DATABASE ENTRY DATE: 2010-12-27
<313> RELEVANT RESIDUES IN SEQ ID NO: (1)..(1062)

```

```

<400> SEQUENCE: 3

```

```

atggcgcgg agctggcgat gggcgccgag ctgcccagca gcccgctggc catcgagtac 60
gtcaacgact tcgacctgat gaagtctgag gtgaagaagg agcctccga ggccgagcgc 120
ttctgccacc gcctgcgcc aggctcgctg tctctgacgc cgtctagcac gccctgetcc 180
tccgtgccct cctcgcccag cttctgcgcg ccagcccgg gcaccggcgg cggcgggcgg 240

```

-continued

---

|  |      |
|--|------|
| gcggggggcg gcgggcgctc gtctcaggcc gggggcgccc ccgggcccgc gagcgggggc  | 300  |
| cccgcgcccg tcgggggcac ctcggggaag ccggcgctgg aggatctgta ctggtatgagc | 360  |
| ggctaccagc atcacctcaa ccccgaggcg ctcaacctga cgcccaggga cgcggtggag  | 420  |
| gcgctcatcg gcagcggcga ccaaggcgcg caccacggcg cgcaccaccc ggcgggccgc  | 480  |
| gcagcctacg aggtcttccg cgggccgggc ttcgcgggcg gcgcgggagc ggacgacatg  | 540  |
| ggcgccggcc accaccacgg cgcgcaccac gccgcccacc atcaccacgc cggccaccac  | 600  |
| caccaccacc accaccacca ccatggcggc gcgggacacg gcggtggcgc gggccaccac  | 660  |
| gtgcgccctg agggagcgctt ctccgacgac cagctgggtg ccatgtcggg gcgagagctg | 720  |
| aaccggcagc tcccgggctt cagcaaggag gaggtcatcc ggctcaagca gaagcgggcg  | 780  |
| acgctcaaga acccgggcta cgcgcagtcg tgccgcttca agcggggtgca gcagcggcac | 840  |
| attctggaga gcgagaagt ccaactccag agccagggtg agcagctgaa gctggagggtg  | 900  |
| gggcgccctg ccaagagcgc ggacctgtac aaggagaaat acgagaagct ggcgggcccg  | 960  |
| ggcgggcccg ggagcgcggg cggggcccgt ttcccgcggg agccttcgcc gccgcaggcc  | 1020 |
| ggtcccggcg gggccaaggg cagggcccgc ttcttctgt ag                      | 1062 |

<210> SEQ ID NO 4  
 <211> LENGTH: 2573  
 <212> TYPE: DNA  
 <213> ORGANISM: Homo sapiens  
 <300> PUBLICATION INFORMATION:  
 <308> DATABASE ACCESSION NUMBER: NM\_000209  
 <309> DATABASE ENTRY DATE: 2010-12-26  
 <313> RELEVANT RESIDUES IN SEQ ID NO: (1)..(2573)

<400> SEQUENCE: 4

|   |      |
|---|------|
| gggtggcgcc gggagtggga acgccacaca gtgccaaatc cccggctcca gctcccact  | 60   |
| cccggtcccc ggctcccggc tcccggtgcc caatcccggg ccgcagccat gaacggcgag | 120  |
| gagcagtact acgcgccac gcagctttac aaggacccat gcggttcca gcgagggccg   | 180  |
| gcgcgggagt tcagcgccag cccccctgcg tgccgtgaca tgggcccga gccccggcg   | 240  |
| ccgcccgcgc acccgttccc tggcgccctg ggcgcgctgg agcagggcag cccccggac  | 300  |
| atctccccgt acgaggtgcc ccccccgcc gacgaccccg cgggtggcga ccttcaccac  | 360  |
| cacctcccgc ctacgtcgc gctccccac ccgcccgcgc ggcccttccc ggagggagcc   | 420  |
| gagccgggag tcctggagga gcccacccgc gtccagctgc ctttcccatg gatgaagtct | 480  |
| accaaagctc acgctgtgaa aggccagtgg gcaggcgcg cctacgctgc ggagccggag  | 540  |
| gagaacaagc ggcgcgcac ggccctacac gcgcacacgc tgctagagct ggagaaggag  | 600  |
| ttcctattca acaagtacat ctacggcg cgccgggtgg agctggctgt catgttgaa    | 660  |
| ttgaccgaga gacacatcaa gatctggttc caaaaccgcc gcatgaagtg gaaaaaggag | 720  |
| gaggacaaga agcgcgcgcg cgggacagct gtcgggggtg gcggggtcgc ggagcctgag | 780  |
| caggactgcg ccgtgacctc cggcgaggag cttctggcgc tgccgcgcgc gccgcccccc | 840  |
| ggaggtgctg tgccgcccgc tgccccgtt gccgcccag agggccgcct gccgcctggc   | 900  |
| cttagcgcgt cgccacagcc ctccagcgtc gcgcctcggc ggccgcagga accacgatga | 960  |
| gaggcaggag ctgctcctgg ctgaggggct tcaaccactc gccgaggagg agcagagggc | 1020 |
| ctaggaggac cccggcgctg gaccaccgc cctggcagtt gaatggggcg gcaattgcg   | 1080 |
| ggccacactt agaccgaagg ggaaaaccgc ctctctcagg cgcatgtgcc agttggggcc | 1140 |
| ccgcggttag atccgcgag gccttcgga agaaaaagag ccattggttt ttgtagtatt   | 1200 |

-continued

---

```

ggggccctct tttagtata ctggattggc gttgtttgtg gctgttgge acatccctgc 1260
cctcctacag cactccacct tgggacctgt ttagagaagc cggctcttca aagacaatgg 1320
aaactgtacc atacacattg gaaggctccc taacacacac agcggggaag ctgggccgag 1380
taccttaate tggcataaag ccattcttac tggggcgacc cctttaagtt tagaaataat 1440
tgaaaggaaa tgtttgagtt ttcaaagatc ccgtgaaatt gatgccagtg gaatacagtg 1500
agtctctctc ttctctctcc tctctctccc cctccccttc ctctctctcc tcttcttttc 1560
cctctctctc ctctctctcc tgtctctctt tctctcccct cctcttttcc ctctctctcc 1620
tcttctctct gctctctctt cctccccttc ctctttctcc tctctctctc cttctctccc 1680
ctctctctcc tctctctctt ctctcccctc ctctctctcc tctctctctt ctctctctcc 1740
ttctctctcc tctctctcca cgtgtctctc ttctctccc ctctctctgc tcccctctct 1800
ccccgtctcc ttctctctcc tctctctctt ctctctctcc ttctctctcc tcttctctcc 1860
tgacctcttt ctttctctcc ctctctcttc tacctcccct tctcatccct cctctctctc 1920
ttctctagct gcacacttca ctactgcaca tcttataact tgcacccctt tcttctgagg 1980
aagagaacat cttgcaaggc agggcgagca gcggcagggc tggcttagga gcagtgcagg 2040
agtccctgtg ctccagttcc aactgctggc cagggaaggc aaggggggac gggcctggat 2100
ctgggggtga gggagaaaga tggacctctg ggtgacct aaaccaaaga tattcggaac 2160
tttctattta ggatgtggac gtaattctctg ttccgaggtg gaggtgtgc tgaagacaag 2220
cacagtggcc tgggtgcgct tggaaaccaa caactattca cgagccagta tgacctcac 2280
atcttttagaa attatgaaaa cgtatgtgat tggagggttt ggaaaaccag ttatcttatt 2340
taacatttta aaaattacct aacagttatt tacaacagg tctgtgcac ccaggctctgt 2400
cttcttttca aggtctgggc ctgtgtctcg ggttatgttt gtgggaaatg cttaataaat 2460
actgataata tgggaagaga tgaaaactga ttctctcac tttgtttcaa acctttctgg 2520
cagtgggatg attcgaattc acttttaaaa ttaaattagc gtgttttgtt ttg 2573

```

```

<210> SEQ ID NO 5
<211> LENGTH: 1116
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<300> PUBLICATION INFORMATION:
<308> DATABASE ACCESSION NUMBER: NM_006168
<309> DATABASE ENTRY DATE: 2010-12-26
<313> RELEVANT RESIDUES IN SEQ ID NO: (1)..(1116)

```

```

<400> SEQUENCE: 5

```

```

cgtgggatgt tagcgggtggg ggcaatggag ggcacccggc agagcgcat cctgctcagc 60
agccctcccc tggccgcctt gcacagcatg gccgagatga agaccccgct gtacctgcc 120
gcgtatcccc cgtgctctgc cggccccccc tctctctctg cctctctctg gtcctctctg 180
tcgcctctcc cgcctctggg caccacaac ccaggcggcc tgaagcccc ggccacgggg 240
gggctctcat ccctcgagc ccccccgcag cagctctctg ccgccacccc acacggcatc 300
aacgatatcc tgagccggcc ctccatgcc gtggcctcgg gggccgcctt gccctccgcc 360
tcgcctctcg gttctctctc ctctctctcc tcgtctcctt ctgctctctc cgcctctgcc 420
gccgcgcggg ctgtctcgcg ggcgcagcc gccgcctcat ccccgccggg gctgctggcc 480
ggactgccac gcttttagcag cctgagcccc ccgcgcgcgc cgcgcgggct ctacttcagc 540
cccagcgcgc cggccgtggc cgcgtgggc cggtaaccca agccgctggc tgagctgcct 600

```

-continued

---

|   |      |
|---|------|
| ggccggacgc ccatcttctg gcccgagtg atgcagagcc cgccctggag ggacgcacgc  | 660  |
| ctggcctgta cccctcatca aggatccatt ttgttgaca aagacgggaa gagaaaaac   | 720  |
| acgagaccca ctttttcgg acagcagatc ttgccttgga agaagacttt cgaacaaaca  | 780  |
| aaatacttgg cggggcccca gagggctcgt ttggcctatt cgttggggat gacagagagt | 840  |
| caggtaagg tctggttcca gaaccgccgg accaagtgga ggaagaagca cgctgccgag  | 900  |
| atggccacgg ccaagaagaa gcaggactcg gagacagagc gcctcaaggg ggctcggag  | 960  |
| aacgaggaag aggacgacga ctacaataag cctctggatc ccaactcgga cgacgagaaa | 1020 |
| atcacgcagc tgttgaagaa gcacaagtcc agcagcggcg gcggcggcgg cctcctactg | 1080 |
| cacgcgtccg agccggagag ctcatcctga acgcgc                           | 1116 |

<210> SEQ ID NO 6  
 <211> LENGTH: 635  
 <212> TYPE: DNA  
 <213> ORGANISM: Homo sapiens

<400> SEQUENCE: 6

|  |     |
|--|-----|
| ggtctcacgg tagctgtcct tgggcttccc atccgcagc gctccgatgt gacctctctc   | 60  |
| tgcgcggaaa atttcgaccc ggggcgcgg catcgcgacg ctccagccagt gccgcgagag  | 120 |
| ctcccaggag atgcggggta gtaaggccct aaaaagagga gcctggacac ggctggatt   | 180 |
| gagaaagaag caagcaaaaca aaaatcctcg gtagctgtgt gtagcttcag gtagtgagag | 240 |
| ccgagacaca ccgacggcgc cggagcgtcg caagaacaat ggttgcgtca gtgggttggg  | 300 |
| agagaggacc cggacaagtt cctaaaggca cgggaggaac gcgggcaaac caggtttagg  | 360 |
| gccccaggcg aattgtggaa ggaatgactt cctcaacctc tcagcacctg ggacaattcc  | 420 |
| cactccaaag gccctgaact tcggcctact agattcagca aaaatctctc ttctccctt   | 480 |
| gcttctctct tctcttctc ccttctctct ttcttctctg ccttccctcc ctccccttc    | 540 |
| tcctccttcc ctctcttcc tcctcctct tcttctctct ttcttctctc tcctccttc     | 600 |
| cactcttccc tgtttgcttt gtttcaaaaa caaaa                             | 635 |

<210> SEQ ID NO 7  
 <211> LENGTH: 17964  
 <212> TYPE: DNA  
 <213> ORGANISM: Homo sapiens

<400> SEQUENCE: 7

|  |     |
|--|-----|
| ctaactatct cacaatatag gtcccaacc actgacaaa ctccagtcca ggagccacc     | 60  |
| agctggcctg gtcttctgctc ttcttttagc ggcttccaag gtccaggagc agggggtctg | 120 |
| ggccaccaag aggtctctgct aggtgtctcc tgcagccaca gccacccac tggaccctg   | 180 |
| cctcccatct gagaggacag cctcttctct ggagctggga tctgacactt gctgatacca  | 240 |
| acggcagata ccaggtaggt cccctccctt tctcttctct gagctcctaa aatgccactc  | 300 |
| ataccaccct ctgcactcgg caaaggccac tgtggcttaa tcaaatcagg caccacaaa   | 360 |
| gcttcaagac tggaaaagat gccttggtta acccaccat ttagtgagc gaaacactga    | 420 |
| ggccgtcagg ggagtggcag ctggccacag actgaacct agacttgggg ccagacctg    | 480 |
| gggcccccca cggagcctca gagggtgaaa gggacttgct caagtccacg cagcggtggt  | 540 |
| gggtgagctt tgtcttaaca acgagactt tctacttcat cacagacct gagtggcatt    | 600 |
| gtgtttgttc acccgatgat gggtgccac tggcttgctt acccgatgat gggtgccac    | 660 |
| tggcttgctc caggagtatt tccgagagga agatgagga gcttggggct gaaggccagt   | 720 |

-continued

---

|  |      |
|--|------|
| gggtttggaa ggaagcaaca ttcattgtgt taactgataa ctgggccccca tccctgggcc | 780  |
| tccttctctcc ctccctgtcc ttagcctgat taagaccaac ttaccagct gctaatacatt | 840  |
| gctgagcctg ttgattttgc cttaaaaaat taactgggca tgagtttgcg gttttcctca  | 900  |
| cccctaacc tgaaaaggcc tgggtgggca ggaggcctcc agggttatgc aagaggccgc   | 960  |
| tggcctccca acgcatagcc cacggccacc tcggctgtcc tccaaagaag aggctttgct  | 1020 |
| caagagtcaa cagtctgctt gtccccctg tgctgggtcc tgagcaaatt tgctctgtta   | 1080 |
| ccaaagagag ataaaggcag ctgggggaga gctttccaaa cagggatggg aagcggcagc  | 1140 |
| tttgagcttg gggttctaga actctgcagt gtcagagcca ggagaatctt taggaggatg  | 1200 |
| tgggtctggg tttttcaagc tgggttccga ggctcccagg agccaagggt atgcattccac | 1260 |
| aggcccagct tcaaccagcg actccctttt acatgtatgc ttaatatattt atttgagggt | 1320 |
| tggaaaacca ctgattcagc cccatcccct cattgcacag atggggagat ggagatcaga  | 1380 |
| gggggaagtg acttgtccaa ggacagaagg tcacctcggg tattcagggg ctccagccag  | 1440 |
| catgggaatg aatggtgggc tctctgtgga cccgggcaat gtcttgaaag acattggtga  | 1500 |
| acaagacggc tctgcaaacg ccttgccatg ccgttctccc cctcctccca gggtggctg   | 1560 |
| gaagcagaga ggtgcctgag agccattgga agaccaagt cagggaatg cacctggctc    | 1620 |
| tgtgtcccat gggccctgtg aggatatgac cagcagccag gcactgcaaa ccggagacta  | 1680 |
| cgttataatc catctcagcc acgtcctgtc tctggaggca tcagcacttt gggaggctga  | 1740 |
| gatgggagga ttacttgagc ccaagagttt gagaccagcc tgggcaacat agtgagacct  | 1800 |
| tgtgtctatt ttttaaaaag attttttaaa attaaagaca gatgccagct cctatcaca   | 1860 |
| aaaaaagatg tagagccctg ccttgactct ctccacctct ctgagcctca gtttcttcac  | 1920 |
| ctgtaaatg ggaattataa tacttaactt ccagggttgt catgaaaatg aaatgaagca   | 1980 |
| aaatatacac attgatcac atggccactg gatatgcagc tgttttagga gctttgcag    | 2040 |
| tgttacttcc ttgatcctcc cagccactct gggaggtagg caatgttttc accaattttt  | 2100 |
| tacacaccag aggcacaggg aggttgagcc atatacccat gctcacacag ctgatgagaa  | 2160 |
| acaagaatg gaattggaac ttgggcagtc tgtctctaga gtctgtgcct ctaactccag   | 2220 |
| ggctaccctt cccttcagg gatgccagt agagatggcc aggagaaggg cagagagcag    | 2280 |
| ggcactgtgg gagatgtga ctgtaaggct ccggaggtag ggagagagt atggtctgga    | 2340 |
| gaatgatcag gaaggagcc aggaggactt ggatctgtgt ggggtggagct tctccgcagg  | 2400 |
| ctgcctctg ccagggtgct tatgacatct gggctgaggg tgttgcctgc ctctgttta    | 2460 |
| tgttcatccc tcctgtttat gttcctgaat ttatctgcag gggtgacctt gggaattaga  | 2520 |
| tgcggccttc ccggcccttg tggggcctga aggctgatgg gagccctgc ctgacctaga   | 2580 |
| ctctgggttg gggagtgagg gctgagccca catcccagaa gccacccttg gtctcccat   | 2640 |
| actctgttc tgagggggcc cagggaattg ccaggctact aaggatgaat gtttggaagt   | 2700 |
| cctgaggctc agatcagagt tactgcctg tacagttgtg caggttgctc actgcacaaa   | 2760 |
| ggttctccag ccaagagggc aggtaggat ggaaaccag cccttgttcc acttgccaag    | 2820 |
| cgaagtgcct atggagctct gcctgccag agtggggtgc ctttttctta ttgacctag    | 2880 |
| ggcttcatgt aagctgtgg gtgtcctgcc ccagctctgg ttccagccac tgtgtgtcct   | 2940 |
| tgggcaagg catttccctc cctggccttg gtttccatt ggagaagttt tgtctaacaa    | 3000 |
| agcagagact catctctgaa gatgaaatag aatcatctga aacctttaa atatacagat   | 3060 |

-continued

---

|   |      |
|---|------|
| gttgcccgaa catggtggct tacacctata atcctagcac tttgggaggc tgagatggga   | 3120 |
| ggtttacttg aaccaggag tttgagacca gcttgggcaa catagtgaga ccctatgtct    | 3180 |
| atTTTTTaaa aagattttttt aaaattaaag acagatgccc agtccctatc acagatcaat  | 3240 |
| gatcgaatct tggggtaggg gtggggaggt gccaggcgtc tatatttttg tgcagccaat   | 3300 |
| attgagaccc actgtagggg ggcttcaa atgaacctgg aaagccttcg atggcatcaa     | 3360 |
| gttctatcac ttactacaac ttactagtca aaacctcagc gaggtcaggt tttccatct    | 3420 |
| gtaaagaggg aatgatgatc gtttctcac aaaatcaaaa tgccaattaa atgagataat    | 3480 |
| gttcagacag tgcttgccac catgttcccc aagtagggag ctctgattc ttgctaccaa    | 3540 |
| gactattatt gttgttatgg gcaattgac gttgacaaaa taaaggcgct ttctaggtea    | 3600 |
| aggattcggg gacttgaaga caggcctcct ctgttgcttt gagtcaattt ctagtacctg   | 3660 |
| ggcctaaatc ttgactgcac accggtcata ttattgaggt atgtgttatt attattattt   | 3720 |
| aatattttac ttaatttggt aacatcttta catttagttt tgaattgggt ctacattcgc   | 3780 |
| atgggtcaga atcaaaacat aaaaggtgta aattgagaag tcttgcttcc agctgtctcc   | 3840 |
| tgttcacctg ttctccttga ctccctcact atggggaacc acatccctta cagatgtatc   | 3900 |
| tgccaaggtt tctttataca gaccagatag catgtaagat catacatgag tagcctctgc   | 3960 |
| tcttacctg ttctgtatct tgtttgggtc atttaatatc acaacctgga gatgcttcca    | 4020 |
| tagcagctga gagcaagctt tgaggatgga aggggtctctg tctcccatca cagggtgagga | 4080 |
| aactgaggct cagagaagaa acatcatttt cccagtgcgc caaggcaatg gtgttagaac   | 4140 |
| tatctctacc tggctccaga gcttggtgtt atgcccctgc accgatacgg ccttccatga   | 4200 |
| agccccggcc agaaaagctt ggagctcgtt tacatctctg ccatgcaggc ctggccttcc   | 4260 |
| caggacaaga ggtgaggagg ggggctgtcg gggctctcac tgtgtctgga ctcagaaatc   | 4320 |
| ccaaagagag gatgaagtgt agaacaaaga atgtcccaag tcatccagat agggaccag    | 4380 |
| tgggaagggt tcccctggat ggaatagtgg gggcctggtg gctgtgcccg tcagcactgg   | 4440 |
| agaacctgcc aggaactctc tgccagctc aggtggtgct ggtggcaggg gaagttagga    | 4500 |
| ggaggatgag aggcaggag ggaagcatgg ccgatgagac aagctctggg tgaggggatg    | 4560 |
| gaggggaccc catgcctgga gctcaggaag gaggtttgg agttcaaggc agaagtggca    | 4620 |
| atgagatttt aaccgattgt tttctgctca gggaacttca gggttccctc tggattcttg   | 4680 |
| acctgcttca gtttctgac tcaactggct tgggcaagtc attttccctc tccgtgctc     | 4740 |
| agtttcccca actgcaaaat gagagagata agagatctgg tctttaggca gccttgact    | 4800 |
| acctctaata ctctacggg ctctctctcac ctgttgagg tctgtggat tctcttctc      | 4860 |
| tgattggaac gtcattcacc catcagggcc atggacgttc ctgggttagg ggatgagggt   | 4920 |
| acaaatctc cacactgctc ccagtctgga atcctcccc ttggttctgt gtctctctcc     | 4980 |
| taccatccca tcttctctc caggcagatg tggagtcagg accatacctg gtgggtctctg   | 5040 |
| ggggaagccc tggccccagt ccgacatcct cctctctctg ctatggggtc ccgcacagt    | 5100 |
| cacaacctct tcatccttga gggagctcct gctggccctc ctacgacccc cagacctgc    | 5160 |
| gagggccgct gggcagagtt aatcccttaa tactggtcac aatgagattt cagggatggt   | 5220 |
| gggaggcggg ctccatggaa actgcagacc tgtccaggat ccatgcaagg aattagcccc   | 5280 |
| agggctctgc aaggggctcc tagagagcca accccaatag gaatgggaga cacagtggtc   | 5340 |
| tggactcctg ggtcctgctc tggccctcct gttgtctctc tggagggtt ggaaaaaac     | 5400 |
| ataactcttg cattgcttca gtattctgct caactggaca gagccatatt cacagggaga   | 5460 |

-continued

---

|             |            |            |            |             |             |      |
|-------------|------------|------------|------------|-------------|-------------|------|
| gccctatcac  | ctttctgagc | gtgtttctcc | atccccctat | tggcattgta  | atccttaacc  | 5520 |
| cagtggcttt  | tctagaagag | tgcaggett  | agagtctgcc | agacctgagc  | ttgaagctca  | 5580 |
| gtttttccct  | ccacgactgt | aaacttagcc | gaggcatttc | acttctctga  | gcctcagctt  | 5640 |
| cctcatctgt  | atgatgggca | caataatagc | aacatggcat | ccctcttggt  | ctggctgggtg | 5700 |
| ggtagtaaca  | tccagtgaat | gtgagtctcc | ttctcacctt | ttctgactg   | ccacgcccac  | 5760 |
| actgcacatt  | tgcctccccc | agccccctgc | agcttcacga | accccggtgt  | ctcaagcaga  | 5820 |
| gagctgtcgc  | acttctctct | ttgccttctc | atcctccaag | tcccatctta  | gtcatcttcc  | 5880 |
| tccgggaaac  | agaacgcggg | ggctctctct | tgtcccccca | tagcccccaa  | agctttacat  | 5940 |
| catcatcggt  | tagtcagatg | gtaattagac | tggttgtgtg | cctcctccac  | tggactgtgt  | 6000 |
| cccatctacc  | attgtattcc | caggacccac | ttgatataaa | taggctggat  | gaataactga  | 6060 |
| gtgaataaag  | gatggaaatc | gtccatcgaa | acagtcaaca | tttattcagc  | accttctgcg  | 6120 |
| tgcacgcgtg  | tgggtgggtg | agatgcagca | gggaagacca | tgggcacaaat | atccccctca  | 6180 |
| gaggggtgca  | gatgagcaaa | taaaaataca | ggatgcccg  | tcaaatgtga  | atttaagata  | 6240 |
| cacaagaaat  | acttcgttag | tatgagcgtg | tcccaaataa | tgcattggac  | ctgcttatac  | 6300 |
| ttttaaaactg | tgggtgtcat | ctgacactca | tatgaaactg | gggtgtcctgt | gttgtgtcgg  | 6360 |
| gcaaccctac  | accctccctc | acagagcttg | cgttttggtg | gagaggcggg  | ttgcagacat  | 6420 |
| aagcaagtaa  | atacatgaaa | aacgaagtca | attacaaaca | gtggttaagt  | gcagtgaaga  | 6480 |
| cgcacagcgc  | gatgtgatag | cacctgggga | tgggcaggac | gatccccga   | gctagtggcc  | 6540 |
| tttgctgca   | caggtcattt | tagctccaat | gagatgccac | tttgcaaaag  | ttctttgagg  | 6600 |
| atcttaaagg  | gcacgggtga | ggctgctaaa | cttgagagaa | ggactctgag  | gagggcaagg  | 6660 |
| ggcgacactg  | agggagtggg | gctgctaagt | ctcacttgat | agactccaca  | gttttgcaac  | 6720 |
| ttggatctgg  | gccttcacaa | accttcgcca | ccccgcagcc | ccaccctcgc  | ggtcagccaa  | 6780 |
| tgtcttctgt  | ggggtctggg | gccaggggaa | gaggccaaag | gaactgtgca  | gagaagcgtg  | 6840 |
| gccaccgggg  | cgcagctggg | gagccctgac | accctttgcc | gccccacctc  | atcccgcggt  | 6900 |
| tgccccaggg  | cgcagggcag | ggcaggcacc | gcgctggggc | ggagggcgctc | ccggaggagg  | 6960 |
| cggccaagac  | tctccgcagt | gctgcgcttt | gcgcttcctg | ggctcctcct  | cgtggccaac  | 7020 |
| gcaggaaactg | gtgttcagaa | acttagatag | ccttagggac | ttcaccaatc  | acagcaatcc  | 7080 |
| cgccaatcac  | aggcccagac | gcactatgtc | tctccaaatc | cagaggaggc  | ctgctcggtt  | 7140 |
| cgatcaccaa  | tcacagctcg | ttggatttag | ttacctaaaa | gaacatctcc  | ccatcacaca  | 7200 |
| ccagcacatg  | gccacggcag | caatcagaac | gtaagatttt | aaaaccagtt  | cccagggtag  | 7260 |
| cagccgctgc  | ccttcaccca | cctactaaac | ttctgttccc | agcaccttgt  | tccaatgtac  | 7320 |
| gggggtgggg  | ggggtctttg | aggaagggtc | caggctttgt | gctgcttcca  | tgtggaagca  | 7380 |
| gatgttagca  | tgtatggggc | atgtataatg | atattactat | cagtaaatgt  | cataccatt   | 7440 |
| atgaaaatta  | agataggcag | ggcgtgatgg | tgcattgctg | taactccagc  | tttaggtggc  | 7500 |
| caagtgggga  | ggatcgctgg | atcccaggag | ttggaggctg | cagtgaacca  | cgatggcgcc  | 7560 |
| actgcactcc  | agcctgggtg | atagagttag | actctgtctc | aatttaaaaa  | aaaaaattaa  | 7620 |
| tgtgtggata  | taggagtgtg | gaaaaattat | aacctttggg | ttagacacac  | ctggagccca  | 7680 |
| tatactatct  | ttgtgaagta | ggacgactca | cctccccctc | ctcagtcgtc  | aaaagagaat  | 7740 |
| gatagtcata  | tctacatgtc | atatatcacc | accacccctc | tctcaattat  | tcaagccaac  | 7800 |

-continued

---

|  |       |
|--|-------|
| atcttgcaag tcacaatctt tgtgttgtgt ttctcatgcc ttccagttca tcagaaaatc  | 7860  |
| cagttcttgc caccctccaa acagaatcta gattttccat ctttccatct ccaccccagc  | 7920  |
| caaccttatg catcatctct ggaggctctgc aaaagtcttt tcacttcttc cctttttttt | 7980  |
| tttttaaacc tgccagggtt ggggagggga tctcccccgc tccacggccc ccccgcctc   | 8040  |
| ccccccccc cgctgcctc caccacccc cttcactttt tctcctgtgg ctccctacc      | 8100  |
| cctactctt cactcagggg ccaagggtga tctgtacaa atgtacattg gctcagatcc    | 8160  |
| tcttctactt aaatttttat gacttcctat gcatttataa caaaactcat acaactccca  | 8220  |
| cttaacactg tgaggccatg cagcccttg tttttatata cctccgtgtc caacctcatt   | 8280  |
| tcattccact tgccccacc cctatcagca gcaggcatat tagccatttt aaagtttttc   | 8340  |
| tttctgtct tgggggcctt tgcataact ttcccctctg cctggaatac ttctttttt     | 8400  |
| ttttttttt ttttttttaa gatgaagttt cgctcttgtc actcagctg gagagcaatg    | 8460  |
| gcacgatctc ggcttgctgc aacctccgc tcccagggtc aagcaattct cctgcctcag   | 8520  |
| cctcctgagt agctgggatc cacaccagc taatttttta atttttagta gagacggggt   | 8580  |
| ttcgccatgt tggccaggct gatctcaaac tctgacctc aggtgatcca cccacctcgg   | 8640  |
| cctcccagag tgctgggatt acaggcatga gccaccacac ctggcctgga atacatttta  | 8700  |
| gtaagtgtt aatggatagt tgttgatga atgactgaaa aggtctttca agaggaaactg   | 8760  |
| atagtgatgt aaacttcaag tgctcgggtc gtaacaggta ttcaatgaaa aggattctat  | 8820  |
| gcataatgta gaaatttttg aaaataaaat aaaaattgaa gatttaaaaa tctgtgtgc   | 8880  |
| tccaacattt agaaagggtc aaactcttaa tggctaacca gggtttcttg acctaagcac  | 8940  |
| taatgacatt tgggctagag aattctttgt cgtggggact gtctgtaca ttgtccctgg   | 9000  |
| cagcatgtct ggctctagc cactagatgt cagcagcact ttccctacc ctcaagggtg    | 9060  |
| gataatcaaa actatctcca gacatttata aatgtccctt gggggttgaa attatctcca  | 9120  |
| ctgagaacca ctgtgctggg cttctaccct tacaagaaat tttctctcag tcattcaatg  | 9180  |
| cttctcaaat cttggtgtcc ataagaatca tctggggcca ttattaaaaa ttcagatggc  | 9240  |
| agctgggcga ggtggcttac acctgtaac ccagcacttc gggaggctga ggcaggtgga   | 9300  |
| ccacttgagt tcaggagtgc gagaccagcc tgccaaacat ggtgagacct cgtctctact  | 9360  |
| aaaaatacaa aattagccga gcgtggtagc acatgcctgt aatcccagct acttgggagg  | 9420  |
| ctgagacagg aaaatcactt aaaccatga ggcagaggtt gtggtgagcc gggatcgtgc   | 9480  |
| cattgcactc cagcctgggt aacaagagca aaactctgtc tcaaaaaaa aaaaaaaaaa   | 9540  |
| aaaaaaaaa gatgggtggc gggcacggtg gctcagcct gtaatcccag cactttggga    | 9600  |
| ggtgggtgga tcacctgagt tcaggagtgc aagaccagcc tggccaacat ggtgaaaccc  | 9660  |
| tgtctctatt aaaaaaaaaa ttagccaggc gtgatgggtc atgcctgtaa tcccagctac  | 9720  |
| tggggaggct gaagcaggag aatcgcttga acctgggagg tggaggttcc agtgagtga   | 9780  |
| gatcgtgcca ctgcactcca gctgggggc cagagcgaga ccctgcctta aaaaaacaa    | 9840  |
| caaaaaaat cagatgcctg gggtcctacc tccagggtgc aggaccaaca gtgggcctag   | 9900  |
| tcacagatt aaaaaaaga aaatatttaa taaatagagg tggggcatgg tggctcatgc    | 9960  |
| ctgtaatccc aacacttttg gaggccagg caggtggatc actggagact aagaattcaa   | 10020 |
| gaccagcctg gccaacatgg tgaaccttg tctctactaa aagtacaaa actagctggg    | 10080 |
| tgtggtggtg catgcctgta atttcagcta cttgggaggc tggggcagga gaattgcttg  | 10140 |
| aacctgggag gcggagggtg cagtgagaag agatcaggcc actacactcc agcctgggcg  | 10200 |



-continued

---

```

acagagtgag agtccataaa ttaataaaca aacaaattaa ttaattaaaa aatagagacg 10260
gggggaggtg tcttgctatg ttgtccaggc ttgtcttgaa cccagcctc aagcaaatca 10320
gcctcccaaa gtgctgggat taaaggcagg agccatggag cacctggccc aagtgtttaa 10380
tgagcttctg ggcaactctg ataccagggt cctcagacc gcactttgaa aactcctcaa 10440
ggaggcctct caatcacctg atcaccaaac cctgtgtgag gctccctacc cacctggacc 10500
ctctccttga attcctctcc ttccaatta ttacccttcc ctagatagca agtggtgaca 10560
gaaccaaacc ctgctcagc caaagcccaa attgcctcat ctcccttcag ggaataggca 10620
aaaaaaaaa aaaaaaaaaa aaaaaaagat cacagagttc agctgaaacc acttaggaaa 10680
tatcagcatc cccacctccc caccacaaag gactcctgag tggcagcctg agagggtgtg 10740
ctgctcatca gaataatgtt gtcagactgt gttctttctg ggggatcatc acactccctt 10800
ttctgggaac aaatgttggc cacttggtgg gatgggcat catgatctac gtcagacaaa 10860
ttcagtgaag catgactcag cctatctctc tagaccatc ttttatgcc ccttacttat 10920
agtctctctg agggctgttc tcaactatc tatttctctc ctttcggca catgatgggg 10980
attacatttt cttgcttctt ttgaaatgag atgtgaccat gttacttgtt tcaggtaacg 11040
agatgtgagc agaacaacc tgtgtcacac ctgggcagaa gctttaaagg ccagtgtgc 11100
cctgtttggg gaagcaagta tagatatgaa tcgttcaca acgcgagcg cccctgccg 11160
acccatgctg ggcgtgtact atagggtgagc aattaacttt gctgttcaa ccattgagac 11220
ttaggggttt tttgtggtt gcaagctaac ttcacttcac ttgactgaac acagtctttc 11280
caaagtttca ctaatttttt aatgaccatt atgatttttt catatctgta acatttttct 11340
tacatcaact cacttctttt tacttcaatt tattttagaa agaaatatta ttactaccaa 11400
atgaaacagt atcataagta gaaagcaatg agaaaaataa cagaatgaaa gaaatcctga 11460
tatcaaatcc tgacttaata ctatttgctt ttcaaagcct ctggaccttt ggtctttatt 11520
taaaaaaaaa aaaaaaaaaa aaaaaaagga gccaggggcc aggcgtgatg gctcacacct 11580
gtaatcccag gaattttgga ggcgaggtg ggaagatcac ctgaggtcag gagttcgaga 11640
ccagcctgac caatatgagg aaaccccatc tctactaaaa atacaaaaat tagccgggtg 11700
tggtggcatg tgcctgtaat cccagctact caggaggctg agacaggaga attgcttgaa 11760
cctgggaggc ggagggtgca gtgagccgag atcgctccat tgcactccag cctgggcaac 11820
aagagtgaag ctccgtctta aaaaaaaaaat gggagccagg tgcgggtggct catgctgtga 11880
atcccagcag tttggggggc tgagggtggc agatcacttg aggtcaggag ttcaagacca 11940
ccctagccaa catggtgata tctgtctct acttaaaatg caaaaattag ctgggcatga 12000
tggtcatgtc ctgtaatatc ccagcctctt gggaggtgga ggcaggagaa tcactgaac 12060
ccaggaggcg gaggttgag tgagctgaga ttgtaccact gcaactccag ctgggggaga 12120
gagttgagac tccgtattta aaaaaaaaaa aaaaaaagag gtcccaaga gtactcttca 12180
atcttttggg tcccaaaagc tgtctaagat tgtcagaata tttgaaggca gcacagtatt 12240
gaggctgagt gtaccaatc tggaaactga catcctgggc ttaaattctg gttcagtcac 12300
ggactagctg tgtgaccctg gacaagttac tgaactgctc tgtgactgtt ttcttatttg 12360
caaaaatagt accataatga tgtgtatggc attaggtcgt ggtggggatt atttgtgtta 12420
atgtataaaa agggcctaga agtgtgcctg gcaacttagt agtgctatgg aggcattacc 12480
tataaaatga tggcaggatc cagatccaaa tagatttggg gaattattgt ttgtttttt 12540

```

-continued

---

|             |             |            |            |             |             |       |
|-------------|-------------|------------|------------|-------------|-------------|-------|
| tgagacaggg  | tctctgtcac  | tcaggtctga | gtgcagtggc | gccatcacag  | ctcactgcag  | 12600 |
| cctccaagtc  | tccaggctca  | gatgatcctc | ctacctcagc | ctccagagta  | gctgggacta  | 12660 |
| catgtgtgga  | ccaccacccc  | tggctaattt | ttctatat   | tgtagatatg  | ggatttcacc  | 12720 |
| atgttgccca  | ggctggtctg  | gaactcttgg | gttcaagcaa | tctgccctt   | cttagtcttc  | 12780 |
| aaagtgttgg  | gattacagac  | gtgagtcacc | ccaccacagc | tggagaaatg  | tttgaactcc  | 12840 |
| atggagataa  | gtaaaaaatc  | ctctgcattg | gttaaaaata | aatcacctgg  | atgatttatt  | 12900 |
| tatttagtgt  | agatgggaaa  | agctacctta | gcagaaagtg | acatagcaaa  | attctagagg  | 12960 |
| ttttacttgg  | tggcagctgc  | ccaaacctct | aaccacgtcg | tatgtatcat  | tagagagaat  | 13020 |
| gtagtcccca  | ggtcagagga  | gctaagaggt | ccttggcatt | ctactcctaa  | ggagcatata  | 13080 |
| tggacaattg  | tgtttagttt  | tcattttaat | atgaatactt | aaaattttcc  | taggatggca  | 13140 |
| gaggatgaga  | aagctatgcc  | ccttaggccg | agtgcagcgg | catggctcat  | gcctgtaatc  | 13200 |
| ctggcgcttt  | gggaggccaa  | ggcggggcga | tcacgaggtc | aagagatcga  | gatcatgttg  | 13260 |
| gccaacatgg  | tgaaaactca  | tctctactaa | aaatacaaaa | attagccttg  | cgtagtggtg  | 13320 |
| cgcacctgta  | gtcccagcta  | cttgggaggc | tgaggcagga | gaattgcttg  | aacctgggag  | 13380 |
| goggaggggtg | cagtgcgcgc  | agatctcgcc | accgcactct | agcccgccag  | cagagcgaga  | 13440 |
| gttcgtctca  | aaaaaaaaaa  | agaaagaaag | aaagaaagaa | agctatgccc  | cttgaagaat  | 13500 |
| aatcaaagat  | ccaaaagagt  | tttgggctgg | gtattggaga | agaggagaga  | aagggtggtg  | 13560 |
| agcagagtgg  | tcaggggccat | tgcccttgaa | atatcagtgg | tgccatttac  | atagctgttg  | 13620 |
| gaccttgcta  | aatcataag   | ctcttcaagc | cttatttgct | tcactataaa  | aataggaatc  | 13680 |
| aatgatagga  | ccttttcata  | gattgctttg | tggagtaaat | gtgttaaacc  | ttataaacct  | 13740 |
| ggcaggtagc  | tgcccagcat  | atagttgcgt | tatttactca | attcaaagta  | ctttcctgcc  | 13800 |
| gggtgcgggtg | gctcaggcct  | gtaatcccag | cactttggga | ggctgaggtg  | ggtggatcac  | 13860 |
| ttgaggtcag  | gagttccaga  | ccagcctgac | caacatgggt | aaaccctgtc  | tctactaaaa  | 13920 |
| acacaaaaat  | tagccggggc  | tggtggcagt | cacctgtaat | cccagctact  | tggggaggctg | 13980 |
| aggcacaaga  | atcacttgaa  | cctgggaggc | agaggttgca | atgagctgag  | atcgtgccgc  | 14040 |
| tgcacgccat  | cctgggtgat  | agattgagac | tcagtctcaa | aaaaaaggca  | acaaagtact  | 14100 |
| ttccttttga  | aaagagtgcc  | cactggctgg | gtgaagtggc | tcacgcctgt  | aatctcagca  | 14160 |
| cttgtggggc  | tgaggcaggc  | agatcagttg | aagccaggag | tttgagacca  | gtttcacgtg  | 14220 |
| gccaacatgg  | tgaaccccg   | tctactaaaa | atacaaaaat | aagccagatg  | tggtgtcatg  | 14280 |
| tgctgtagt   | cccagctact  | caggagagtg | agacaggaga | atcatttgaa  | ccctggagtt  | 14340 |
| ggaggttgca  | gtgagcagag  | atcgtgccac | tgactccag  | cctgggtgac  | agagtaaaac  | 14400 |
| tctgtctcaa  | aaaaaaaaaa  | aaaaaaagct | ctcactgatt | cctacagctt  | cagagaaatga | 14460 |
| acgaggacca  | aaatgtggat  | gctacaggga | ggaaacttga | ggctcaaaaat | ggagatcttt  | 14520 |
| ctataaaata  | caattgttct  | accacaggaa | aagctgcttt | attaagtagt  | gagtattccg  | 14580 |
| tcattggaag  | tattaagccc  | aagctaaatg | gtcaactgtc | agggaaaggat | ggtgagagga  | 14640 |
| ttccagtggg  | ttagaggtca  | aagagcgtct | accaggtgca | aaagtcttaa  | ttaacaaagt  | 14700 |
| actatcaaaa  | ccaaattcat  | gtttgggaaa | ctgtatatcc | acatgcaaaa  | gaatgaaatc  | 14760 |
| agactctttc  | cttacaccat  | atacgaaaat | taactaaaaa | tgagtttgac  | ggaaaagtat  | 14820 |
| aaaacctttg  | gaataaaaca  | taagggaaaa | gcttcatgat | attagatttg  | gtgatgattt  | 14880 |
| cttggatatg  | acacaaaaag  | cacaggaaat | ttttaaaaaa | tagataaatt  | ggactacatc  | 14940 |

-continued

---

```

aaaattagaa aaatttgtgc accaaaggac acttgactga gtgaaaaagc aacttacaga 15000
atgggagaaa atatttgcca atcatatatac tgataagggg ttaatgtccg aaatatataa 15060
agaactctta caactcaata acaacaacca aaaactttaa aaatggacaa agaggccagc 15120
tgtagtggtc caagtctgta atctcaccac tttgtgagcg agaggcagga ggattgcttg 15180
agctcaggag tttaagacca gcctggggcaa catagtgaac ctttgtctct acagaaaaat 15240
ttaaaaaata gccaggcatg ctgcacacct gtagtcccag cttacttggg aggccgaggt 15300
gggaggacca cttgagtcac ggagtttgag gctgtggtga gccacgatcc tgctgctgca 15360
ctctagcctg ggtgacagag caagacctgt ctcaagaaaa caaaaaaatt ggcaaaggac 15420
ttgaataggc atttctccaa ggaagatata caaataacca ttaagcacat aaaaagatac 15480
ttaacatcac taatcattag ggaagtgcac atcaaaactg caataagagg ctgggcacag 15540
tggctcatgc ctgtaatccc agcactttgg gaggccaggc caagtggatc acttgaggtc 15600
aggagtttga gaccagcctg gccaacatgg caaaatccca aatctactaa acaatataaa 15660
aattatctgg gtgtggggcca ggcacagtgg ctcacgcctg taatcccagc actttgggag 15720
gccaaaggcg gcggatcacg aggtcaggag ttcaagacca gcctggccag catggtgaaa 15780
ccccatctct actaaaaata caaaaattag ccgggcatgg tggcatgcat ctgtaatccc 15840
agctactcag gaggtcaggg taggagaatc gcttgaacct gggaggcaga ggttgacgtg 15900
agccaagatc gcgccactgc accccagtct gtgccacaca gtgagactct gtctcaaaaa 15960
aaaaaaaaa aaaaaggcaa aagaaaaatt atccgggtgt gatggcacat gcctgtaatc 16020
tcagctacct gggaggctga agcaggagaa tcgcttgaac cctggaggag aagtttgacg 16080
tgagctgaga ctgcactact gcactccagc ctgggcgaca gagcaagact atgtctccaa 16140
aaaaaaccaa gacaaacaaa caaacaaaac acacaataag agaccacctc acaccatta 16200
ggatggatat tataaaacaa caacaaaaca gacaatagta agtggttggtg aagatgtgga 16260
gaaattgtaa cccttttacg ttcttatcac tgctggtggg aacgtaaaat agtgcagctt 16320
ctgtggcaag cagtatggcg gcttcctaaa aaatgaaaaa tagaactatc atatgatcta 16380
gcaattgtac tcccagtat ataccacaaa gaaccaaaag tagcatctgg aagagagatt 16440
tgtatactca agttcatagc agcattattc ataatagcca aaaggtagag gcaacccaag 16500
tgtcaatcaa tggatgaatg gatcaataaa atgtggtata tgcatacaat ggaatattat 16560
tcagccttaa aaaggatgga aattctgaca catgctacaa catggatgga tcttgagggc 16620
attatgctag gggaaaagct agtcacaaag aacaaatact gtatgattcc actagcctac 16680
aggaaagtag tcaaatcac agagacagaa agtagaaggg gtttgccagg gcctgggaag 16740
aaaggagaac tattttcttt tcttttcttt tctttttttt ttttttttga gacgggggtct 16800
ctctctgtgg ccagggctgg agtgacagtgg tgcgatctcg gctcactgca acctccactt 16860
cccggttca agcagatctc ctgcctcagc ctcctgagta cctgggatta caggcacgca 16920
ccaccacgcc cggtaattt ttttgtattt ttagtattta ttttgtattt ttagtagaga 16980
cgaggtttct ccatgttagc ctcccaaggg gagctatttt ctaatgggta cagtttcagt 17040
gtgggaagat gaaaaaagtt cagggtgatg atggtgctga tgggtgtatt acaatgtgaa 17100
tatatttaat gtctctgaac tgtacgttta aaaatggctg gctgggcgtg gtggctcaca 17160
cctgtaatcc cagcactttg ggaggctgag gtggatggat cacctttggg cagggtgtca 17220
agaccagcct gggcaacata gtgaaacct gtctctacta aaaatacaaa aatcagctgg 17280

```

-continued

---

```

gtgcggcgggt gcatgcctgt aaccccagct actcgggagg ctgaggcaga aaaatcactt 17340
gaacctggga ggtggagggt gtagtgagcc gagatcacgc cactgcactc cagccgggcg 17400
acagagtaag actctgtttc aaaaaaaaaa aaaaatacat gcataaaaga tgtttctaag 17460
agtgcataaa aatgcctaca aattgataag gaaaggtaaa taatacaata gataaatggt 17520
caaaggatag aaacaagcac actcataatg taggaagctc aaatggcaaa agagcctctc 17580
cttctctagt aatagaggaa atgtaaattt gaaagtgaag cataatttta cattcagtat 17640
cttacaaaat caagtgtctg tagggttgta gagcaaccaa aactctgtaa ctattgttgg 17700
aagtgggaagt tggcattcaa gaatgagcaa tttagcaaca tctcttaaaa gtgttgatat 17760
ccactgtcta agatacagaa attccatctc tgcattgtac ctagagaaac tctcatccac 17820
aggtataaga atagtctttg gagcatcatc tgagatagtg agccaagatc gtgcaactgc 17880
actccagcct gagtaacaga gtgagactcc atctcaaac aaacaaataa acaaacaga 17940
ataaatatac tcaggatatt taca 17964

```

```

<210> SEQ ID NO 8
<211> LENGTH: 30003
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

```

```

<400> SEQUENCE: 8

```

```

agtgcacagc agctgcctcc tcaccctagc tgagctgacc acaagattcc agacctcagc 60
tggagctgca gcctcatact ggctgagtggt ctccaagaca cagaagggaag cagggtggca 120
ggctgacctc agccagctgc ctgccccctc tcctctgagg ctggcctggg accgatgggg 180
ctcttccctc caggaggggt ttccgggctt cctcttttcc cctacctccc tgtggagaac 240
tgtccacccc tcagatatg ctccagtgat gtccggagggg atgcctcaat ctggcgagac 300
gcagcggcaa caaatctgc tcagagacaa acggacatgt tgctgatatg aatctcactt 360
ggtagtggtg aacaacagag tctgtcattt gggctgtgac agtcgtgcac accagagacc 420
gctgaccccc gcccgagca cagggaactg catatataca cagcaggtag aaatatgggc 480
acacgacaaa acgcccatac aggataaaga tgcaggaaga acagggcact ccaacaggtc 540
cgcatgcaca aacgatgtg ctctatgacc cgcacacaca gcacacatgt acaaacatcc 600
acagacacaa gtacacacac atacacactt acatacataa gcaagatcaa caccgggaac 660
tcctaagaca caaacacaga cccactcaat gaatacaaag gaaaatagac ccagaactca 720
cacacagaga caaatgaaca cacatatgca aatgggttcc tgaaggcatc accccaccca 780
tacaacctac atggaacctc actatcacac acgaacgcac acacaacaca cacagtgtgt 840
agttggcttc gtagttagca aaacttcctt gagagctcca ttttcctaa gtgccaattt 900
catttcccta ggaagtccc aaagacaccg agaaatgcgg ttatgtctcc aaccaccatc 960
tccagggata caacatccct tgccgtctct ctgaacctag gcccaagggg ttcacgaagg 1020
ggccgtgctg ggctgaatcg ctggagctgg gcaccaaggg ggagctcacc atcacgtcac 1080
tgtgccaaag gccaaagcaga gccactgtga ggcagtgagg actggaaggg cctgggagga 1140
atagccggga tcgacttttg ctggaaattg gcccttgacg gcctcccttc acccagaatg 1200
cctgtgatca ctgtgcctgg gcacatgggc ttcacttggc aacacctgtg ctggcctgta 1260
ggaccaacct accattttgt atcattctcc tcccacccca aagttgagtg ccaaagatct 1320
gctcctggac ccaggcacac ctgcccccac tggcacacct gggcacatct gccccacct 1380
accattgccc atcgtcaaca cctgcacatt ctcaaattcc aggggtggtg aggctgggtc 1440

```

-continued

---

|             |            |            |            |             |             |      |
|-------------|------------|------------|------------|-------------|-------------|------|
| cagtgcagca  | ctgtagtogg | ccatgtccat | gtcgacgagg | gttttgaga   | gtcgattct   | 1500 |
| ccctgcctcc  | acgcgcggc  | cacctgcct  | accctgggcg | cccacccga   | aggcccccgc  | 1560 |
| cctccgcct   | cccactgcct | cctcccagtg | ccctctctgc | cttcctttca  | aacgcctctc  | 1620 |
| tgggaagatc  | tgtctggagt | cttgccctag | cctctgtgaa | gggttgagg   | ctctgccggg  | 1680 |
| gaggggtggg  | ggttaatggt | taatcggtcc | ccgcgcggtg | gataggctgg  | gcggggctgc  | 1740 |
| agggatttgg  | ctgtttgttg | gtttctggct | gacacccggg | gtgctaatta  | caactgctgg  | 1800 |
| ggccctaact  | caccgatgtt | cagttatcaa | ttgtacaagg | caggcatcat  | gactcacggg  | 1860 |
| cactcatttg  | acccttgact | caccacccc  | tccaagccat | tgtcacccca  | agtcaggcat  | 1920 |
| tctaactgat  | actatcaggc | actgacagcc | tacctccgag | atccccta    | tcaataactt  | 1980 |
| cccaaatcat  | tgactcttac | cctcaatgct | tttgacagag | taaggctgcc  | ccatggccca  | 2040 |
| cgatttagaa  | acctaaatcc | caggccccag | atgccaatct | tctggatcct  | tgttctggga  | 2100 |
| gtccctctcc  | agtccccccg | cagtttcccg | gttccctggg | gagcagaatg  | gactggaagt  | 2160 |
| ttgggagggc  | cagattcacc | tccaattccc | cgctcctgct | ccctgtgate  | ccacctgcc   | 2220 |
| cctctccgtc  | tcccacagct | cccagtggtt | ctggcccagg | ctggctccat  | ctcggatttt  | 2280 |
| cccatacat   | tctcctgttt | ccctcacccc | cacccctccc | cggagcaggc  | agagacctgg  | 2340 |
| atttacattc  | aggcacctac | cgtctactaa | ctgggacctt | gggtaaatga  | ttctcctctc  | 2400 |
| cgagcctcag  | tttcttttcc | tgtaaaatgt | acaatcaact | tcaaaggggtg | gtttgagaag  | 2460 |
| gaaatgagat  | ggcataaatc | aagcaccaag | tggggcctgg | tagacgtcca  | tcctcttccc  | 2520 |
| cctctccctc  | ctccctgttt | cgtatcccc  | ttgccatccc | cctgtttctc  | tccacccgtc  | 2580 |
| tcctaccttc  | agagtgggct | ttgtgggggt | atcgccagtg | cagtcacagg  | caaccaacc   | 2640 |
| cttagaaaagt | cctggttcct | ggttcagtgc | tctgctgtgg | ttgtcctaaa  | attcatcatg  | 2700 |
| acttttgaac  | aagggattgt | gcatttttgt | tttgacggg  | gccctgaaaa  | ttacacagct  | 2760 |
| ggtcctggct  | gtctgaagct | catggtgcac | tctgttcttc | tactccctc   | cagccctcat  | 2820 |
| tgccttctgt  | gcagacattt | tcaagggctg | ccaatcaatc | tggggaagta  | aagtcttgat  | 2880 |
| gtagaaggca  | gagagtgagg | gcagaggaag | aaaagcctga | gacttgggag  | gcctgggagc  | 2940 |
| ctgtcctcca  | ctgctggctg | gaagggcagg | ttggagggcc | tcggtgacac  | ctgtgagcaa  | 3000 |
| gagtgggcga  | attagtggga | gcaccaatta | atgagtgagt | gtgtggggga  | attgatgagt  | 3060 |
| gggtgaatta  | ggagtgagt  | aattagagac | agggagaatt | aatgagtgag  | ttgagtgaat  | 3120 |
| gcatgaatga  | gtgagtgaat | gaacgaatga | gggtaaatta | ctgagtaagt  | gagcaaatgg  | 3180 |
| gtgggtgaat  | taatgagtga | atgggtgggt | gaattaatga | gtgagtgaat  | gagtgaatgt  | 3240 |
| gtgggtggat  | taatgagtga | gcaaatcggg | agtcagggca | tgtgtgttcg  | agtgggtatga | 3300 |
| ggaggcatct  | tcattgttct | tccactgcta | gaagcccttt | ctctgccctg  | cttagcttta  | 3360 |
| ttctgtccac  | ttgatctgac | ctctgaagct | gagatgactg | gggagtgcta  | ttgcctgtag  | 3420 |
| ggaaagggga  | gagggagcaa | ctgtttgtga | ggacaagaga | ggctagattt  | gatgtcagga  | 3480 |
| gacctgggg   | taggaactag | ctcagtcact | attccgataa | ctttattttac | atcgtctctt  | 3540 |
| ctcagggtct  | caatttctcc | ctctgtaaaa | tagaaagatg | atcctggctc  | agttttctgt  | 3600 |
| tagccaggac  | aagactctga | gggagggagc | aagaggcagc | cccctgcaac  | ccacactatg  | 3660 |
| agacttgata  | aggggctgaa | agagacccaa | taccggcggg | ttcctcccat  | gcctacctca  | 3720 |
| ggagtatctg  | acctggctcc | accggccttg | ggggcagtcg | agagggtggga | agaaacagaa  | 3780 |

-continued

---

|  |      |
|--|------|
| gatccgacca aggggtaaac acagaagaga tgtggagggc agctccggga ggagcctcca  | 3840 |
| agggctgagc ccaggcctct gccacctgcc tggcacctat ggcaggccac aggcacagct  | 3900 |
| actccccaca caatccagga atacatggcc tcttccactc tgaggcacag ttccacattg  | 3960 |
| cttaacgggg aatgtgatca atgtcatgtc agaatttcat tggcaacaaa aataacaatg  | 4020 |
| cattttttcca tagatgacat cttagattca attaaataag gtctacgac aaccaagatc  | 4080 |
| aaccacacca tgccacagcc atgaccggtt atatccaaga gctactaggt ggacactgca  | 4140 |
| aatgaagagc tattagatac atgaatcatg acatacctga cttaccaaat gcacaatctg  | 4200 |
| catgactgcc taggaggcac attctagatt cacatcccac cacattataa cctaccccat  | 4260 |
| aagtaaatct atccactcat cactgtaaat tgcataatct attacatata tgattcattc  | 4320 |
| cacccttagc caacgccaaa cagtatctcc tagatacaca ttcctcatat aaatgacgca  | 4380 |
| ccacctataa gatctgtctg ctctgtgacc tcaggcaagc tattatttct tttgttcttg  | 4440 |
| ttgttcattg ttactacata gttttattaa accaagctat gataatacag ctgccagaa   | 4500 |
| tctttgtgga ttacagatgc aaagtaactg gagacgtgtc cttgcaccta tagttcagta  | 4560 |
| atagacagaa agttttgttac atttactaag tacagagaac tgaatacaca tgacattgta | 4620 |
| catccatctt tttgctttgt atttccattt taaacatatg tatgttataa ctttacattt  | 4680 |
| taaatatgac tccatgtatt ttgtgacaat ggctaagaac gcaatgatcc catgccctg   | 4740 |
| aaataagcac actttgtctt gcaatgcaga atgttttcat tggggtagca aacaaaccct  | 4800 |
| taacacataa cagacaaaaa ctcccttaaa atcagattta atacaatgtt cttcatgtta  | 4860 |
| gataaggaga aagaacggga ggtggaaaag gaaaacattg gggtagctta aatgtacagt  | 4920 |
| gtcttgagac cttgaaagt ttacggccagg cacaggggct cacacctgta atcctagcat  | 4980 |
| cttgggaggc cgaggcaggc agatcacctg aggtcaggag ttcaagacca gcctggccaa  | 5040 |
| catggagaaa cctgtctctt actaaaaata caaaaatcaa aaattagcta ggcatggtag  | 5100 |
| catgccccctg cagtcacagg tacttgggag gctgaggcag gagaatcact tgaacctggg | 5160 |
| aggtggaagc tgcagtgagc cgagattgtt ccactgcacc tgggtgacag agcaagactc  | 5220 |
| tgtctaaaaa aaaaaaaga atgttttctt caggggatga agagacgttg gttcatgggt   | 5280 |
| acaaaaataa gtgagataga aggaataaga tctagtctt atagcacagt agagcgatta   | 5340 |
| tagttaacaa tcattttact tatatttcaa aatagccaga agagaagatc tgaatgtac   | 5400 |
| ccaacacaaa gaaatgataa atgtttgagg tgatggatat cctaaatact ttgcatggta  | 5460 |
| tgcatgtatc aaaatacatg tgctccatat atatgtacaa ttattatgta tcaattataa  | 5520 |
| aaagtttcat tcccttctc caagggattt tttttttaac tagtggaata aagaaagcaa   | 5580 |
| cttcataacg cctccagtg aggaagaaca ttatcctgac aatgcttagg tgctttcata   | 5640 |
| tgagcacata ataaatacag gaagtcacag agcaaatgtc acagtattgg tttggttttt  | 5700 |
| atttctatgc ttataaaaaa tattaagctt ctttctgttg actgagtggt tgtagcctg   | 5760 |
| tgggtatttg tctctgtgtc ctgtatacca gtgactattt atattccaag cccagggcc   | 5820 |
| gctgtctgca caaggcaagt ttttatttcg aagccttggt tactccttct gtacaagggg  | 5880 |
| tctaacttgt cgtttgtcgt gaagattaaa tgagagagta gataagcttc ttagcctctc  | 5940 |
| ttccctgac ctctctttag gggaataaac cacagacctt gtgggtcaga tagatctagg   | 6000 |
| ttaaaatcca ggcagtgcc atgtacaaaa ctctgtgacc tcaacttcta cttttctcag   | 6060 |
| ccttagttta agcatcagaa aaattgggtt gataccttct ttgtagggat ggttcaagca  | 6120 |
| ttaaatgacc acgtgtaggc atacagtaca atagtagcaa tcaactgtcat tggtcattga | 6180 |

-continued

---

|  |      |
|--|------|
| ttgcatgaca cactggccac ataatcagtt ggaatcagga cccctgctca ggacagctcc  | 6240 |
| aggtaccaca caccagcca tgaacaagca cttagcctcaa tgccatcaat ttagcagctg  | 6300 |
| ttctttacct ctgctcactt gctgtcgggc cccagctcaa gaggcagcag attccagggg  | 6360 |
| atagcagagg acctcagagc ccacagagag acccagttga gacgggaagg gattgccctg  | 6420 |
| ggcaacctgc agttggggag gcatgtgtag ggagcttgtg cctctgctgt ggacgggtgt  | 6480 |
| aaggagctg cactacgaa ccacattgtt tctcttttac attataataa ggtctaattgt   | 6540 |
| ttacagagaa attttgtgct agccctgggtg ctaaaaacct tctagccttc tcatattatc | 6600 |
| tgctgttga gataggggct attgtcatcc ccattttaaa gatgatgaaa ttgaggtca    | 6660 |
| gagaggtgaa gtgacttgcc caaagccaca cagctcgtaa gggaggggct gttgtttgaa  | 6720 |
| cccgagtctg cctccagagc ttgagggctt caccctcta cgcattgcct gcatcatgac   | 6780 |
| tcttggaatc cctgaaagga cttcggaatt ctaaggcact ggagctgggt gtttcaactgc | 6840 |
| ctcagtcttg caggggaact caaggacctg agaagtaaag caccttatcc cggggtatag  | 6900 |
| gcaggggcag gggcatctc cacaagcctg gccacccag ggtgcttgg catcttcaact    | 6960 |
| tccccttggc gctcaccaca ccattatctc ctatcttttc tccccaccc accactccg    | 7020 |
| gagaggtgca gaaaaactg ggacttatca agacaaagaa caaagtcgt ggaggaaaga    | 7080 |
| agccaagagc catctctact ctggggtagg gcccttcagt tttgccctt tgaaatttca   | 7140 |
| aattccagtt tgtggacaaa gtcctaacta tctcacaata taggtcccca accactgacc  | 7200 |
| aaactccagt ccaggcagcc accagctggc ctggtcttgc tgcttccttt agcggttcc   | 7260 |
| aaggtccagg gacagggggt ctggggccacc aagaggtctt gctaggtgtt cctgcagcc  | 7320 |
| acagccccc cactggacc ctgcctcca tctgagagga cagccctctt cctggagctg     | 7380 |
| ggatctgaca cttgctgata ccaacggcag ataccaggtg ggtccctcc ctttctcttc   | 7440 |
| cttgagctcc taaaaatgcca ctcataccac cctctgcact cggcaaaggc cactgtggct | 7500 |
| taatcaaatc aggcaccac aaagcttcaa gactggaaaa gatgccttgg ctaaccacc    | 7560 |
| catttagtgg acgaaaacac tgaggccgtc aggggagtg cagctggcca cagactgaac   | 7620 |
| catagacttg gggcccagac ctggggcccc tcacggagcc tcagaggggt aaagggactt  | 7680 |
| gctcaagtcc acgcagcggg ggtgggtgag ctttgtctta acaacgagca ctttctactt  | 7740 |
| catcacagac catgagtggt attgtgtttg ttcacccgat gatgggtggc cactggcttg  | 7800 |
| ttcacccgat gatgggtggc cactggcttg tcacaggagt atttccgaga ggaagatgag  | 7860 |
| ggagcttggg gctgaaggcc agtgggtttg gaaggaagca acattcatgt ggtaactga   | 7920 |
| taactgggcc ccacccctgg gccctcttc tccctccctg tccttagcct gattaagacc   | 7980 |
| aacttaccac gctgctaact attgctgagc ctgttgattt tgccttaaaa aattaactgg  | 8040 |
| gcatgagttt gcggttttcc tcaccctaa cctgaaaag gcctgggtgg gcaggaggcc    | 8100 |
| tccaggggta tgcaagaggc cgtggcctc ccaacgcata gccacggcc acctcggctg    | 8160 |
| ctctccaaag aagaggcttt gctcaagagt caacagtctg cttgttcccc ctgtgctggg  | 8220 |
| tccctgagca atttgctctg ttaccaaaaga gagataaagg cagctggggg agagctttcc | 8280 |
| aaacagggat gggaaaggc agctttgagc ttgggggtct agaactctgc agtgcagag    | 8340 |
| ccaggagaat ctttaggagg atgtgggctg gggtttttca agctgggttc cgaggctccc  | 8400 |
| aggagccaag ggtatgcac cacaggccca gcttcaacca gcgactccct ttacatgta    | 8460 |
| gtcttaatat tttatttgag ggttgaaaa ccactgattc agcccatcc cctcattgca    | 8520 |

-continued

---

|   |       |
|---|-------|
| catgatgggga gatggagatc agaggggggaa gtgacttgtc caaggacaga aggtcacctc | 8580  |
| gggtattcag gggctccagc cagcatggga atgaatggtg ggctctctgt ggacccgggc   | 8640  |
| aatgtcttga aagacattgg tgaacaagac ggctctgcaa acgccttgcc atgccgttct   | 8700  |
| ccccctctc ccagggctgg ctggaagcag agaggtgcct gagagccatt ggaagacca     | 8760  |
| agtcagggga atgcacctgg ctctgtgtcc catgggccct gtgaggatat gaccagcagc   | 8820  |
| caggcactgc aaaccggaga ctacgttata atccatctca gccacgtcct gtctctggag   | 8880  |
| gcatcagcac tttgggaggc tgagatggga ggattacttg agcccaagag tttgagacca   | 8940  |
| gcctgggcaa catagtgaaga cctgtgtct atttttttaa aagattttt aaaattaaag    | 9000  |
| acagatgccc agtcctatc acaaaaaaag atgtagagcc ctgccctgac tctctccacc    | 9060  |
| tctctgagcc tcagtttctt cacctgtaaa ttgggaatta taatacttaa cttccagggt   | 9120  |
| tgtcatgaaa atgaaatgaa gcaaaatata cacattgac atcatggcca ctggatatgc    | 9180  |
| agctgtttta ggagctttgc atgtgttact tcttgatcc tccagccac tctgggaggt     | 9240  |
| aggcaatgtt ttcaccaatt tttacacac cagaggcaca gggagggtga gccatatacc    | 9300  |
| catgctcaca cagctgatga gaaacaagaa gtggaattgg aacttgggca gtctgtctct   | 9360  |
| agagtctgtg cctctaactc cagggctacc ctcccttcc agggatgcca gtgagagatg    | 9420  |
| gccaggagaa gggcagagag cagggcactg tgggagatgc tgactgtaag gctccggagg   | 9480  |
| tagggcagag agtatggtct ggagaatgat caggaaggaa gccaggagga cttggatctg   | 9540  |
| tgtgggtgga gcttctccgc aggcctgcctc ctgccaggtg gcttatgaca tctgggctga  | 9600  |
| gggtgttctg gtcctcctgt ttatgttcat cctcctgtt tatgttctg aatttatctg     | 9660  |
| caggggtgac cttgggaatt agatgcggcc ttcccgccc ttgtggggcc tgaaggctga    | 9720  |
| tgggagcccc tgctgaacc agactctggt ttggggagtg agggctgagc ccacatccca    | 9780  |
| gaagccccc ttggtctccc cactactctt ttctgagggg cccagggat ttgccaggtc     | 9840  |
| actaaggatga agtggttggga agtcctgagg ctcatgatc agttactgcc ctgtacagtt  | 9900  |
| gtgcagggtg ctactgcac aaaggttctc cagccaagag ggcaggtagg gatggaaacc    | 9960  |
| cagcccttgt tccacttgcc aagcgaagtg cccatggagc tctgcctgcc cagagtgggg   | 10020 |
| tgccttttct ttatttggcc tagggcttca tgtaagctgc tgggtgtcct gccccagctc   | 10080 |
| tggttccagc cactgtgtgt ccttgggcaa ggtcatttcc ctccctggcc ttgggttccc   | 10140 |
| attggagaag ttttgtctaa caaagcagag actcatctct gaagatgaaa tagaatcatc   | 10200 |
| tgaaaccttt aaaatataca gatgttggcc gaacatggtg gcttacacct ataactctag   | 10260 |
| cactttggga ggctgagatg ggagggttac ttgaaccag gagtttgaga ccagcctggg    | 10320 |
| caacatagtg agaccctatg tctatttttt aaaaagattt tttaaaatta aagacagatg   | 10380 |
| cccagtcctc atcacagatc aatgatcgaa tcttgggcta ggggtgggga ggtgccaggc   | 10440 |
| gtctatattt ttgtgcagcc aatattgaga cccactgtag gggggcttca aatttgaaac   | 10500 |
| tggaaagcct tcgatggcat caagttctat cacttactac aacttactag tcaaaacctc   | 10560 |
| agcagggtc agttttccca tctgtaaaga gggaatgatg atcgtttcct cacaaaaatca   | 10620 |
| aatgccaat taaatgagat aatgttcaga cagtgttgg caccatgttc cccaagtagg     | 10680 |
| gagctcctga ttctgtctac caagactatt attgttgta tgggcaattt gacgttgaca    | 10740 |
| aaataaaggg cctttctagg tcaaggatc ggtgacttga agacaggcct cctctgttgc    | 10800 |
| tttgagtcaa tttctagtac ctgggcctaa atcttgactg cacaccgggc atattattga   | 10860 |
| ggtatgtgtt attattatta tttaatattt tacttaattt gtgaacatct ttacatttag   | 10920 |



-continued

---

|             |            |             |            |             |            |       |
|-------------|------------|-------------|------------|-------------|------------|-------|
| ttttgaattg  | gtgctacatt | cgcattggtc  | agaatcaaaa | cataaaaggt  | gtaaattgag | 10980 |
| aagtcttget  | tccagctgtc | tctgtttcac  | ctgttctcct | tgacttcctc  | actatgggga | 11040 |
| accacatccc  | ttacagatgt | atctgccaaag | gtttctttat | acagaccaga  | tagcatgtaa | 11100 |
| gatcatacat  | gagtagcctc | tgtctttaca  | ctgttctgta | tcttgtttgg  | ttcatttaat | 11160 |
| atcacaaact  | ggagatgett | ccatagcagc  | tgagagcaag | ctttgaggat  | ggaagggttc | 11220 |
| tcgctcctcc  | tcacaggtga | ggaactgag   | gctcagagaa | gaaacatcat  | tttcccagtg | 11280 |
| agccaaggca  | atggtgttag | aactatctct  | acctggctcc | agagcttggt  | tttatgcccc | 11340 |
| tgcaccgata  | cggccttcca | tgaagcccg   | cccagaaagc | tttggagtct  | ggttacatct | 11400 |
| ctgccatgca  | ggcctggcct | tcccaggaca  | agaggtgagg | aggggggctg  | tcggggctct | 11460 |
| cactgtgtct  | ggactcagaa | atcccaaaga  | gaggatgaag | tgtagaacia  | agaatgtccc | 11520 |
| aagtcattcca | gatagggacc | cagtgggaag  | gtgtcccctg | gatggaatag  | tgggggctct | 11580 |
| gtggctgtgc  | ccgtcagcac | tggagaacct  | gccaggaaat | ctctgccagc  | ctcaggtggt | 11640 |
| gcggtgtgca  | ggggaagtca | ggaggaggat  | gagaggcagg | gagggaaagc  | tggccgatga | 11700 |
| gacaagctct  | gggtgagggg | atggagggga  | ccccatgcct | ggagctcagg  | aaggaggatt | 11760 |
| tggagttaa   | ggcagaagt  | gcaatgagat  | tttaaccgat | tgttttctgc  | tcagggaact | 11820 |
| tcagggttcc  | ctctggatcc | ttgacctgct  | tcagtttget | gaactcactg  | ctttgggcaa | 11880 |
| gtcattttcc  | ctctccgtgc | ctcagtttcc  | ccaactgcaa | aatgagagag  | ataagagatc | 11940 |
| tggctcttag  | gcagccttgg | actaccctta  | atactctacg | gggctcctct  | cacctgtgtg | 12000 |
| aggtcgtctg  | gatttctcct | ctctgattgg  | aacgtcattc | acctcatcag  | gcatgggacg | 12060 |
| ttcctgggtt  | aggggatgag | ggtacaaatc  | ctccacactg | ctcccagtct  | ggaatcctcc | 12120 |
| cccttggttc  | tgtgtctctc | tctaccatc   | ccatccttcc | ttccaggcag  | atgtggagtc | 12180 |
| aggaccatac  | ctggtgggtc | ctgggggaag  | ccctggcccc | agtcggacat  | cctcctcctg | 12240 |
| ctgctatggg  | gtcccgacac | gtgcacaacc  | tcttcatcct | tgagggagct  | cctgctggcc | 12300 |
| cctctcagca  | ccccagaccc | tgcgagggcc  | gctgggcaga | gttaatccct  | taatactggt | 12360 |
| cacaatgaga  | tttcagggat | gggtgggagg  | ggtctccatg | gaaactgcag  | acctgtccag | 12420 |
| gatccatgca  | aggaattagc | cccagggttc  | tgcaaggggc | tcctagagag  | ccaaccccaa | 12480 |
| taggaatggg  | agacacagtg | gtctggactc  | ctgggtcctg | ctctggccct  | cctgttgtct | 12540 |
| ctctggaggg  | cttggaaaaa | accataactc  | ttgcattgct | tcagtattct  | gctcaactgg | 12600 |
| acagagccat  | attcacaggg | agagccctat  | cacctttctg | agcgtgtttc  | tccatcccc  | 12660 |
| tattggcatt  | gtaatcctta | accagtggtc  | ttttctagaa | gagtgcaggc  | ttcagagtct | 12720 |
| gccagacctg  | agcttgaagc | tcagcttttc  | cctccacgac | tgtaaaacta  | gccgaggcat | 12780 |
| ttcactttct  | tgagcctcag | cttcctcatc  | tgtatgatgg | gcacaataat  | agcaacatgg | 12840 |
| catccctctt  | gtgctggctg | gtgggttagta | acatccagtg | aatgtgagtc  | tccttctcac | 12900 |
| cttttctga   | ctgccacgcc | cacactgcac  | atttgccctc | cccagcccc   | tgcagcttcc | 12960 |
| agaacccctg  | ggtctcaagc | agagagctgt  | cgcacttcct | tctttgcctt  | ctcatcctcc | 13020 |
| aagtcctatc  | ttagtcatct | tctccggga   | aacagaacgc | cgggggtcctc | ctctgtcccc | 13080 |
| ccatagcccc  | caaagcttta | catcatcacc  | gtttagtcag | atggtaatta  | gactggttgt | 13140 |
| gtgcctcctc  | cactggactg | tgtcccatct  | accattgtat | tcccaggacc  | cacttgatat | 13200 |
| aaataggctg  | gatgaataac | tgagtgaata  | aaggatggaa | atcgtccatc  | gaaacagtca | 13260 |

-continued

---

|             |             |             |            |             |             |       |
|-------------|-------------|-------------|------------|-------------|-------------|-------|
| acattttatc  | agcaccttct  | gcgtgcatcg  | ttgtgggtgg | tggagatgca  | gcaggggaaga | 13320 |
| ccatggggcaa | aatatccccc  | tcagaggggt  | gcagatgagc | aaataaaaaat | acaggatgcc  | 13380 |
| cagtcaaattg | tgaatttaag  | atacacaaga  | aatacttcgt | tagtatgagc  | gtgtcccaaa  | 13440 |
| taatgcatgg  | gacctgctta  | tacttttaaa  | ctgtgggtgt | catctgacac  | tcatatgaaa  | 13500 |
| ctgggtgtcc  | tgtgttgtgt  | cgggcaaccc  | tacaccctcc | ctcacagagc  | ttgcgttttg  | 13560 |
| gtggagaggg  | gggttgacaga | cataagcaag  | taaatacatg | aaaaacgaag  | tcaattacaa  | 13620 |
| acagtgggta  | agtgacgtga  | agacgcacag  | cgcgatgtga | tagcacctgg  | ggatgggcag  | 13680 |
| gacgatcccc  | tgagctagtg  | gcctttgcct  | gcacaggtea | ttttagctcc  | aatgagatgc  | 13740 |
| cactttgcaa  | aagttctttg  | aggatcttaa  | agggcacggt | ggaggctgct  | aaacttgaga  | 13800 |
| gaaggactct  | gaggagggca  | aggggacgac  | ctgagggagt | ggggctgcta  | agtcctactt  | 13860 |
| gatagactcc  | acagttttgc  | aacttggatc  | tgggccttca | caaaccttcg  | cgaacccgca  | 13920 |
| gccccacccc  | tcgggtcagc  | caatgtcttc  | tgtggggctg | ggagccaggg  | gaagaggcca  | 13980 |
| aaggaaactgt | gcagagaagc  | gtggccaccc  | gggacgcagc | tgggagccct  | gacacccttt  | 14040 |
| gccgccccac  | ctcatcccg   | ggttgcccca  | gggacgcagg | cagggcaggc  | accgcgctgg  | 14100 |
| gccggagggc  | gtcccgagg   | agggcgccaa  | gactctccg  | agtgtctg    | tttgcgcttc  | 14160 |
| ctgggctcct  | cctcgtggcc  | aacgcaggaa  | ctgggtgtca | gaaacttaga  | tagccttagg  | 14220 |
| gacttcacca  | atcacagcaa  | tcccgcgaat  | cacaggccca | gacgcactat  | gtctctccaa  | 14280 |
| atccagagga  | ggcctgctcg  | gttcgatcac  | caatcacagc | tcgttggtat  | tagttaccta  | 14340 |
| aaagaacatc  | tccccatcac  | acaccagcac  | atggccacgg | cagcaatcag  | aacgtaagat  | 14400 |
| tttaaaacca  | gttcccagg   | tagcagccgc  | tgcccttcca | ccacctacta  | aacttctgtt  | 14460 |
| cccagcacct  | tgttccaatg  | tacgggggtg  | gggggggtct | ttgaggaagg  | ttccaggctt  | 14520 |
| tgtgtctgtt  | ccatgtggaa  | gcagatgtta  | gcatgtatgg | ggcatgtata  | atgatattac  | 14580 |
| tatcagtaaa  | tgtcataccc  | attatgaaaa  | ttaagatagg | cagggcgtga  | tgggtgcatgc | 14640 |
| ctgtaactcc  | agcttttagt  | ggccaagggt  | ggaggatcgc | tggatcccag  | gagttggagg  | 14700 |
| ctgcagttag  | ccacgatggc  | gccactgcac  | tccagcctgg | gtgatagagt  | gagactctgt  | 14760 |
| ctcaatttaa  | aaaaaaaaat  | taattgtgtg  | atataggagt | gtggaaaaat  | tataaccttt  | 14820 |
| gggttagaca  | cacctggagc  | ccatatacta  | tctttgtgaa | gtaggacgac  | tcacctcccc  | 14880 |
| ttcctcagtc  | gtcaaaagag  | aatgatagtc  | atatctacat | gtcatatata  | atcaccacc   | 14940 |
| ttctctcaat  | tattcaagcc  | aacatcttgc  | aagtcacaat | ctttgtgttg  | tgtttctcat  | 15000 |
| gccttcagtc  | tcacagaaaa  | atccagttct  | tgccaccctc | caaacagaat  | ctagattttc  | 15060 |
| catctttcca  | tctccacccc  | agccaacctt  | atgcatcatc | tctggagggtc | tgcaaaagtc  | 15120 |
| ttttcacttc  | ttcccttttt  | ttttttttta  | acctgccagg | gttggggagg  | ggatctcccc  | 15180 |
| cgtccaccg   | ccccccccgc  | ctcccccccc  | ccccgcctgc | ctccacccca  | cccccttact  | 15240 |
| ttttctctg   | tggcttcctt  | acccccctact | cttcactcag | gggccaaggg  | tgatcttgta  | 15300 |
| caaatgtaca  | ttggctcaga  | tcctcttcta  | cttaaatttt | tatgacttcc  | tatgcattta  | 15360 |
| taacaaaact  | catacaactc  | ccacttaaca  | ctgtgaggcc | atgcacgccc  | ttgtttttat  | 15420 |
| atccctccgt  | gtccaacctc  | atttcattcc  | acttgccccc | acccctatca  | gcagcaggca  | 15480 |
| tactagccat  | tttaaaagttt | ttctttctctg | tcttgggggc | ctttgcatat  | actttccctt  | 15540 |
| ctgcctggaa  | tacttctttt  | tttttttttt  | tttttttttt | taagatgaag  | tttcgctctt  | 15600 |
| gtcactcagg  | ctggagagca  | atggcacgat  | ctcggttgc  | tgcaacctcc  | gcctcccagg  | 15660 |

-continued

---

```

ttcaagcaat tctcctgct cagcctcctg agtagctggg atccacaccc agctaatttt 15720
ttaattttta gtagagacgg ggtttcgcca tgttgccag gctgatctca aactcctgac 15780
ctcaggtgat cccccacct cggcctccca gagtgcctggg attacaggca tgagccacca 15840
cacctggcct ggaatacatt ttagtaagt ttaaatggat agttgttggg tgaatgactg 15900
aaaaggctct tcaagaggaa ctgatatga tgtaaaactc aagtgcctgg tgcgtaacag 15960
gtattcaatg aaaaggattc tatgcataa gtagaaattt tggaaaataa aataaaaatt 16020
gaagatttaa aaatcgtatg tgcctcaaca tttagaaagg ttcaaaactc taatggctaa 16080
ccagggttct ttgacctagg cactaatgac atttgggcta gagaattctt tgcctggggg 16140
actgtcctgt acattgtccc tggcagcatg tctggcctct agccactaga tgtcagcagc 16200
acttttcctt accctcaagg tgtgataatc aaaactatct ccagacattt ataaatgtcc 16260
cttgggggtt gaaattatct ccactgagaa ccactgtgct gggcttctac ccttacaaga 16320
aattttctct cagtcattca atgcttctca aatcttgggtg tccataagaa tcatctgggg 16380
ccattattaa aaattcagat ggcagctggg cgaggtggct tacacctgta atcccagcac 16440
ttcgggaggc tgaggcaggt ggaccacttg agttcaggag ttcgagacca gcctgccaaa 16500
catggtgaga cctcgtctct actaaaaata caaaattagc cgagcgtggt agcacatgcc 16560
tgtaatccca gctacttggg aggctgagac aggaaaatca cttaaaccca tgaggcagag 16620
gttgtgtgta gccgggatcg tgccattgca ctccagcctg gttacaaga gcaaaactct 16680
gtctcaaaaa aaaaaaaaaa aaaaaaaaaa tcagatgggt gctgggcacg gtggctcacg 16740
cctgtaatcc cagcactttg ggaggtgggt ggatcacctg agttcaggag ttcaagacca 16800
gcctggccaa catggtgaaa cctcgtctct attaaaaaaa aaattagcca ggcgtgatgg 16860
tgcatgcctg taatcccagc tactcgggag gctgaagcag gagaatcgt tgaacctggg 16920
agggtggagg tccagtgagt gaagatcgt ccactgcact ccagcctggg cgccagagcg 16980
agacctgcc ttaaaaaaaaa caacaaaaaa aatcagatgc ctggggctct acctccaggt 17040
gccaggacca acagtgggcc tagtcatcag attaaaaaaa agaaaatatt taataaatag 17100
agggtgggca tgggtgctca tgctgtaat cccaacactt tgggaggcca aggcagggtg 17160
atcactggag actaagaatt caagaccagc ctggccaaca tggtgaaacc ttgtctctac 17220
taaaagtaca aaaactagct ggggtgtgtg gtgcatgcct gtaatttcag ctacttggga 17280
ggctgggcca ggagaattgc ttgaacctgg gaggcggagg ttgcagtga aagagatcag 17340
gccactacac tccagcctgg gcgacagagt gagagtccat aaattaataa acaacaaat 17400
taattaatta aaaaatagag acgggggggag gtgtcttgct atgttgcca ggcttgctt 17460
gaaccccagc ctcaagcaaa tcagcctccc aaagtgcctg gattaaaggc aggagccatg 17520
gagcacctgg cccaagtgtt taatgagctt ctgggcactt ctgataccag gtgccctcag 17580
accgcacttt gaaaaactct caaggaggcc tctcaatcac ctgatcaca aaccctgtgt 17640
gaggctccct acccaactgg accctctct tgaattctc tcttttccaa ttattaccct 17700
tccctagata gcaagtgggt acagaaccaa accctagctc agccaaagcc caaattgcct 17760
catctccctt cagggaatag gcaaaaaaaaa aaaaaaaaaa gatcacagag 17820
ttcagctgaa accacttagg aaatatcagc atccccacct cccacccaa aaggactcct 17880
gagtggcagc ctgagagggt tgtctgctca tcagaataat gttgtcagac tgtgttcttt 17940
ctgggggatc atcacactcc cttttctggg aacaaatgtt ggccacttgg tgggatgggc 18000

```

-continued

---

|             |            |             |             |             |             |       |
|-------------|------------|-------------|-------------|-------------|-------------|-------|
| catcatgac   | tacgtcagac | aaattcagtg  | agtcagtgact | cagcctatct  | ctctagaccc  | 18060 |
| atcttttatg  | cccccttact | tatagtctct  | ctgagggtctg | ttctcaacta  | ttctatttct  | 18120 |
| ctcctttccg  | gcacatgatg | gggattacat  | tttcttgctt  | cctttgaaat  | gagatgtgac  | 18180 |
| catgttactt  | gtttcaggta | acgagatgtg  | agcagaaaca  | acctgtgtca  | cacctgggca  | 18240 |
| gaagctttaa  | aggccagtg  | tgcccttggt  | ggggaagcaa  | gtatagatat  | gaatcggtcc  | 18300 |
| acaacgcgga  | gcgccccctg | ccgacccatg  | ctgggcgtgt  | actatagggtg | agcaattaac  | 18360 |
| tttgctgttc  | aaaccattga | gacttagggg  | tttttttggtg | gttgcaagct  | aacttcactt  | 18420 |
| cacttgactg  | aacacagtct | ttccaaagtt  | tcactaattt  | tttaatgacc  | attatgattt  | 18480 |
| tttcatact   | gtaacatttt | tcttacatca  | actcacttct  | ttttacttca  | atttatttta  | 18540 |
| gaaagaaata  | ttattactac | caaatgaaac  | agtatcataa  | gtagaaagca  | atgagaaaat  | 18600 |
| aaacagaatg  | aaagaaatcc | tgatatcaaa  | tcttgactta  | atactatttg  | cctttcaaaag | 18660 |
| cctctggacc  | tttggctctt | atttaaaaaa  | aaaaaaaaaa  | aaaaaaaaaa  | ggagccaggg  | 18720 |
| gccaggcgtg  | atggctcaca | cctgtaatcc  | caggaatttg  | ggaggccgag  | gtgggaagat  | 18780 |
| cacctgaggt  | caggagtctg | agaccagcct  | gaccaatatg  | aggaaacccc  | atctctacta  | 18840 |
| aaaatacaaa  | aattagccgg | gtgtggtggc  | atgtgcctgt  | aatcccagct  | actcaggagg  | 18900 |
| ctgagacagg  | agaattgctt | gaacctggga  | ggcggaggtt  | gcagtgagcc  | gagatcgctc  | 18960 |
| cattgcactc  | cagcctgggc | aacaagagtg  | aaactccgtc  | ttaaaaaaaa  | aatgggagcc  | 19020 |
| agggtcgggtg | gctcatgcct | gtaatcccag  | cagtttgggg  | ggctgagggtg | ggcagatcac  | 19080 |
| ttgaggtcag  | gagttcaaga | ccaccctagc  | caacatggtg  | atctcctgtc  | tctacttaaa  | 19140 |
| atgcaaaaat  | tagctgggca | tgatggcatg  | tgccctgtaat | atcccagcct  | cttgggaggc  | 19200 |
| tgaggcagga  | gaatcacttg | aacccaggag  | gcggaggttg  | cagtgaagctg | agattgtacc  | 19260 |
| actgcactcc  | agcctggggg | agagagttag  | gactccgtat  | ttaaaaaaaa  | aaaaaaaaaa  | 19320 |
| gaggteccca  | agagtacttc | tcaatctttt  | ggatccccc   | agctgtctaa  | gattgtcaga  | 19380 |
| atatttgaag  | gcagcacagt | attgaggctg  | agtgtaccaa  | ttctggaact  | tgacatcctg  | 19440 |
| ggcttaaatt  | ctggttcagt | catggactag  | ctgtgtgacc  | ctggacaagt  | tactgaactg  | 19500 |
| ctctgtgact  | gttttcttat | ttgcaaaata  | gtgaccataa  | tgatgtgtat  | ggcattaggt  | 19560 |
| cgtgtggggg  | attatttgtg | ttaatgtata  | aaaagggtt   | agaagtgtgc  | ctggcactta  | 19620 |
| gtgagtgcta  | tggaggcatt | acctataaaa  | tgatggcagg  | atccagatcc  | aaatagattt  | 19680 |
| gggtgaattat | tgtttgtttt | ttttgagaca  | gggtctctgt  | cactcagggt  | ggagtgcagt  | 19740 |
| ggcgccatca  | cagctcactg | cagcctccaa  | gtctccaggc  | tcagatgatc  | ctcctacctc  | 19800 |
| agcctccaga  | gtagctggga | ctacatgtgt  | ggaccaccac  | ccctggctaa  | tttttctata  | 19860 |
| ttttgtagat  | atgggatttc | accatgttgc  | ccaggctggt  | ctggaactct  | tgggttcaag  | 19920 |
| caatctgccc  | cttcttagtc | ttcaaagtgt  | tgggattaca  | gacgtgagtc  | acccacccca  | 19980 |
| gcctggagaa  | atgtttgaac | tccatggaga  | taagtaaaaa  | atcctctgca  | ttggttaaaa  | 20040 |
| ataaatcacc  | tggatgattt | atttatattag | tgtagatggg  | aaaagctacc  | ttagcagaaa  | 20100 |
| gtgacatagc  | aaaattctag | aggttttact  | tgggtggcagc | tgcccaaacc  | tctaaccacg  | 20160 |
| tcgtatgtat  | cattagagag | aatgtagtcc  | ccaggtcaga  | ggagctaaga  | ggtccttggtc | 20220 |
| attctactcc  | taaggagcat | atatggacaa  | ttgtgttttag | ttttcatttt  | aatatgaata  | 20280 |
| cttaaaaattt | tcctaggatg | gcagaggatg  | agaaagctat  | gccccttagg  | ccgagtgcag  | 20340 |
| cggcatggct  | catgcctgta | atcctggcgc  | tttggggaggc | caaggcgggc  | ggatcacgag  | 20400 |

-continued

---

```

gtcaagagat cgagatcatg ttggccaaca tggtgaaact ccatctctac taaaaataca 20460
aaaattagcc ttgcgtagtg gtacgcacct gtagtcccag ctacttggga ggctgaggca 20520
ggagaattgc ttgaacctgg gaggcggagg gtgcagtgag ccgagatctc gccaccgcac 20580
tctagcccgg cagcagagcg agagttcgtc tcaaaaaaaa aaaagaaaga aagaaagaaa 20640
gaaagctatg ccccttgaag aataatcaaa gatccaaaag agttttgggc tgggtattgg 20700
agaagaggag agaaggtgg tgtagcagag tggtcagggc cattgccttt gaaatatcag 20760
tggtgccatt tacatagctg ttggaccttg ctaaaatcat aagctcttca agccttattt 20820
gcttcactta taaaatagga atcaatgata ggaccttttc atagattgct ttgtggagta 20880
aatgtgttaa acctataaaa cctggcagggt agctgcccg catatagtgt cgttattttac 20940
tcaattcaaa gtactttcct gccgggtgcg gtggctcagg cctgtaatcc cagcactttg 21000
ggaggctgag gtgggtggat cacttgaggt caggagttcc agaccagcct gaccaacatg 21060
gtgaaacct gtctctacta aaaacacaaa aattagccgg gcgtggtggc agtcacctgt 21120
aatcccagct acttgggagg ctgaggcaca agaatacactt gaacctggga ggcagaggtt 21180
gcaatgagct gagatcgtgc cgctgcacgc catcctgggt gatagattga gactcagtct 21240
caaaaaaag gcaacaaagt actttccttt ggaaaagagt gcccaactggc tgggtgaagt 21300
ggctcacgcc tgtaatctca gcacttgtgg ggctgaggca ggcagatcag ttgaagccag 21360
gagtttgaga ccagtttcac gtggccaaca tggtgaaacc ccgtctacta aaaatacaaa 21420
aataagccag atgtggtgtc atgtgcctgt agtcccagct actcaggaga gtgagacag 21480
agaatcattt gaacctgga gttggagggt gcagtgaaca gagatcgtgc cactgcactc 21540
cagcctgggt gacagagtaa aactctgtct caaaaaaaaa aaaaaaaaaa gctctcactg 21600
attctacag cttcagagaa tgaacgagga ccaaaatgtg gatgctacag ggaggaaact 21660
tgaggctcaa aatggagatc tttctataaa atacaattgt tctaccacag gaaaagctgc 21720
tttattaagt agtgagtatt ccgtcattgg aagtattaag cccaagctaa atggccaact 21780
gtcaggggag gatggtgaga ggattccagt gggtttagagg tcaagagcg tctaccagg 21840
gcaaaagtct taattaacaa agtactatca aaaccaaatt catgtttggg aaactgtata 21900
tccacatgca aaagaatgaa atcagactct ttccttacac catatacgaa aattaactaa 21960
aatgagttt gacggaaaag tataaaacct ttggaataaa acataaggga aaagcttcat 22020
gatattagat ttggtgatga tttcttggt atgacaccaa aagcacagga aattttttaa 22080
aattagataa attggactac atcaaaatta gaaaaatttg tgcaccaaag gacacttgac 22140
tgagtgaata agcaacttac agaatgggag aaaatatttg ccaatcatat atctgataag 22200
gggttaatgt ccgaaatata taaagaactc ttacaactca ataacaaca ccaaaaactt 22260
taaaaatgga caaagaggcc aggtgtagtg gctcaagtct gtaatctcac cactttgtga 22320
ggcagaggca ggaggattgc ttgagctcag gagtttaaga ccagcctggg caacatagtg 22380
aaactttgtc tctacagaaa aatttaaaaa ttagccaggc atgctgcaca cctgtagtcc 22440
cagcttactt gggaggccga ggtgggagga ccacttgagt caaggagttt gaggctgtgg 22500
tgagccacga tctgctgct gcactctagc ctgggtgaca gagcaagacc tgtctcaaga 22560
aaacaaaaaa attggcaaag gacttgaata ggcattttct caaggaagat atacaaataa 22620
ccattaagca cataaaaaa tacttaacat cactaatcat tagggaagtg caaatcaaaa 22680
ctgcaataag aggctgggca cagtggctca tgctgtaat ccagcactt tgggaggcca 22740

```

-continued

---

|             |            |            |             |             |             |       |
|-------------|------------|------------|-------------|-------------|-------------|-------|
| gggcaagtgg  | atcacttgag | gtcaggagtt | tgagaccagc  | ctggccaaca  | tggcaaaatc  | 22800 |
| cctaaatctac | taaacaatat | aaaaattatc | tggtgtgtgg  | ccaggcacag  | tggctcacgc  | 22860 |
| ctgtaatccc  | agcactttgg | gaggccaagg | cgggcggatc  | acgaggtcag  | gagttcaaga  | 22920 |
| ccagcctggc  | cagcatgggt | aaaccccatc | tctactaaaa  | atacaaaaat  | tagccgggca  | 22980 |
| tggtggcatg  | catctgtaat | cccagctact | caggaggctg  | aggtaggaga  | atcgcttgaa  | 23040 |
| cctgggaggc  | agaggttgca | gtgagccaag | atcgcgccac  | tgcaccccag  | tctgtgccac  | 23100 |
| acagtgagac  | tctgtctcaa | aaaaaaaaaa | aaaaaaaaag  | gaaaagaaaa  | attatccggg  | 23160 |
| tgtgatggca  | catgcctgta | atctcagcta | cctggggaggc | tgaagcagga  | gaatcgcttg  | 23220 |
| aacctgggag  | gagaagtttg | cagtgaagtg | agactgcact  | actgcactcc  | agcctgggag  | 23280 |
| acagagcaag  | actatgtctc | caaaaaaac  | caagacaaac  | aaacaacaaa  | aacacacaat  | 23340 |
| aagagaccac  | ctcacacca  | ttaggatgga | tattataaaa  | caacaacaaa  | acagacaata  | 23400 |
| gtaagtgttg  | gtgaagatgt | ggagaaattg | taacctttt   | acgttctctat | cactgctggt  | 23460 |
| gggaacgtaa  | aatagtgcag | cttctgtggc | aagcagtatg  | gcggcttctc  | aaaaaatgaa  | 23520 |
| aaatagaact  | atcatatgat | ctagcaattg | tactcccgag  | tatataccca  | aaagaaccaa  | 23580 |
| aagtagcatc  | tggagagag  | atgtgtatc  | tcaagttcat  | agcagcatta  | ttcataatag  | 23640 |
| ccaaaaggta  | caggcaacc  | aagtgtcaat | caatggatga  | atggatcaat  | aaaatgtggt  | 23700 |
| atatgcatac  | aatggaatat | tattcagcct | taaaaaggat  | ggaaattctg  | acacatgcta  | 23760 |
| caacatggat  | ggatcctgag | ggcattatgc | taggggaaaa  | gctagtccca  | aagaacaaat  | 23820 |
| actgtatgat  | tccactagcc | tacaggaaa  | tagtcaaatt  | cacagagaca  | gaaagtagaa  | 23880 |
| ggggtttggc  | agggcctggg | aagaaaggag | aactattttc  | ttttcttttc  | ttttcttttt  | 23940 |
| tttttttttt  | tgagacgggg | tctctctctg | tggcccaggc  | tggagtgcag  | tgggtgcgac  | 24000 |
| tgggtcactc  | gcaacctcca | cttcccgggt | tcaagcgagt  | ctcctgcctc  | agcctcctga  | 24060 |
| gtacctggga  | ttacaggcac | gcaccaccac | gcccggctaa  | tttttttgta  | tttttagtat  | 24120 |
| ttattttgta  | tttttagtag | agacgagggt | tctccatggt  | agcctcccaa  | ggggagctat  | 24180 |
| tttctaattg  | gtacagtttc | agtgtgggaa | gatgaaaaaa  | gttcaggtga  | tggatgggtgc | 24240 |
| tgatgggtgt  | attacaatgt | gaatatattt | aatgtctctg  | aactgtacgt  | ttaaaaatgg  | 24300 |
| tgggtggggc  | gtggtggctc | acacctgtaa | tcccagcact  | tggggaggct  | gaggtggatg  | 24360 |
| gatcaccttt  | ggtcagggtg | tcaagaccag | cctgggcaac  | atagtgaac   | cctgtctcta  | 24420 |
| ctaaaaatc   | aaaaatcagc | tggtgctggc | ggtgcatgcc  | tgtaacccca  | gctactcggg  | 24480 |
| aggctgaggc  | agaaaaatca | cttgaacctg | ggaggtggag  | gttgtagtga  | gccgagatca  | 24540 |
| cggcactgca  | ctccagccgg | gcgacagagt | aagactctgt  | ttcaaaaaaa  | aaaaaaaata  | 24600 |
| catgcataaa  | agatgtttct | aagagtgcga | aaaaatgcct  | acaaattgat  | aaggaaagggt | 24660 |
| aaataataca  | atagataaat | ggtcaaagga | tacaaacaag  | cacactcata  | atgtagggaag | 24720 |
| ctcaaatggc  | aaaagagcct | ctccttctct | agtaatagag  | gaaatgtaaa  | tttgaaagtg  | 24780 |
| aagcataatt  | ttacattcag | tatcttataa | aatcaagtgc  | tgatgaggtt  | gtagagcaac  | 24840 |
| caaaactctg  | taactattgt | tggaaagtga | agttggcatt  | caagaatgag  | caatttagca  | 24900 |
| acatctctta  | aaagtgttga | tatccactgt | ctaagataca  | gaaattccat  | ctctgcatgt  | 24960 |
| tacctagaga  | aactctcatc | cacaggtata | agaatagtct  | ttggagcatc  | atctgagata  | 25020 |
| gtgagccaag  | atcgtgcaac | tgcactccag | cctgagtaac  | agagtgagac  | tccatctcaa  | 25080 |
| aacaacaaaa  | taaacaaaac | agaataaata | tactcaggat  | atttacagac  | acttttattt  | 25140 |

-continued

---

|             |             |             |             |            |             |       |
|-------------|-------------|-------------|-------------|------------|-------------|-------|
| tattttttgt  | tatttcaact  | ttgttttttt  | tacctgcctc  | ccaggtttaa | gcgattctca  | 25200 |
| tgcctcagcc  | tcccaagtgg  | ctgggattac  | aggtgccac   | caccaggcct | ggtaatttt   | 25260 |
| tatattttca  | atagagatag  | ggtttcacca  | tgttgccag   | gcttgctcgc | aactcctgat  | 25320 |
| ctcaagtgat  | ccaccgcct   | cggcctccca  | aagtgcttgg  | attacaggca | tgagctaccg  | 25380 |
| cgcctggctg  | catgtgtttt  | taaacattgc  | ctggcccggt  | atttcaactt | ttattttcga  | 25440 |
| atcaggaggt  | acacgtatag  | gtttgttaca  | aaggtatatt  | gcatgatgct | gggggtttcca | 25500 |
| gtatgaatga  | attcatcacc  | caggtaatga  | gcatggtacc  | caataggtag | tttttcaaca  | 25560 |
| tttgccccct  | ccctctctaa  | cccctttggt  | ttctccagtg  | cctattgttc | ccatctttat  | 25620 |
| gtccatgtgt  | acccaagggt  | tagcccccac  | gtatagggtga | gaacatatgt | tatttgaatt  | 25680 |
| tctgtttctg  | cattagtttg  | cttcggataa  | tggtttccag  | ccatatccat | gttctgcag   | 25740 |
| aggacatgat  | ttcattcttt  | tttatgactg  | tatagtactt  | catggataga | cagcatttta  | 25800 |
| tctattttat  | ttctttttta  | ttttattttt  | tgatagagac  | agggtttcac | catgttgccc  | 25860 |
| aggetggctc  | ttgaactcct  | gggcttaagt  | gatctacttg  | cctcggcctc | ccaaagtgtt  | 25920 |
| ggaattacag  | gtgagccact  | gcaccagcc   | tacacagcat  | tttaaagag  | tggtctggtg  | 25980 |
| caacttgtat  | catcatgaaa  | agatccagag  | acctattatg  | aggagtaata | aaaggaagtt  | 26040 |
| gctgcaggat  | atgtacagta  | tatcatttaa  | ataaattttc  | cagataagca | aaatatttta  | 26100 |
| ctttgcttat  | atagccacgt  | atggtagaac  | tgtgaaaatg  | tgtctggtaa | tgacacatta  | 26160 |
| ccagataaat  | accaaataca  | catgataaat  | accaaagtgt  | gaccatgatc | accactgata  | 26220 |
| aggggtggcag | gggtgatggga | tcaggaagac  | aaggggcttc  | aactctaagt | gtaatgttta  | 26280 |
| atttgtcatt  | aaaacaaaca  | aacaaacaaa  | caacatccaa  | agaaaacatg | gtcatgtagt  | 26340 |
| aagatttgac  | aaaattgaga  | ggtaggataca | taaatgttca  | taatattatt | ctctatactt  | 26400 |
| ctctgcatat  | ttgtaatat   | tcttacttta  | aaaaaaggag  | aaatgagatt | ataaaaaaaa  | 26460 |
| gtcaaccatc  | ttcctacata  | ccagcgacag  | acaatttggg  | agtataat   | taaaaatcat  | 26520 |
| acaatttgca  | caatgacaac  | aatttgcaca  | atgacaagca  | accgtggata | aaaatctaga  | 26580 |
| aatctatata  | tatatttttt  | tctttgagac  | agagtctcag  | tctgttgccc | aggctggagt  | 26640 |
| gcagtggcat  | gatctcggct  | cactgcaacc  | tctgcctccc  | gggttgaagc | aattctcctg  | 26700 |
| cctcagcctc  | ctgagtagct  | aggattacag  | gtgcatgcca  | ccatgcccgg | ctaattacca  | 26760 |
| tgcccggtca  | attttttttg  | tatttttagt  | agagacagag  | tttcatcatg | ttggtcaggc  | 26820 |
| tgatctcaaa  | ctcttaacct  | cgtgatccgc  | ctgcctcaac  | ctcccaaagt | gctgggatta  | 26880 |
| caggcatgag  | ccaccatgcc  | cggccctaga  | atcctatttt  | ttaaaagcaa | ctaggagtat  | 26940 |
| atctaagata  | tagcattttc  | ctgtctgaga  | gcagggagag  | cttgcatagg | tgtcaatgtc  | 27000 |
| cttcaaggga  | ctcttgaaac  | taattcaggg  | ccctatacac  | tgaggcatt  | tcttgagtg   | 27060 |
| gccaaggat   | tgtcatgtgt  | taagaattct  | gagaagttct  | cggataatga | aatttgtgca  | 27120 |
| gctttcttta  | attcagcagt  | tttcaaacat  | ctaacaatag  | aatccttctt | gtctgagggg  | 27180 |
| cctcgcctta  | ggaaaggctg  | ccctaacaac  | ctcaaagttc  | ccttccaaca | cccacagtcc  | 27240 |
| accattctag  | tcttggtctc  | gccactaact  | tactgtatga  | ctttggccga | atcacctttc  | 27300 |
| ctcttggggg  | ctcagtttgt  | taagttatta  | acaccctggg  | tgacagagca | agaccctgtc  | 27360 |
| tcaaaaaaaaa | aaaacaaaaa  | catttcctcg  | gcaaaaaatt  | tatgactaaa | tcctccaaag  | 27420 |
| caatcgcaac  | aaaacaaaaa  | attgacaagt  | gacaccta    | taaactaaag | agcctctaca  | 27480 |

-continued

---

|   |       |
|---|-------|
| cagcaaaaga aactatcaac agagtaaaca ggcaacctac agaatgggag aaaatatttg   | 27540 |
| cgaactctga atccaacaaa ggtctacaag gaacttagca attctacaag gagctagaac   | 27600 |
| ctacaaggaa ctttaacaat tcaacaagca aaaaacaaag aacccaaca aaaagtggat    | 27660 |
| agagcacatg aacagacact tctcaaaaga agatgtacaa gcggccaaca aagatgaaaa   | 27720 |
| aatgttcaac atcactaatc atcagagaaa tgcaaatgaa atcgtgagat accatctcac   | 27780 |
| actagtcaaa atgattatta agtttctttt tttgtcccca cccttgatat ctgaagaatg   | 27840 |
| gctgtcatta aaaagtcaaa aaaataacag atgttggcaa ggctgtggaa aaaagggaa    | 27900 |
| acttatacac tgttgggtgg aatataaatt agttcagcca ctgtggaaag ctatttggag   | 27960 |
| atcttctcaa gaacttaaaa cagaaccacc attcaattta gcaatttcat gatttggat    | 28020 |
| ataaccaaag gaaaatgaat tcttctacca aaaagacaca tgcacttata tgttctcac    | 28080 |
| agcactattc acaatagaaa gacatcagcc aagcacagtg gctcacgct gtaatcctag    | 28140 |
| cactttggga ggccgaggcg ggccggtcac ctgagggtcag gagttcgaga ccaacctggc  | 28200 |
| taacatggta aaactgtgtc tctactaaaa atacaaaaat tagccaggca tgggtgcaca   | 28260 |
| tgcctgtaat ccagctact tgggaggctg agacaggaga atggcctgaa cctgggaggc    | 28320 |
| agaggttgca gtgagctgag attgcgccac tgcactccag cctgggtgac agagtggag    | 28380 |
| tccatctcaa acaaaacaaa acagtagaaa gacatggaat caacctaatg gcccatcagc   | 28440 |
| agtggaatgg ataataaaaa tgtggtacat atacactatg gaatagtatg cagccataaa   | 28500 |
| agggaaacaaa acctcaacca agttcaagga cagtgtcaaa aaaataaaaa agggaaacaaa | 28560 |
| gtcgtgtcct ttgccacacc aggaatggag ctggaggacc tcctcctaag tgaatcaaca   | 28620 |
| cagaaacaaa aaaacaaata ctgcatgttc tcaattgtaa aaggaagcta aacattgggt   | 28680 |
| acacgttgac atcaagagag gaacaataga cgctcgggac ttctagagga agggcaagg    | 28740 |
| ctaaaaaact ctctgttggg tactatgtc actacttggg tgatgagctc aatcatagcc    | 28800 |
| taaacttcag tgtcacacaa tatacccatg taacaaacct gtacatgtac ccctgaatc    | 28860 |
| taaaataaaa gtttaattaa ggctgtgtgc agtggctcac acctgtaatc ccagcagttt   | 28920 |
| gggaggctga ggtagggtga tcaccagagg tcaggagttc gagatcaggc tggccaacat   | 28980 |
| ggtgaaaccc cacctctact aaaaatacaa aaagaagcca ggcatggtgg tgcgtgcctg   | 29040 |
| tagttccagc tactcaggag gctgaggcag gagaattgct tgaaccagg aggcggagg     | 29100 |
| tgcagtgagc cgagatcatg ccattattct agcctgggca atggagcaag actgtctctg   | 29160 |
| aaaaaactaa aaagttaaat ttaaaaaaaa aagggtgtgt atagtattgat ctcttacctt  | 29220 |
| ttcccagcca taacacctca tgttggacct cagtttagg gggtttattg gggcttttta    | 29280 |
| ggggtttggt tttatttctc ctccccagc taactgttct ttaacttaact aaagcagggt   | 29340 |
| catggtagag gaattacaaa aatgcagaga aggatgatta aaaaagaatt aaactaggct   | 29400 |
| gggtgtggtg gctaacacct gtaatcccag tgctttggga ggctgagttg gaaggatcat   | 29460 |
| ttcaggctag gagtttgaga ccagcctggg caacacagta agaccccatc tctacagaaa   | 29520 |
| attttaaaac ttaaaaaaat taaaaagtaa acgttagaca ggcatggtgg tgtgtgtctg   | 29580 |
| tagtccagc tacttgtgag gcttaggcga gaggatggct tgagcccagg aatttgaggc    | 29640 |
| tgtagtgggt tttgactatg ccactgcact ccagcccggtg tgacacagca aaacctatc   | 29700 |
| tcttaaaac aaatcagatt tactccaaat gccacttttg gctctttatg atgacagctg    | 29760 |
| acatttatag agcctttatg tgcaaagcgc agtggttaga tatctcggtt cacttctcgt   | 29820 |
| tgaagtggaa gtcaagtcta ttcttatcct tattttacag atgaggagac tgaggatcag   | 29880 |



-continued

---

```

agagataaag tcacctgtcc aaggtcatatc tgtggatgta gctctaacc aagccctccc 29940
gactgcagca caaattctca gccactaccc tattagcccc ttcatttgaa ggtgtcttca 30000
tca 30003

```

```

<210> SEQ ID NO 9
<211> LENGTH: 486
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

```

```

<400> SEQUENCE: 9
ggactgaagg acagagagaa attgcatgcc tggagtctca ctgctagtac atagaggtgt 60
tatcttcctt tcacttaaca tatttattga gcacctacta tgtaccaggc cttgtgctag 120
actctgggga tatggaaatg agcaaagtag atgtaccccc gaaacttggt gactaatgga 180
ggagacggac cttaatcaga tcgtcattca aagatactat taaaaactgt tctgagagcc 240
gaggaagcag gaaggagctg tgagagactg agctctaacc ttggccatca aagacaagct 300
gtgcagctct ggttttttga gggcaggaca tggagggtca ggcccagctg gagggcgcacc 360
aaagcccaga gaaaattcag aaccacgtga acttgttgga ttccagcccc ttgaagcaca 420
tgttgctatt gcagctgcct tgataactgg ggggacagga ggagcacggc ttcccatct 480
tgtacg 486

```

```

<210> SEQ ID NO 10
<211> LENGTH: 494
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

```

```

<400> SEQUENCE: 10
gtggtgcgcg ccgtggtgcg cgcctggtg gccgctgccg atgagcgcc ccccgcgctc 60
ctcgggcgtc aggttgagcg cctcggggtt gaggtgatgc tggtagccgc tcaccagta 120
cagatcctcc agcgccggct tccccgaggt gcccccgacg gcgcgggggc ccccgctcgg 180
cggccccggg gcgcccccg cctgagacga gccgcccgcg ttttcgcgc gcgcggcgcc 240
gccggtgccc gggctgggag cgcagaagct gggcgaggag ggcacggagg agcagggcgt 300
gctgagcggc gtcgaggaca gcgagcctgg cggcaggcgg tggcagaagc gctcgccctc 360
gggaggtccc ttcttcacct cgaacttcac caggtcgaag tcgttgacgt actcgatggc 420
cagcgggctg ctgggcagct cggcgcccat cggcagctcc gcgggcatcg cccggggccc 480
gcgccccggc gcgc 494

```

```

<210> SEQ ID NO 11
<211> LENGTH: 1992
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

```

```

<400> SEQUENCE: 11
cggctccccg ctccgggaaa gaccttctgt tctctgccgg cgcggagggc cgcaggaacc 60
aggcctctcg cctccccacc agctaggcag ggagcgccca tctcctgaaa aattacttcc 120
tgggaagcgg tgcggggaga cagcttcaat tgctttcggt tggtgaaaaa cgaattcgct 180
tctcagattg ctctcctagc tgccaggctc tgacgttgag aggcgggctt tcagcctcgc 240
gctggacctt ccacaagtgt ttgcacatga cctggaagac agtcagaggc agaagtcctt 300
gcaaatgctc ctggctactt cctgcaggca gctcatgctg ctgcagcaga agactttcct 360

```

-continued

---

|  |      |
|--|------|
| atgtctagct gccagtattc tgggtgctgg gggcatcctg ttcttaggat cacagccatg  | 420  |
| gtggtatggt ctagaactca gaaatttacc aaatcactgg atggaccaga ggagttagct  | 480  |
| ccaggttggg tttccagaag ggactcccag aactcttcca ccatacaggc ctctcaggga  | 540  |
| gctgctccct ctgccatggt cagttagagg gggaagcagg agccgccatt ggggttggtg  | 600  |
| agtctgtggc tgcaaccacg gtagtaggaa gctgctgcta cacaccatg aagctgatgc   | 660  |
| ctggacataa atccctactg ataagtgtt acgacatttc cagcgtgggtg ccgacactgc  | 720  |
| atggaaatgc tgcattgaaa gtccttatac atctatcttt gtgcatttat tgtgagcacc  | 780  |
| tactatgagt aaaacctggg ctggtggctg gagaacatg aagatgagta agagccaatt   | 840  |
| cctgttcttg gggatttaat aatatattca agggaaaaga caaaaataa ccatttcacg   | 900  |
| gtaaactctg gtggggaggg tgggaggaga accgtggttt gcttttgtgc ccaacacttc  | 960  |
| acattcctta cctctttctc cccaccgaga cctttaggag cagcctgagc cagaggacca  | 1020 |
| gcatectcat cttctctcca cctcttacta ggggggtggc tttgggccag tttcttacct  | 1080 |
| tctttgggcc actttagttt ccttattgaa aaatggggat aataatagtg gctacatctc  | 1140 |
| agtgtgattc tgaggaaacc agaattgtac atgcagagca catgcacaga acagtgcctg  | 1200 |
| gcacagtcag taattgatca atgtgcgcta ttgttggtgt gtatattagt tctccctga   | 1260 |
| tacagatgag agctatctct aactcagaga cttgccacat cattaaatta ggagtgagaa  | 1320 |
| ctgagcctgg ataaggaaga ggaacaggaa ttcaacacag tgaacacagc aggaaaggct  | 1380 |
| tgtgcgaagg ctctgggctg gagatgtgta aagcatgtct ggagatgggg aagggtccatt | 1440 |
| gggccaggaa accacaggct ctgctctcct ggagcagaag cacagcgaaa tcacagccga  | 1500 |
| gcagaggagg gcaagggaga gggccgcccc agtctgagag ctgcagggtc tggctggaac  | 1560 |
| tgctcccgcc cagcggactt caccggggcg cggggggcgc acctgccggg cgcggcctgc  | 1620 |
| tctatggcgc cctctgctgt tagtccgccc caggctccgc gccggcctct cctgggtccg  | 1680 |
| tggggcctgc gggctgctgg gatcacagag acccacattc ccgtggccag cagcctttctg | 1740 |
| ctctgctcag aggagaggca gaagggcata ttgctgtttc ccagtcgctt tttacacctg  | 1800 |
| ccttcttcgg ataaacccaa aaatcttcct tcagagaaga cggcccgat tttccgttat   | 1860 |
| ttgggggtgg aggtggggct aaggcgctca tagggagagc cttactttca acattctgca  | 1920 |
| ttatgaaacc aaggggagact ttttttccca acaagtgtga acattttttt tcaagagaat | 1980 |
| taaatcgttt at  | 1992 |

&lt;210&gt; SEQ ID NO 12

&lt;211&gt; LENGTH: 1767

&lt;212&gt; TYPE: DNA

&lt;213&gt; ORGANISM: Homo sapiens

&lt;400&gt; SEQUENCE: 12

|  |     |
|--|-----|
| gggttgaact gcgggctgga gaaggaaaac cctttgacaa ttttgagaat tcagcatgtt  | 60  |
| aaagtaacac accattggaa ggtggtcgct acagcaaatt tggatgagat cattaattac  | 120 |
| aattttaatg agcagaaaac agaataaac gcaataaatg gctcaagaat aaaatttgat   | 180 |
| cagcaccacc gacggatgga gtttagctat tgggtgtcaa gcgctcattt ggggtccaagc | 240 |
| acgaaaagcc aggaggcgct actccgcttc gataaccttc gtttactaag cactagtttt  | 300 |
| taagggtcag cttgagtttg agtctgaaac tgggggaagg aagggttata tttgccagtt  | 360 |
| ttatttcctt ctaagataga agcaatgtta tttggtcctc ctcttccttt atctttcttc  | 420 |
| attaacttca agactggttt aaatctatta tttcatggac tttagaatct gacctggggt  | 480 |

-continued

---

```

aaggtgaagt ccttcgtcag catgaatagt gctaaggagt caagccaaga cttgcttcag 540
aagagagctg atgtgcggac cttctgcatt tccacgcggg gatccagtcg ttgggtctaa 600
acccacagcg cctgccacct cgccaggaa gctgcgggag gatggtggca ggcatagccc 660
gtcctagcct tgaacctggg gggcctatgt ctctggcttc gttacaaacg aaacgtttct 720
cgccttcgga cactccaccc tggcgttgtt acccaacctt cagtctccac tctgcgctg 780
gccctocagc gacctctca catcctocag gacactgcat tctcaaggac taggtaggaa 840
ttgggaggaa aagaggccag tcaccccaa agattccaat gttaaagagt gatcccttt 900
ttatctcatg taaatattat gactcggaag agagtgaat atttccctat tgagaatgtt 960
agtatctact attggaggcg ggggttccaa agagagacac gggggtggg gagagattga 1020
gactgagatt caactcaatc caactcaggg tgaactgtct tgagtaaata gttgcaacgc 1080
ttggtgtaag gatgtctcca tcgttcactt ttacgtatca tttgcattgc caaattaaaa 1140
tggcagcatt gttcttaatt atgacaataa aaaattccgg atccgtgtac cttgatccct 1200
ggtagtgagg gggtagagcc cggtgtctcg atcccgctga gacgagctg tattgcagac 1260
gcacgctggg cagcacggga aggcaggcgg gtgcctcctg ccagggtgcta gttgtagtgg 1320
atctgctgcc tgtctacagc tgggagcggg gacaacgatg gacgctcctc ggagagggtg 1380
ggctgcccc tgctactccc gggggaagat cgccctgccc tccgctctaa ctgcgtggtt 1440
gaaaccagtt tcgggacccg agtcttggtc ccgctgacgc gggaggcttg tttctggtgg 1500
ggcagtctta acgcatggcc ttcagatgcc tttgagatc aggacttgct ctttcttggg 1560
gatctccga aaccagcatg ccttctgcc cagcacctaa taaagtggga ctttttcaag 1620
tacccttgg gagtgacgt gtaacacgtg gtcgcaagga tcccggcgca tctctacgca 1680
gtatatctaa tggggatggg ggggctctgt ttgaaagcaa atgatttgca ttttaattga 1740
aaaataaatg aaagcgggtt ggcaaat 1767

```

```

<210> SEQ ID NO 13
<211> LENGTH: 19
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense oligonucleotide

```

```

<400> SEQUENCE: 13

```

```

tcctctctcc caaccact 19

```

```

<210> SEQ ID NO 14
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense oligonucleotide

```

```

<400> SEQUENCE: 14

```

```

tgtctcggct ctccactct 20

```

```

<210> SEQ ID NO 15
<211> LENGTH: 21
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Antisense oligonucleotide

```

```

<400> SEQUENCE: 15

```

-continued

---

cattccttcc acaattcgcc t 21

<210> SEQ ID NO 16  
<211> LENGTH: 19  
<212> TYPE: DNA  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Antisense oligonucleotide

<400> SEQUENCE: 16

gttcctcccg tgcctttag 19

<210> SEQ ID NO 17  
<211> LENGTH: 21  
<212> TYPE: DNA  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Antisense oligonucleotide

<400> SEQUENCE: 17

acctatagta cagcccagc a 21

<210> SEQ ID NO 18  
<211> LENGTH: 20  
<212> TYPE: DNA  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Antisense oligonucleotide

<400> SEQUENCE: 18

gcttctgccc aggtgtgaca 20

<210> SEQ ID NO 19  
<211> LENGTH: 19  
<212> TYPE: DNA  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Antisense oligonucleotide

<400> SEQUENCE: 19

cagcaagtgt cagatccca 19

<210> SEQ ID NO 20  
<211> LENGTH: 21  
<212> TYPE: DNA  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Antisense oligonucleotide

<400> SEQUENCE: 20

agtgtcagat cccagctcca g 21

<210> SEQ ID NO 21  
<211> LENGTH: 21  
<212> TYPE: DNA  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Antisense oligonucleotide

<400> SEQUENCE: 21

ggagtttggt cagtggttgg g 21

<210> SEQ ID NO 22  
<211> LENGTH: 20  
<212> TYPE: DNA  
<213> ORGANISM: Artificial Sequence

-continued

---

<220> FEATURE:  
<223> OTHER INFORMATION: Antisense oligonucleotide

<400> SEQUENCE: 22

gtgtcagatc ccagctccag 20

<210> SEQ ID NO 23  
<211> LENGTH: 21  
<212> TYPE: DNA  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Antisense oligonucleotide

<400> SEQUENCE: 23

ctcgttacct cttgtcctgg g 21

<210> SEQ ID NO 24  
<211> LENGTH: 20  
<212> TYPE: DNA  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Antisense oligonucleotide

<400> SEQUENCE: 24

agtcgggagg gcttgggtta 20

<210> SEQ ID NO 25  
<211> LENGTH: 20  
<212> TYPE: DNA  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Antisense oligonucleotide

<400> SEQUENCE: 25

ccctgcttcc ttctgtgtct 20

<210> SEQ ID NO 26  
<211> LENGTH: 20  
<212> TYPE: DNA  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Antisense oligonucleotide

<400> SEQUENCE: 26

gccaccctgc ttccttctgt 20

<210> SEQ ID NO 27  
<211> LENGTH: 20  
<212> TYPE: DNA  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Antisense oligonucleotide

<400> SEQUENCE: 27

tcttgcttcc tcggtctca 20

<210> SEQ ID NO 28  
<211> LENGTH: 20  
<212> TYPE: DNA  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Antisense oligonucleotide

<400> SEQUENCE: 28

cctccatgtc ctgccctcaa 20

-continued

---

<210> SEQ ID NO 29  
<211> LENGTH: 21  
<212> TYPE: DNA  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Antisense oligonucleotide  
  
<400> SEQUENCE: 29  
  
tccgtctcct ccattagtcc a 21

<210> SEQ ID NO 30  
<211> LENGTH: 20  
<212> TYPE: DNA  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Antisense oligonucleotide  
  
<400> SEQUENCE: 30  
  
tccgtctcct ccattagtcc 20

<210> SEQ ID NO 31  
<211> LENGTH: 21  
<212> TYPE: DNA  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Antisense oligonucleotide  
  
<400> SEQUENCE: 31  
  
gtccgtctcc tccattagtc c 21

<210> SEQ ID NO 32  
<211> LENGTH: 21  
<212> TYPE: DNA  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Antisense oligonucleotide  
  
<400> SEQUENCE: 32  
  
ctaccagcat cacctcaacc c 21

<210> SEQ ID NO 33  
<211> LENGTH: 21  
<212> TYPE: DNA  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Antisense oligonucleotide  
  
<400> SEQUENCE: 33  
  
agttcgaggt gaagaaggag c 21

<210> SEQ ID NO 34  
<211> LENGTH: 21  
<212> TYPE: DNA  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Antisense oligonucleotide  
  
<400> SEQUENCE: 34  
  
cgctggagga tctgtactgg a 21

<210> SEQ ID NO 35  
<211> LENGTH: 20  
<212> TYPE: DNA  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Antisense oligonucleotide

-continued

---

&lt;400&gt; SEQUENCE: 35

cctgatgaag ttcgaggtga

20

&lt;210&gt; SEQ ID NO 36

&lt;211&gt; LENGTH: 21

&lt;212&gt; TYPE: DNA

&lt;213&gt; ORGANISM: Artificial Sequence

&lt;220&gt; FEATURE:

&lt;223&gt; OTHER INFORMATION: Antisense oligonucleotide

&lt;400&gt; SEQUENCE: 36

gtacgtcaac gacttcgacc t

21

&lt;210&gt; SEQ ID NO 37

&lt;211&gt; LENGTH: 19

&lt;212&gt; TYPE: DNA

&lt;213&gt; ORGANISM: Artificial Sequence

&lt;220&gt; FEATURE:

&lt;223&gt; OTHER INFORMATION: Antisense oligonucleotide

&lt;400&gt; SEQUENCE: 37

gcaattgaag ctgtctccc

19

&lt;210&gt; SEQ ID NO 38

&lt;211&gt; LENGTH: 19

&lt;212&gt; TYPE: DNA

&lt;213&gt; ORGANISM: Artificial Sequence

&lt;220&gt; FEATURE:

&lt;223&gt; OTHER INFORMATION: Antisense oligonucleotide

&lt;400&gt; SEQUENCE: 38

cggcagagaa cagaaggtc

19

&lt;210&gt; SEQ ID NO 39

&lt;211&gt; LENGTH: 19

&lt;212&gt; TYPE: DNA

&lt;213&gt; ORGANISM: Artificial Sequence

&lt;220&gt; FEATURE:

&lt;223&gt; OTHER INFORMATION: Antisense oligonucleotide

&lt;400&gt; SEQUENCE: 39

tttcaggaga tggcgctc

19

&lt;210&gt; SEQ ID NO 40

&lt;211&gt; LENGTH: 21

&lt;212&gt; TYPE: DNA

&lt;213&gt; ORGANISM: Artificial Sequence

&lt;220&gt; FEATURE:

&lt;223&gt; OTHER INFORMATION: Antisense oligonucleotide

&lt;400&gt; SEQUENCE: 40

ggagagcaat ctgagaagcg a

21

&lt;210&gt; SEQ ID NO 41

&lt;211&gt; LENGTH: 20

&lt;212&gt; TYPE: DNA

&lt;213&gt; ORGANISM: Artificial Sequence

&lt;220&gt; FEATURE:

&lt;223&gt; OTHER INFORMATION: Antisense oligonucleotide

&lt;400&gt; SEQUENCE: 41

gcctctcaac gtcagagcct

20

&lt;210&gt; SEQ ID NO 42

-continued

<211> LENGTH: 20  
 <212> TYPE: DNA  
 <213> ORGANISM: Artificial Sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Antisense oligonucleotide

<400> SEQUENCE: 42

tctcagtcctc aatctctccc

20

<210> SEQ ID NO 43  
 <211> LENGTH: 21  
 <212> TYPE: DNA  
 <213> ORGANISM: Artificial Sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Antisense oligonucleotide

<400> SEQUENCE: 43

gttacacgtc cactcccaag g

21

<210> SEQ ID NO 44  
 <211> LENGTH: 20  
 <212> TYPE: DNA  
 <213> ORGANISM: Artificial Sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Antisense oligonucleotide

<400> SEQUENCE: 44

gctatgcctg ccaccatcct

20

<210> SEQ ID NO 45  
 <211> LENGTH: 20  
 <212> TYPE: DNA  
 <213> ORGANISM: Artificial Sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Antisense oligonucleotide

<400> SEQUENCE: 45

tttctctcca attcctacct

20

40

What is claimed is:

1. A method of modulating a function of and/or the expression of a Pancreatic Developmental gene polynucleotide in patient cells or tissues in vivo or in vitro comprising:

contacting said cells or tissues with at least one antisense oligonucleotide 5 to 30 nucleotides in length wherein said at least one oligonucleotide has at least 50% sequence identity to a reverse complement of a polynucleotide comprising 5 to 30 consecutive nucleotides within nucleotides 1 to 1235 of SEQ ID NO: 6, 1 to 17,964 of SEQ ID NO: 7, 1 to 1 to 50,003 of SEQ ID NO: 8, 1 to 486 of SEQ ID NO: 9, 1 to 494 of SEQ ID NO: 10, 1 to 1992 of SEQ ID NO: 11, or 1 to 1767 of SEQ ID NO: 12; thereby modulating a function of and/or the expression of the Pancreatic Developmental gene polynucleotide in patient cells or tissues in vivo or in vitro.

2. A method of modulating a function of and/or the expression of a Pancreatic Developmental gene polynucleotide in patient cells or tissues in vivo or in vitro comprising:

contacting said cells or tissues with at least one antisense oligonucleotide 5 to 30 nucleotides in length wherein said at least one oligonucleotide has at least 50% sequence identity to a reverse complement of a natural antisense of a Pancreatic Developmental gene polynucleotide; thereby modulating a function of and/or the

expression of the Pancreatic Developmental gene polynucleotide in patient cells or tissues in vivo or in vitro.

3. A method of modulating a function of and/or the expression of a Pancreatic Developmental gene polynucleotide in patient cells or tissues in vivo or in vitro comprising:

contacting said cells or tissues with at least one antisense oligonucleotide 5 to 30 nucleotides in length wherein said oligonucleotide has at least 50% sequence identity to an antisense oligonucleotide to the Pancreatic Developmental gene polynucleotide; thereby modulating a function of and/or the expression of the Pancreatic Developmental gene polynucleotide in patient cells or tissues in vivo or in vitro.

4. A method of modulating a function of and/or the expression of a Pancreatic Developmental gene polynucleotide in patient cells or tissues in vivo or in vitro comprising:

contacting said cells or tissues with at least one antisense oligonucleotide that targets a region of a natural antisense oligonucleotide of the Pancreatic Developmental gene polynucleotide; thereby modulating a function of and/or the expression of the Pancreatic Developmental gene polynucleotide in patient cells or tissues in vivo or in vitro.

5. The method of claim 4, wherein a function of and/or the expression of the Pancreatic Developmental gene is increased in vivo or in vitro with respect to a control.



6. The method of claim 4, wherein the at least one antisense oligonucleotide targets a natural antisense sequence of a Pancreatic Developmental gene polynucleotide.

7. The method of claim 4, wherein the at least one antisense oligonucleotide targets a nucleic acid sequence comprising coding and/or non-coding nucleic acid sequences of a Pancreatic Developmental gene polynucleotide.

8. The method of claim 4, wherein the at least one antisense oligonucleotide targets overlapping and/or non-overlapping sequences of a Pancreatic Developmental gene polynucleotide.

9. The method of claim 4, wherein the at least one antisense oligonucleotide comprises one or more modifications selected from: at least one modified sugar moiety, at least one modified internucleoside linkage, at least one modified nucleotide, and combinations thereof.

10. The method of claim 9, wherein the one or more modifications comprise at least one modified sugar moiety selected from: a 2'-O-methoxyethyl modified sugar moiety, a 2'-methoxy modified sugar moiety, a 2'-O-alkyl modified sugar moiety, a bicyclic sugar moiety, and combinations thereof.

11. The method of claim 9, wherein the one or more modifications comprise at least one modified internucleoside linkage selected from: a phosphorothioate, 2-O-methoxyethyl (MOE), 2'-fluoro, alkylphosphonate, phosphorodithioate, alkylphosphonothioate, phosphoramidate, carbamate, carbonate, phosphate triester, acetamidate, carboxymethyl ester, and combinations thereof.

12. The method of claim 9, wherein the one or more modifications comprise at least one modified nucleotide selected from: a peptide nucleic acid (PNA), a locked nucleic acid (LNA), an arabino-nucleic acid (FANA), an analogue, a derivative, and combinations thereof.

13. The method of claim 1, wherein the at least one oligonucleotide comprises at least one oligonucleotide sequences set forth as SEQ ID NOS: 13 to 45.

14. A method of modulating a function of and/or the expression of a Pancreatic Developmental gene in mammalian cells or tissues in vivo or in vitro comprising:

contacting said cells or tissues with at least one short interfering RNA (siRNA) oligonucleotide 5 to 30 nucleotides in length, said at least one siRNA oligonucleotide being specific for an antisense polynucleotide of a Pancreatic Developmental gene polynucleotide, wherein said at least one siRNA oligonucleotide has at least 50% sequence identity to a complementary sequence of at least about five consecutive nucleic acids of the antisense and/or sense nucleic acid molecule of the Pancreatic Developmental gene polynucleotide; and, modulating a function of and/or the expression of a Pancreatic Developmental gene in mammalian cells or tissues in vivo or in vitro.

15. The method of claim 14, wherein said oligonucleotide has at least 80% sequence identity to a sequence of at least about five consecutive nucleic acids that is complementary to the antisense and/or sense nucleic acid molecule of the Pancreatic Developmental gene polynucleotide.

16. A method of modulating a function of and/or the expression of a Pancreatic Developmental gene in mammalian cells or tissues in vivo or in vitro comprising:

contacting said cells or tissues with at least one antisense oligonucleotide of about 5 to 30 nucleotides in length specific for noncoding and/or coding sequences of a sense and/or natural antisense strand of a Pancreatic Developmental gene polynucleotide wherein said at least one antisense oligonucleotide has at least 50% sequence identity to at least one nucleic acid sequence set forth as SEQ ID NOS: 1 to 12; and,

modulating the function and/or expression of the Pancreatic Developmental gene in mammalian cells or tissues in vivo or in vitro.

17. A synthetic, modified oligonucleotide of 10 to 22 nucleotides in length comprising at least one modification wherein the at least one modification is selected from: at least one modified sugar moiety; at least one modified internucleotide linkage; at least one modified nucleotide, and combinations thereof; wherein said oligonucleotide is an antisense compound which hybridizes to a natural antisense polynucleotide of a Pancreatic gene and upregulates the function and/or expression of a Pancreatic Developmental gene in vivo or in vitro as compared to a normal control.

18. The oligonucleotide of claim 17, wherein the at least one modification comprises an internucleotide linkage selected from the group consisting of: phosphorothioate, alkylphosphonate, phosphorodithioate, alkylphosphonothioate, phosphoramidate, carbamate, carbonate, phosphate triester, acetamidate, carboxymethyl ester, and combinations thereof.

19. The oligonucleotide of claim 17, wherein said oligonucleotide comprises at least one phosphorothioate internucleotide linkage.

20. The oligonucleotide of claim 17, wherein said oligonucleotide comprises a backbone of phosphorothioate internucleotide linkages.

21. The oligonucleotide of claim 17, wherein the oligonucleotide comprises at least one modified nucleotide, said modified nucleotide selected from: a peptide nucleic acid, a locked nucleic acid (LNA), analogue, derivative, and a combination thereof.

22. The oligonucleotide of claim 17, wherein the oligonucleotide comprises a plurality of modifications, wherein said modifications comprise modified nucleotides selected from: phosphorothioate, alkylphosphonate, phosphorodithioate, alkylphosphonothioate, phosphoramidate, carbamate, carbonate, phosphate triester, acetamidate, carboxymethyl ester, and a combination thereof.

23. The oligonucleotide of claim 17, wherein the oligonucleotide comprises a plurality of modifications, wherein said modifications comprise modified nucleotides selected from: peptide nucleic acids, locked nucleic acids (LNA), analogues, derivatives, and a combination thereof.

24. The oligonucleotide of claim 17, wherein the oligonucleotide comprises at least one modified sugar moiety selected from, a 2'-O-methoxyethyl modified sugar moiety, a 2'-methoxy modified sugar moiety, a 2'-O-alkyl modified sugar moiety, a bicyclic sugar moiety, and a combination thereof.

25. The oligonucleotide of claim 17, wherein the oligonucleotide comprises a plurality of modifications, wherein said modifications comprise modified sugar moieties selected from: a 2'-O-methoxyethyl modified sugar moiety, a 2'-methoxy modified sugar moiety, a 2'-O-alkyl modified sugar moiety, a bicyclic sugar moiety, and a combination thereof.

26. The oligonucleotide of claim 17, wherein the oligonucleotide is of at least about 12 to 21 nucleotides in length and hybridizes to a natural antisense strand of a Pancreatic Developmental gene polynucleotide wherein said oligonucleotide has at least about 80% sequence identity to a sequence of at least about 12 consecutive nucleic acids of the sense coding and/or noncoding nucleic acid sequences of the Pancreatic Developmental gene polynucleotide.

27. The oligonucleotide of claim 26, wherein the oligonucleotide has at least about 90% sequence identity to a sequence of at least about 12 consecutive nucleic acids of sense coding and/or noncoding nucleic acid sequence of the Pancreatic Developmental gene polynucleotide and wherein said Pancreatic Developmental gene is selected from HNF4A SEQ ID NO: 2.

**28.** The oligonucleotide of claim **17**, wherein said oligonucleotide hybridizes to a natural antisense polynucleotide selected from SEQ ID NOS: 7, 8 or 9 and upregulates expression and/or function of at least one Pancreatic Developmental gene polynucleotide in vivo or in vitro, as compared to a normal control.

**29.** The oligonucleotide of claim **17**, wherein the oligonucleotide comprises the sequences set forth as SEQ ID NOS: 13 to 45.

**30.** A composition comprising one or more oligonucleotides according to claim **17** and a pharmaceutically acceptable excipient.

**31.** The composition of claim **30**, wherein the oligonucleotides have at least about 80% sequence identity as compared to any one of the nucleotide sequences set forth as SEQ ID NOS: 13 to 45.

**32.** The composition of claim **30**, wherein the oligonucleotides comprise nucleotide sequences set forth as SEQ ID NOS: 13 to 45.

**33.** The composition of claim **32**, wherein the oligonucleotides set forth as SEQ ID NOS: 13 to 45 comprise one or more modifications or substitutions.

**34.** The composition of claim **33**, wherein the one or more modifications are selected from: phosphorothioate, methylphosphonate, peptide nucleic acid, locked nucleic acid (LNA) molecules, and combinations thereof.

\* \* \* \* \*